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Fig. 6.2: Raman spectra of the chemical components (blue solid lines) colocalizing with 
hippocampal Aβ plaques, obtained from the Q-US/PS-NMF analysis of AD human brain tissues 
together with non-demented controls. ℂ1 (A) has spectral characteristics resembling 
phosphatidylcholine. ℂ2 (B) resembles actin. ℂ6 (C) is attributed to a mixture of fibrin and 
saturated lipids with cholesteryl derivatives. ℂ9 (E) can be represented as a mixture of aggregated 
Aβ peptide and trans lipids such as a trans isomer of arachidonic acid.  The chemical attribution 
of components ℂ1, ℂ2, ℂ6 and ℂ9 is based on the comparison with analytical standard Raman 
spectra of pure chemical species. Fits are shown by the red dotted lines and found using NLS 
algorithm. Corresponding R2 are also indicated. The fit in (A) is the Raman spectrum of 
phosphatidylcholine. The fit in (B) is the Raman spectrum of actin. The fit in (C) is a superposition 
of fibrin (magenta line) and cholesteryl palmitate (green line); the contributions are shown in the 
separate figure D. The fit in (E) is a superposition of the Raman spectrum of synthetic Aβ1-42 fibrils 
(magenta line) and arachidonic acid (green line); the contributions are separately shown in the 
figure F for the fingerprint region................................................................................................ 110 
Fig. 6.3: 3D spatial distributions of the Raman concentration and the corresponding component 
spectra of ℂ1 from the measured AD hippocampal brain regions and non-demented controls 
labelled according to the sample source as AD1, AD2, AD3, and C1 on colour scales as indicated, 
retrieved from the simultaneous Q-US/PS-NMF unmixing analysis of 3D Raman images of the 
human AD tissues affected by Aβ pathology together with non-demented control regions. 3D 
distribution is shown by a sequential representation of each image plane of a representative z-stack 
as AD1_01z1, AD1_01z2, AD1_01z3;…; C1_01z01-z10. A typical step between neighbour 
planes was 3 µm, except for the AD1_01z1-z3 stack, where a 5 µm step was used. In all panels, a 
typical image size is 127×127 µm2, except for the AD1_02z1-z7 images of a 127×98 µm2 in size.
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Fig. 6.4: 3D spatial distributions of the Raman concentration and the corresponding component 
spectra of ℂ2 from the measured AD hippocampal brain regions and non-demented controls 
16 
 
labelled according to the sample source as AD1, AD2, AD3, and C1 on colour scales as indicated, 
retrieved from the simultaneous Q-US/PS-NMF unmixing analysis of 3D Raman images of the 
human AD tissues affected by Aβ pathology together with non-demented control regions. 3D 
distribution is shown by a sequential representation of each image plane of a representative z-stack 
as AD1_01z1, AD1_01z2, AD1_01z3;…; C1_01z01-z10. A typical step between neighbour 
planes was 3 µm, except for the AD1_01z1-z3 stack, where a 5 µm step was used. In all panels, a 
typical image size is 127×127 µm2, except for the AD1_02z1-z7 images of a 127×98 µm2 in size.
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Fig. 6.5: 3D spatial distributions of the Raman concentration and the corresponding component 
spectra of ℂ6 from the measured AD hippocampal brain regions and non-demented controls 
labelled according to the sample source as AD1, AD2, AD3, and C1 on colour scales as indicated, 
retrieved from the simultaneous Q-US/PS-NMF unmixing analysis of 3D Raman images of the 
human AD tissues affected by Aβ pathology together with non-demented control regions. 3D 
distribution is shown by a sequential representation of each image plane of a representative z-stack 
as AD1_01z1, AD1_01z2, AD1_01z3;…; C1_01z01-z10. A typical step between neighbour 
planes was 3 µm, except for the AD1_01z1-z3 stack, where a 5 µm step was used. In all panels, a 
typical image size is 127×127 µm2, except for the AD1_02z1-z7 images of a 127×98 µm2 in size.
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Fig. 6.6: 3D spatial distributions of the Raman concentration and the corresponding component 
spectra of ℂ9 from the measured AD hippocampal brain regions and non-demented controls 
labelled according to the sample source as AD1, AD2, AD3, and C1 on colour scales as indicated, 
retrieved from the simultaneous Q-US/PS-NMF unmixing analysis of 3D Raman images of the 
human AD tissues affected by Aβ pathology together with non-demented control regions. 3D 
distribution is shown by a sequential representation of each image plane of a representative z-stack 
as AD1_01z1, AD1_01z2, AD1_01z3;…; C1_01z01-z10. A typical step between neighbour 
planes was 3 µm, except for the AD1_01z1-z3 stack, where a 5 µm step was used. In all panels, a 
typical image size is 127×127 µm2, except for the AD1_02z1-z7 images of a 127×98 µm2 in size.
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Fig. 6.7: Unmixed label-free Raman image of the plaque composition (B) in human AD brains: 
the core enriched with Aβ fibrils and oxidized trans polyunsaturated lipids such as AA (green) and 
the surrounding halo composed of lipoproteins with high CEs content (red). Combined 
fluorescence images of Aβ-stained (green) plaques co-labelled for GSDMD (red) and 
microglia (blue) (A) as well as ASC specks (red) (C), showing the localization of ASC specks and 
pore-forming GSDMD (indicated by white square) to the microglial membranes all correlated to 
the sites of the CE-rich plaque halo in the representative Raman image (B), indicating pyroptotic 
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cell death of highly inflammatory immune response around the plaque. In panel B, Ox-trans-AA 
= oxidized trans isomer of arachidonic acid. ............................................................................... 118 
Fig. 7.1: Individual and merged channels fluorescence images of the thresholded Aβ, microglia 
and ASC speck fluorescence intensities for one cortical (A) and one hippocampal (B) plaques. In 
all panels, the white circles of smaller and larger radius indicate the area of plaque core and halo, 
respectively, selected for the quantification. ............................................................................... 124 
Fig. 7.2: Individual and merged channels fluorescence images of activated microglia (Iba1, blue) 
and ASC specks (AL177, red) around Aβ plaque (6E10, green) in the frontal lobe brain region of 
a patient with AD. Colocalization of anti-Aβ/ASC specks within Iba1-positive microglia supports 
the hypothesis of inflammasome activation in response to Aβ aggregation. Scale bars, 10 µm. 126 
Fig. 7.3: Representative fluorescence image of co-deposition of Aβ with ASC speck-positive 
microglia in the hippocampal brain region of a patient with AD. The zoom of the outlined image 
area is shown on the right and indicates the inflammasome activation within microglia in close 
proximity to the Aβ plaque resulting in the distinct ASC speck formations. Scale bars, 20 µm.
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Fig. 7.4: Individual and merged channels fluorescence images of ASC specks (AL177, red) 
integrated into the Aβ cores and microglia (Iba1, blue) around in the frontal lobe (A) and 
hippocampal (B, C) brain regions of two patients with AD. Scale bars, 10 µm in all panels. .... 128 
Fig. 7.5: (A-C) Quantification of relative microglia, ASC speck and Aβ-positive volumes within 
the plaque core, halo and whole plaque for cortical versus hippocampal plaques of AD human 
brains. Data are represented as histogram distributions (top panels) and mean ± SEM (bottom 
panels). The examination of each antibody reactivity for hippocampal plaque (AD) versus non-
demented control (non-AD) regions is also given, confirming a statistically significant increase of 
microglia, ASC and Aβ immunoreactivity in plaque regions. .................................................... 130 
Fig. 7.6: Quantification of cortical and hippocampal plaques revealing a high degree of the Aβ-
microglia (A) and Aβ-ASC speck (B) colocalization in the plaque core, halo and whole plaque, 
except hippocampal core with a statistically non-significant microglial Aβ coverage. Data are 
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Fig. 7.7: (A-B) Quantification of the Aβ-ASC speck-microglia immunolabelled fluorescence 
images revealing a significant shift of the microglial activation to the pro-inflammatory state in 
the cortical plaque cores compared to the hippocampal ones. Data are represented as mean ± SEM.
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Fig. 8.1: Individual and merged channels fluorescence images of the thresholded Aβ, C9 and ASC 
speck fluorescence intensities for one cortical (A) and one hippocampal (B) plaques. In all panels, 
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the white circles of smaller and larger radius indicate the area of plaque core and halo, respectively, 
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Fig. 8.2: Individual and merged channels fluorescence images of the MAC pores (C9, blue) 
integrated into the Aβ  core (Th-S, green) and ASC specks (AL177, red) around in the hippocampal 
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Fig. 8.3: Individual and merged channels fluorescence images showing the ring-shaped deposits 
of MAC pores (C9, blue) within the Aβ  core (Th-S, green) and ASC specks (AL177, red) around 
in the hippocampal brain region of AD patient. Scale bars, 10 µm. ........................................... 141 
Fig. 8.4: Individual and merged channels fluorescence images revealing the presence of MAC 
pores (C9, blue) within the Aβ core (Th-S, green) with ASC specks (AL177, red) around in the 
hippocampal brain region of AD patient. Scale bars, 10 µm. ..................................................... 142 
Fig. 8.5: Activation of the NLRP3 inflammasome and ASC speck assembly are triggered in 
response to sublytic MAC deposition in AD human brains. Figure shows the colocalization of the 
MAC (С-9, blue) and ASC specks (AL177, red) to the membranes of apoptotic cells activated 
within the core of the Aβ plaque (Th-S, green) in the hippocampal brain region of AD patient 5. 
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Fig. 8.6: Individual and merged channels fluorescence images showing the co-accumulation of 
MAC pores (C5b-9, blue) and ASC specks (AL177, red) throughout the cortical Aβ plaque (Th-
S, green) in the frontal lobe brain region of AD patient 4. Scale bars, 10 µm. ........................... 144 
Fig. 8.7: Individual and merged channels fluorescence images showing the significant 
accumulations of MAC pores (C9, blue) and ASC specks (AL177, red) in the cortical Aβ plaque 
(Th-S, green) of the hippocampal brain region of AD patient 2. Scale bars, 10 µm. .................. 145 
Fig. 8.8: (A-C) Quantification of relative C9, ASC speck and Aβ-positive volumes within the 
plaque core, halo and whole plaque for cortical versus hippocampal plaques of AD human brains. 
Data are represented as histogram distributions (top panels) and mean ± SEM (bottom panels). 
The examination of each antibody reactivity for hippocampal plaque (AD) versus non-demented 
control (non-AD) regions is also given, confirming a statistically significant increase of C9, ASC 
and Aβ immunoreactivity in plaque regions and the specificity of the used antibodies. ............ 146 
Fig. 8.9: (A-B) Quantification of cortical and hippocampal plaques revealing a high degree of the 
Aβ-C9 colocalization in the plaque core, halo and whole plaque that indicate the significance of 
the pore-forming C9 accumulation within the core and halo of the Aβ plaques. Data are represented 
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Abstract 
Accumulation of amyloid-β (Aβ) peptide in plaques, aberrant lipid metabolism, and 
neuroinflammation are considered by many of utmost biological importance for Alzheimer’s 
disease (AD) progression. Despite this significance, the link among these three aspects is still 
under study. To that end, there is a great need for the research which investigates in detail the 
relationship among aggregated proteins, lipids and neuroinflammatory components of AD human 
brains. 
My thesis utilizes cutting edge label-free optical technique, Raman micro-spectroscopy, combined 
with an efficient quantitative biomedical image unmixing analysis, to investigate in detail the 
spatio-chemical composition and correlation of Aβ plaques with both neuroinflammatory 
biomarkers and lipids in post-mortem AD human brains. Two types of post-mortem human brain 
samples from AD patients together with non-demented elderly controls were investigated using 
point- and line-scan Raman micro-spectroscopy modalities: 5 μm thick formalin-fixed-paraffin-
embedded and 20-50 μm thick frozen brain sections.  
For the formalin-fixed samples studied by point-scan Raman micro-spectroscopy, the analysis 
reveals significant structural and functional changes in lipid and protein (including Aβ fibrils of 
cross-β sheet structure and tau filaments) chemical composition as well as increased concentrations 
of oxidative stress and inflammatory biomarkers strongly co-localizing in Aβ plaques of diseased 
tissues compared to controls. In particular, Aβ plaques are found to consist of the micro-scale 
accumulations of chemical components attributed to cholesteryl esters with saturated long-chain 
fatty acids (FAs), Aβ fibrils, fibrin/arachidic acid, collagen-like amyloidogenic 
component (CLAC), β-carotene, magnetite, and calcium phosphate, which altogether reflect the 
persistent presence of neuroinflammation in AD brains. The oxidation status of lipids is supported 
by the presence of trans double bonds in the Raman spectrum of the identified component, forming 
during lipid peroxidation. Furthermore, the presence of arachidic acid indicates the conversion of 
arachidonic acids to eicosanoids occurring in the process of oxidative damage. Importantly, I also 
demonstrated that the statistical parameters of identifying biomolecules differentiate AD brains 
from non-demented ones, implying their potential to be used in the diagnosis of AD. Therefore, 
my PhD thesis presents a new tool for the biomolecular characterization and correlative imaging 
of the AD brain tissues, providing a better understanding of the relationship between Aβ plaques 
and their lipid and inflammatory microenvironment. These findings could open the prospect for 
new anti-inflammatory and antioxidant drug strategies.  
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For the frozen tissues without fixative artefacts, 3D line-scan Raman micro-spectroscopy allowed 
to distinguish intracellular and extracellular volumeric accumulations of pathogenic Aβ species 
assembled into the cross-β structured fibrils as retrieved from the label-free AD brain samples. 
The analysis reveals two types of lipid aggregates spatially colocalizing with the Aβ plaques. In 
particular, the Aβ plaque core and neuronal cell bodies are found to contain the significant 
accumulations of polyunsaturated lipids, spectrally assigned to an oxidized form of a trans isomer 
of arachidonic acid, that are co-aggregated with the Aβ protein in one chemical component. The 
high content of the oxidised polyunsaturated trans lipids within the Aβ deposits is indicated by an 
enhanced Raman band of trans lipids at 1668 cm-1, appearing during lipid peroxidation of the 
cellular membranes by free radicals, combined with an absent Raman band of cis lipids 
near 1656 cm-1. The oxidation modification of the Aβ-associated polyunsaturated acid is also 
suggested by the missing band around 3004 cm-1, which is a diagnostic band of unsaturated FAs.  
The significant accumulations of the oxidatively-modified arachidonic acid with the pathogenic 
Aβ fibrils might indicate unresolved neuroinflammation and oxidative damage implicated in 
human AD brains in response to chronic Aβ accumulation. The halo surrounding the Aβ core is 
revealed to consist of lipoproteins with a high cholesteryl ester content found colocalizing with the 
activated microglial processes and spatially correlated with the pro-inflammatory components of 
the immune system including a pore-forming gasdermin D protein, reflecting the cell pyroptosis. 
The analysis also discovered the ellipsoid-shaped cloud accumulated around the Aβ-positive 
neurons and consisting of an actin protein, possibly representing the lytic material of the dead 
neuronal cells underwent the cell pyroptosis. Altogether, Raman micro-spectroscopy has proven 
to distinguish the spatially resolved chemically specific lipid and protein accumulations, 
characteristic of oxidative damage and neuroinflammation, colocalizing to Aβ-affected brain 
regions in label-free human AD brains, thereby providing a useful imaging tool for the 
identification of the molecular signs of AD tissue pathology. 
My thesis utilizes high-resolution confocal fluorescence microscopy to characterise inflammation 
coupled to Aβ aggregation in human AD brains, that can underline the causes of AD and deliver 
new treatment strategies. Formalin-fixed-paraffin-embedded post-mortem brain tissues were 
recruited from human individuals affected by AD. Brain tissues were assessed in the hippocampus 
and frontal lobe by co-immunostaining for spatial correlation and distribution of specific 
neuroinflammatory protein components with microglia and Aβ plaques. These are the nucleotide-
binding oligomerization domain (NOD)-like receptor protein 3 (NLRP3)-derived apoptosis-
associated speck-like protein containing a caspase recruitment domain (ASC), and complement 
cytolytic pathway activation protein component 9 of a membrane attack complex (MAC). 
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Quantitative analysis reveals the accumulations of numerous ASC specks, indicative of the NLRP3 
inflammasome activation, and the MAC pores both colocalizing to the Aβ core and halo, thereby 
indicating the MAC as a possible driver of the pro-inflammatory immune response in AD brains. 
My data support the hypothesis that MAC at the sites of Aβ accumulation induces the activation 
of the inflammasomes, immunological pattern recognition receptors (PRRs),  that results in the 
secretion of the ASC specks and maturation of the pro-inflammatory cytokines into the 
extracellular space through the MAC-induced permeable membranes of the Aβ-affected cells, both 
contributing to Aβ pathology spreading. Importantly, the quantification of Aβ plaques shows that 
the MAC pores incorporated into the Aβ core can contribute to shrinkage of the Aβ plaque area 
through phagocytosis, observed to be a more profound effect for newly formed deposits of a 
smaller diameter. The quantification of microglial processes in the Aβ plaque regions reveal the 
significance of the disease-associated microglia phenotype activation, characterising by presence 
of numerous ASC specks within their soma. This microglia phenotype might represent a sustained 
pro-inflammatory population of microglia evolved due to continuous Aβ aggregation in AD human 
brains.  
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Chapter 1. Introduction 
Alzheimer’s disease (AD) is an age-related neurodegenerative disorder, characterized by the 
extracellular accumulation of amyloid-β (Aβ) peptide in the senile plaques and the intracellular 
deposits of the microtubule-associated protein tau in the neurofibrillary tangles. According to the 
World Alzheimer Report 2019, over 50 million people worldwide live with AD in 
2019 (Alzheimer’s Disease International 2019). Patients show a gradual onset and progression of 
memory loss and other cognitive deficits. Although most patients are diagnosed at 65 years or 
later, scientists believe that AD pathology begins two or even three decades before the disease 
onset with the clinical symptoms pronounce (Jack et al. 2013), therefore implying that AD is a 
progressive disease of the middle age population. Alongside obesity and diabetes, AD is a modern 
disorder with a consistently increasing number of patients. For instance, AD is estimated to affect 
about 152 million people globally by 2050 (Alzheimer’s Disease International 2019). Despite 
being considered as a 21st century epidemic, there is still no cure for AD and the etiology of the 
disease remains obscure.  
The study of the spatio-chemical composition and correlation of Aβ plaques with both 
neuroinflammatory biomarkers and lipids in post-mortem AD human brains is of great importance 
to understanding the underlying causes and progression of AD. There is an increasing body of 
evidence that aggregation of Aβ, aberrant lipid metabolism and neuroinflammation are involved 
in AD pathology. Therefore, research elucidating the link among these three aspects can open the 
prospect for new drug strategies to be potentially tested and successfully utilised in Alzheimer’s 
disease treatment. Furthermore, the study reporting correlative chemical imaging of Aβ plaques 
and their bioenvironment in AD human brains with high spatial resolution and chemical specificity 
in a non-destructive manner is very demanding due to the need of development of new reliable 
methods and biomarkers to perform such studies. 
According to the literature, a range of spectroscopic and imaging techniques have been applied to 
the study of AD human brains. These include but are not limited to Fluorescence Microscopy 
(FM), Mass spectrometry (MS), Liquid Chromatography-MS (LC-MS), Positron-Emission 
Tomography (PET), Magnetic Resonance Imaging (MRI), etc. Alternatively, a promising method 
to study the biochemical composition of tissues is vibrational optical micro-spectroscopy. The 
basic principle of these methods is originated from excitation and further detection of the intrinsic 
vibrations of chemical bonds in molecules using laser light, and therefore the unique ability of 
these techniques to provide a non-invasive label-free chemically specific imaging of biomedical 
samples make them very attractive for many biological applications. Therefore, the study 
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presenting a direct application of high-resolution label-free vibrational micro-spectroscopy to 
biochemical characterization of human AD brain tissues is very demanding. This biomedical study 
can reveal specific imaging biomarkers of the altered AD metabolism associated with the Aβ 
plaque pathology, which is directly relevant for the disease diagnosis. In combination with high-
resolution fluorescence microscopy, such studies can link amyloid aggregation and defective 
microglia-mediated Aβ clearance to specific inflammatory pathways, which might point to new 
drug strategies for possible AD treatment and prevention.  
In the course of the Literature Review (Chapter 1), I will report the current knowledge on major 
contributors to AD pathogenesis (Section 2.1). Specifically, I will discuss in detail why and how 
Aβ plaques (Section 2.1.1), aberrant lipid metabolism (Section 2.1.2) and 
inflammatory/immunological processes (Section 2.1.3) might be involved in AD initiation and 
progression. In Section 2.2, I will cover cutting edge imaging techniques in the study of brain 
tissue. In Section 2.3, I will discuss existing multivariate hyperspectral unmixing methods applied 
to biomedical image analysis.  
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Chapter 2. Literature Review 
2.1. Major contributors to Alzheimer’s disease pathogenesis 
A number of hypotheses such as amyloid cascade, lipid dysregulation and inflammation have been 
proposed for the AD pathogenesis, suggesting that AD is a multifactorial complex disorder. Aβ 
plaques, aberrant lipid metabolism and neuroinflammation can be considered as the three major 
contributors to AD. 
2.1.1. Amyloid-β plaques in Alzheimer’s disease 
It is widely accepted that the extracellular accumulation of Aβ in senile plaques is a principal event 
in the pathogenesis of AD (Selkoe 2001a) and there are many lines of evidence supporting a 
dominant role of Aβ dyshomeostasis in the initiation of AD (Selkoe and Hardy 2016). Genetic 
studies in early-onset familial forms of AD, which account for 5-10% of all AD cases, suggest that 
the mutations in Aβ precursor protein (APP), presenilin 1 (PSEN1) and PSEN2 genes, which 
encode the proteins that generate Aβ by proteolytic processing, lead to the overproduction of Aβ 
peptides and their subsequent self-aggregation into advanced phase transition stages ranging from 
monomers to misfolded monomers, dimers, oligomers, protofibrils, fibrils and ultimately to Aβ 
plaques (Bertram et al. 2010). In sporadic late-onset AD, which represents 90-95% of the total AD 
cases, it is thought that the dysregulations of Aβ clearance pathways may cause persistent Aβ 
aggregation, leading to neuronal dysfunction (Mawuenyega et al. 2010). Importantly, the initial 
model of AD, which helped to support amyloid hypothesis, was Down syndrome (DS), caused by 
trisomy of chromosome 21. Since the APP gene is encoded on chromosome 21 and it is 
overexpressed in DS brains, DS is considered to be a unique model for study AD 
pathology (Iwatsubo et al. 1995). The link between the overproduction of APP and Aβ 
accumulation has been widely studied and the results show that DS brains develop Aβ-associated 
pathology manifesting by progressive accumulation of the Aβ plaques starting in the teenage 
years (Lemere et al. 1996). Furthermore, human AD cellular model using cortical neurons 
differentiated from induced pluripotent stem (iPS) cells and embryonic stem cells of DS patients 
indicates that these generated neurons secrete high-level of Aβ peptides, shown to form Aβ 
aggregates, and cause increased tau phosphorylation (Shi et al. 2012).  
Fundamentally, Aβ peptides of different lengths are generated from the sequential APP cleavages 
by β-secretase (BACE) and γ-secretase (Selkoe 2001b). Initially, β-secretase cuts APP to produce 
soluble APP (β-APPs) and a membrane-bound C-terminal fragment (C99). Then, cleavage by γ-
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secretase of C99 generates Aβ and the APP intracellular domain (AICD) counterparts. The 
resulting products of such C99 processing are amyloidogenic peptides: Aβ1-40 and Aβ1-42. 
However, it had not been clear until 2009 what are the intermediate steps of C99 processing. At 
that time, it was elucidated that C99 is firstly cut at the membrane–cytoplasm boundary, generating 
two long Aβ1-48 and Aβ1-49 intermediates, which are in turn processed by the sequential release of 
tripeptides, finally resulting in the generation of Aβ1-42 and Aβ1-40, respectively (Takami et al. 
2009).  The longer Aβ1-42 fragments tend to be more hydrophobic and more prone to aggregation 
into toxic Aβ oligomers (Haass and Selkoe 2007), which were found to be the major chemical 
component of neuritic plaques (Jarrett et al. 1993). Recently, it has been shown in vitro and in vivo 
that mild increases in temperature significantly affect the γ-secretase processing function resulting 
in a release of longer Aβ1-n (n ≥ 42) peptides, which might be potentially more toxic (Szaruga et 
al. 2017). It was also suggested that the disturbance of the γ-secretase stability (e.g.: by increased 
temperature or mutations in PSEN), might increase the risk of sporadic forms of AD, similarly to 
the familial AD, where the mutations in PSEN and APP induce the abnormal APP processing and 
further release of long Aβ peptides. Additional evidence demonstrates that the inhibition of γ-
secretase activity leads to the undetectable levels of pathogenic Aβ production by iPS-cell cortical 
neurons derived from DS patients, thereby indicating the possible use of stem-cell therapy in AD 
treatment (Shi et al. 2012).  
Prevailing evidence suggests that soluble Aβ oligomers are more pathogenic compared to inert 
insoluble Aβ aggregates. These toxic Aβ oligomers can easily flow into synapses and disrupt the 
connections between neurons (Shankar et al. 2008). Aβ oligomer-induced toxicity is mediated by 
interactions with neuron receptors and lipid membranes (Kayed et al. 2003). It has been shown 
that injection with soluble Aβ oligomers into wild-type mouse leads to impairment of synaptic 
plasticity via overstimulation of extrasynaptic N-methyl-D-aspartate receptor (NMDA) death 
signalling (Li et al. 2011). Similarly, pathogenic Aβ dimers isolated from human AD brain are 
demonstrated to induce AD pathology in rodent hippocampus by decreasing dendritic spine 
density, inhibiting long-term potentiation, and enhancing long-term synaptic depression (Shankar 
et al. 2008).  
Amyloid hypothesis is also supported by clinical evidence. Specifically, the studies in humans 
demonstrate that abnormal levels of cerebrospinal fluid (CSF) Aβ1-42 marker and amyloid-positive 
PET scans precede other AD symptoms by many years and even decades (Selkoe and Hardy 2016). 
Importantly, ongoing immunotherapeutic trials using monoclonal Aβ antibodies such as 
solanezumab, crenezumab, and aducanumab have already showed positive affect on slowing 
cognitive decline in mild AD patients (Cummings et al. 2018). Altogether, prevailing evidence 
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widely accepts that an imbalance between production and clearance of toxic Aβ peptides occurs 
very early in disease and can be considered as an initiating factor for AD. Therefore, targeting Aβ 
dyshomeostasis represents a therapeutic strategy with already promising results  (Kumar et al. 
2015). 
2.1.2. Lipid-amyloid interplay in Alzheimer’s disease 
There is a growing body of research evidence that the dysregulation of lipid pathways is implicated 
in several neurodegenerative disorders, including AD. In his early studies in 1910, Alois 
Alzheimer noted the higher occurrence of “adipose inclusions” in the brain of AD patients 
suggesting aberrant lipid metabolism is involved in the course of AD (Di Paolo and Kim 2011). 
Only recently this link between lipid metabolism and AD has been strengthened with the discovery 
indicating that the apolipoprotein E (APOE) gene has the strongest known genetic risk factor for 
the development of late-onset AD (Corder et al. 1993). APOE encodes a ~34kDa protein that 
regulates cholesterol metabolism in the brain and triglyceride metabolism throughout the body. It 
binds Aβ and modulates its aggregation and clearance, suggesting a link between these hallmarks 
of AD.  
It has been shown that the aggregation of Aβ is mediated by the interaction with different classes 
of lipids, including cholesterol (Sparks et al. 1994; Refolo et al. 2000; Paolo and Kim 2011), 
ganglioside (Yanagisawa et al. 1995; L. P. Choo-Smith et al. 1997; Matsuzaki and Horikiri 1999), 
phospholipids (McLaurin and Chakrabartty 1997; Lee et al. 2002) and fatty acids (FAs) (Prasad 
et al. 1998), leading to a cascade of pathological events including neuroinflammation and 
oxidative stress. One of the possible mechanisms elucidating the toxicity of Aβ-lipid interaction 
can be the formation of amyloid peptide ion channels in the neuronal membranes, leading to the 
disruption of intracellular calcium homeostasis (Kayed et al. 2009). It has been shown that the 
interaction of Aβ peptides with lipid bilayer membranes results in the formation of amyloid cation-
specific ion channels or pores through which Ca2+ can pass into the cytosol. Specifically, Aβ-
induced channel formation  is demonstrated to increase the intracellular calcium 
concentration (Kawahara et al. 2000). It has been also suggested that Aβ incorporated into the lipid 
membranes can modify their structure and subsequently undergo aggregation in these 
membranes (Kawahara et al. 2000). Interestingly, the membrane fluidity quantified by the ratio of 
cholesterol to phospholipids influences the ability of antibiotic peptides to form ion 
channels (Warnock et al. 1993). Other studies hypothesised that the specific oligomer of pore-like 
morphology named annular protofibril can induce the ion dysregulation of membranes (Kayed et 
al. 2009) and the formation of toxic Aβ channels during Aβ oligomer internalization into the lipid 
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membranes requires the interaction with other Aβ species (Jang et al. 2013). More importantly, 
the relationship between Aβ-induced Ca2+ influx and neurotoxicity has been suggested by the 
finding showing that the voltage-sensitive Ca2+ channel blocker, nimodipine, attenuates the Aβ-
mediated cell death (Weiss et al. 1994). Collectively, after Aβ channels are formed in the 
membranes of neuron cells, the disruption of ion homeostasis (including calcium) triggers a 
cascade of pathological processes, such as oxidative stress (Yatin et al. 1998) and tau 
phosphorylation (Takashima et al. 1993), which are able to boost neurodegeneration.  
It has been suggested that the excessive production of free radicals results from the damage of cell 
membranes by Aβ (Butterfield et al. 1994). These free radicals such as reactive oxygen 
species (ROS) as well as redox metal ions can be considered as a reservoir of neurotoxicity in AD 
brains, which catalyse a continuous oxidation of lipid membranes (Markesbery 1997). A self-
amplified reaction of lipid peroxidation releases very reactive products, which favour to interact 
with other biomolecules and generate new neurotoxic species responsible for 
neurodegeneration (Esterbauer et al. 1991; Butterfield et al. 2011). As an evidence, it has been 
shown that 4-hydroxy-2-trans-nonenal (HNE), the product of lipid peroxidation, can covalently 
modify the histidine side chains of Aβ, leading to increased aggregation of this peptide (Liu et al. 
2008). In addition, neprilysin (NEP), a major protease that cleaves Aβ in vivo, has also been 
reported to be HNE modified in AD brains (Wang et al. 2003). On the other hand, there is a line 
of evidence that lipids themselves have detergent properties, promoting the disintegration of 
amyloid fibrils into toxic protofibrils and oligomers (Widenbrant et al. 2006; Martins et al. 2008). 
These free oligomers can bind to synaptic contacts (Deshpande et al. 2006), where they disrupt 
lipid membrane homeostasis (Milanesi et al. 2012). Altogether, these findings suggest that the 
amyloid-lipid interaction induce the overproduction of neurotoxic species through the pathogenic 
formation of amyloid ion pores in the neuronal membranes (linked to severe Ca2+ dyshomeostasis) 
as well as stimulate the continuous generation of free Aβ oligomers, both contributing to AD 
neurodegeneration. 
An increasing body of evidence indicates that clustered gangliosides that reside in neuronal raft 
microdomains promote Aβ oligomer assembly into toxic membrane-associated fibrils (Matsuzaki 
et al. 2010) and the following mechanism has been suggested. Aβ binds to ganglioside-containing 
liposomes (Choo-Smith and Surewicz 1997), where it undergoes structural changes from α-helix 
to β-sheet conformation (McLaurin et al. 1998) possibly through interaction with liposomal lipid 
bilayers, which ultimately lead to the generation of Aβ fibrils (L.-P. Choo-Smith et al. 1997). It is 
important to note that Aβ binding to gangliosides is suggested to occur in presynaptic ganglioside-
clustered raft membranes (Kakio et al. 2002), particularly rich in cholesterol (Kakio et al. 2001). 
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Furthermore, it has been indicated that the interaction of Aβ oligomers and gangliosides in 
neuronal lipid raft-like membranes results in the formation of the 
monosialotetrahexosylganglioside (GM1)-ganglioside-bound Aβ (GAβ) complex, which 
accelerate Aβ assembly, induced by the conformation changes, into membrane β-sheet-rich fibrils, 
acting as a seed for further Aβ aggregation (Matsuzaki et al. 2010). Specifically, the 
immunostaining against GAβ complexes reveals the presence of GAβ-containing lysosomes in the 
AD brains accompanied by molecular characterization of GAβ showing that both GAβ and Aβ at 
the ends of growing fibrils exhibit a specific conformation which is required for Aβ 
polymerization (Hayashi 2004).  
2.1.3. Inflammation in Alzheimer’s disease 
An increasing body of evidence suggests that inflammation is the central event in the initiation 
and progression of AD. Recently, association of inflammation and AD has been strongly supported 
by genome-wide association studies (GWAS), which identified CR1 and TREM2 genes encoding 
a complement component (3b/4b) receptor 1 and a triggering receptor expressed on microglia to 
be the risk genes for the development of sporadic late-onset forms of AD (Harold et al. 2009; 
Lambert et al. 2009; Guerreiro et al. 2013; Karch and Goate 2015). For instance, it has been 
suggested that the dysregulation of the TREM2 protein expression affected through the variants in 
the TREM2 gene can cause functional defects in microglial response to Aβ aggregation as well as 
promote a pro-inflammatory cascade in AD brains (Guerreiro et al. 2013). Furthermore, the 
association studies of the relationship between CR1 single-nucleotide polymorphisms (SNPs) 
genotypes and increased Aβ CSF levels indicated a positive correlation of these two, and therefore 
providing an additional evidence of the complement component (3b/4b) receptor 1 (CR1) 
implication in Aβ metabolism (Brouwers et al. 2012).  
The inflammation hypothesis of AD is also supported by the epidemiological and preclinical 
evidences which indicate that anti-inflammatory drug therapy might be beneficial for the treatment 
of AD (Aisen 2002). Such studies suggest inhibiting inflammatory response using non-steroidal 
anti-inflammatory drugs (NSAIDs) in order to reduce AD pathology (Lim et al. 2000; Sung et al. 
2004; McKee et al. 2008). In turn, the anti-inflammatory effect of NSAIDs can be explained 
through their association with inhibition of cyclooxygenase (COX) expression. Note, COX is the 
enzyme that converts arachidonic acid into prostaglandins and thromboxane known as the 
proinflammatory mediators. This enzyme has two isoforms: COX-1 and COX-2 (Aisen 2002).  
Given that COX might be considered as a promising therapeutic target for AD. Indeed, a 
preclinical study in triple transgenic AD (3×Tg-AD) mouse model demonstrates that the COX-1 
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selective inhibitor SC-560 protects the aged AD mice from inflammation, neuropathology and 
development of cognitive decline (Choi et al. 2013). However, several clinical studies in AD 
patients with mild to severe AD stage have shown no beneficial effect of NSAIDs, which 
specifically inhibit COX-2, on the protection from AD pathology (Aisen et al. 2000; Sainati et al. 
2000).  
During the course of disease, deposition of Aβ in the brain of AD patients constantly activate the 
brain-resident immune cells such as microglia and astrocytes (Rubio-Perez and Morillas-Ruiz 
2012). Upon activation, microglia and astrocytes can initiate a pro-inflammatory cascade, resulting 
in the release of potentially cytotoxic molecules, such as cytokines (interleukin-1β (IL-1β), IL-6 
and tumor necrosis factor-α (TNF-α)), complement factors (C1q, C3, C4, and C9), nitric 
oxide (NO), reactive oxygen species (ROS), etc., which may ultimately cause 
neurodegeneration (Meraz-Rios et al. 2013). Although the glial immune cells are abundantly 
found near Aβ plaques of AD brains, the conclusive role of microglia and astrocytes in the Aβ 
plaque development and neurodegeneration is still unknown (Condello et al. 2015; Chun et al. 
2018; Merlo et al. 2018). Furthermore, the activation of glial cells in response to Aβ aggregation 
leads to a series of immunological events, involving the activation of various receptor signalling 
pathways and complement cascade, which an ultimate role in AD has not yet been elucidated.   
In the following section, I will highlight the current knowledge and evidence from the literature 
on microglia as a cellular mediator as well as the NLRP3 inflammasome and complement 
component proteins as the molecular mediators of neuroinflammation in AD.  
Microglia activation in AD 
Microglia, resident phagocytes of the central nervous system (CNS), constantly survey the brain 
via their branching projections to defend, maintain and repair potential tissue damage. Microglia 
also play a crucial role in the brain development. As the primary innate immune cells of the brain, 
microglia can phagocytose dying cells, cellular debris, toxic protein aggregates including 
Aβ (Simard et al. 2006) as well as damaged and unnecessary neurons and synapses known as the 
synaptic pruning (Neumann et al. 2009; Schafer et al. 2012). By secreting various functional 
molecules (e.g.: cytokines and chemokines) and free radicals, microglia communicate with 
neighbouring immune cells and stimulate their activation. It is strongly suggested that abnormal 
Aβ aggregation in the brain causes microglia to move to the pathological area (Meyer-Luehmann 
et al. 2008) and secrete pro-inflammatory immune molecules including cytokines and chemokines 
after activation (Halle et al. 2008), that can further recruit neighbour immune cells as well as 
phagocytes from blood (Simard et al. 2006).  
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Fig. 2.1: Acute (A) versus chronic (B) activation of microglia in the course of neuroinflammatory diseases including 
AD. Treatment allowing to stimulate the conversion of a pro-inflammatory M1 microglia phenotype into anti-
inflammatory state and inhibit neuroinflammation using a selection of therapeutic agents, such as glatiramer 
acetate (GA), bexarotene, and peroxisome proliferator-activated receptor γ (PPARγ) agonists (C). EAE = 
experimental autoimmune encephalomyelitis, MS = multiple sclerosis. Reproduced from (Cherry et al. 2014) under 
the terms of the Creative Commons Attribution License 4.0 (CC BY 4.0) in line with the BioMed Central Ltd 
license agreement. 
On the other hand, there is a growing body of evidence that the subpopulation of microglia 
associated with the neurodegenerative disease progression has an unique phenotype, which is 
significantly different from the primary one, which is initially activated in response to Aβ 
aggregation in early AD stage (Sarlus and Heneka 2017). Furthermore, it has been hypothesised 
that the middle/late-stage disease subtype of microglia can promote AD pathology, therefore 
indicating the possible microglia impairment in response to chronic Aβ aggregation, leading to the 
failure of microglia to clear Aβ (Wang et al. 2015; Sarlus and Heneka 2017).  This suggested 
hypothesis can be explained as follows. Fundamentally, there are two polar states of microglia 
corresponding to the M1 and M2 phenotypes. The M1 phenotype is believed to provide pro-
inflammatory impaired phagocytosis, associated with brain tissue damage and chronic 
inflammation. During this state, microglia secrete pro-inflammatory cytokines (IL-1β, IL-6, IL-
12, IL-17, IL-18, IL-23), TNF-α, interferon-γ (IFN- γ), ROS and chemokines (Subramaniam and 
Federoff 2017). In contrast, the M2 phenotype is thought to ensure anti-inflammatory 
neuroprotective phagocytosis promoting brain tissue healing (Cherry et al. 2014). The M2 
microglia produce IL-4, IL-13 and IL-10 cytokines, transforming growth factor-β (TGF-
β) (Subramaniam and Federoff 2017). According to (Cherry et al. 2014), in the course of 
prolonged/chronic inflammation, abundant levels of inflammatory cytokines skew the microglial 
polarization towards the M1 state. This skewed population of M1 microglia in turn generate new 
inflammatory cytokines, thereby promoting a conserved loop of continuous inflammation and 
propagation of the M1 state. To switch to the phagocytosis-promoting M2 phenotype of microglia, 
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bexarotene (retinoid X receptor agonist) has been used in the therapy of familial AD (FAD) mice, 
resulting in the significant reduction of Aβ plaque-affected brain areas and impressive recovery of 
cognitive function (see also Fig. 2.1) (Cramer et al. 2013).  
It is important to note that the M1 phenotype of microglia prevail with age, i.e.: aged brains are 
more prone to activate the pro-inflammatory M1 microglia, thereby having the increased risk of 
pathology and neurodegeneration. This hypothesis is supported by studies in old non-demented 
mice having downregulation of receptors associated with Aβ engulfment (scavenger receptor A) 
and the Aβ degradation enzymes (neutral endopeptidase (Nep), insulin-degrading enzyme (IDE), 
and matrix metallopeptidase 9 (MMP-9) (Hickman et al. 2008). Furthermore, in vitro studies show 
that lipopolysaccharide (LPS)-induced M1 microglia lose the ability to phagocyte 
Aβ (Koenigsknecht-Talboo 2005). Furthermore, treatment with pro-inflammatory cytokines, such 
as IFN-γ and TNFα stimulating M1 microglia phenotype, results in the decreased Aβ uptake by 
M1 microglia and inefficient degradation of internalised Aβ (Yamamoto et al. 2008), therefore 
implying the limited ability of M1 microglia to clear Aβ. In contrast, the M2 population of 
microglia which has been stimulated by cytokines IL-4 and IL-10 show efficient phagocytic 
function and robust degradation of Aβ (Koenigsknecht-Talboo 2005; Balce et al. 2011). 
Furthermore, in vivo studies in an AD mouse model indicate that the 6-month-old mice already 
exhibiting Aβ aggregation has a clear presence of chitinase-like protein-1 (YM1)-positive 
microglia (marker of M2 phenotype) in the CNS. Whereas, by the advanced stage of disease (18 
months) there was a decrease in YM1 mRNA levels together with a significant upregulation in 
pro-inflammatory factors, indicating a switch from M2 to M1 phenotype (Jimenez et al. 2008).  
 
NLRP3 inflammasome activation in AD 
As presented in the previous section, a conserved pattern of continuous Aβ aggregation causes the 
chronic activation of the innate immune system and impairment in phagocytic function of 
microglia (Heneka et al. 2015). Additional supporting evidence indicates that the increased 
expression of IL-1β impairs microglial function to clear Aβ, leading to the further accumulation 
of Aβ in the AD brain (Heneka et al. 2010). Similarly, cells of individuals with severe AD are 
observed to contain increased amounts of pro-inflammatory cytokines and activated 
inflammasomes (Condello et al. 2015). One more data report the elevated pro-inflammatory 
cytokine IL-1β levels in response to Aβ aggregation (Lucin and Wyss-Coray 2009). The link 
between IL-1β and the inflammasome activation in response to toxic Aβ can be explained as 
follows.  IL-1β is generated from a chemically inactive precursor pro-IL-1β and requires caspase-
1-dependent processing for activation. Caspase-1 activation in turn is regulated by cytosolic 
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multiprotein complexes called inflammasomes, which can sense not only the microbial 
pathogen (Lamkanfi and Dixit 2012) but also misfolded proteins including Aβ (Halle et al. 2008) 
and pathological crystals (Latz 2010). Specifically, NLRP3 inflammasome can detect the 
pathological amyloid as a danger signal (Halle et al. 2008).  This observation is consistent with 
the experimental studies indicating that aged APP/PS1 transgenic mice with NLRP3 or caspase-1 
knock-out genes have reduced microglia-mediated IL-1β production and Aβ pathology 
accompanied by  improved cognitive function (Heneka et al. 2013). Additional evidence of the 
NLRP3 implication in AD pathology is supported by in vitro studies showing  that soluble 
oligomeric Aβ cause the increased processing of mature-IL-1β from pro-IL-1β through ROS-
induced activation of NLRP3 in microglia (Parajuli et al. 2013). 
Recently, the discovery in an AD mouse model has elucidated the link between Aβ pathology and 
ASC specks (Venegas et al. 2017). In this study (Venegas et al. 2017), extracellular ASC species 
were indicated to spread Aβ toxicity by seeding Aβ oligomer assembly and the following 
mechanism has been suggested: ASC specks secreted by microglia rapidly bind to Aβ, where they 
seed Aβ nucleation. This hypothesis has been investigated in the same study (Venegas et al. 2017) 
by a series of experiments showing that intra-hippocampal injections of ASC specks lead to 
propagation of Aβ pathology in the FAD mice, whereas the FAD mice deficient in ASC expression 
is shown to be protected from this pathology. Also, it has been proven that anti-ASC antibody 
treatment stops the increase of Aβ pathology. Fundamentally, once activated, NLRP3 induce the 
polymerization of the adaptor apoptosis-associated speck-like protein containing a caspase 
(CARD)-recruitment domain (ASC) into large helical filaments via self-interactions of the pyrin 
domains (PYDs) of ASC. Then, ASC fibrils trigger the activation of caspase-1 via CARD 
interactions followed by proteolytic self-cleavage and further assembly of ASC fibrils into a 
micrometre-sized perinuclear complex called ASC speck (Venegas et al. 2017). By accumulation 
in the extracellular space, ASC specks show prion-like (prionoid) functions to recruit new ASC 
and caspase-1 in cells ingested ASC specks, thereby propagating inflammation (Franklin et al. 
2014). 
Complement component activation in AD 
The complement system is an important innate and adaptive immune response effector. This 
system made of a number of proteins and proteases that are activated in cascade can be considered 
to play a crucial role in AD (Meraz-Rios et al. 2013). Generally, the activation of complement 
system (see Fig. 2.2 for details) involves the recruitment of the C1q molecule (classical pathway), 
mannose-binding lectin (mannose-binding (MB) lectin pathway) or C3 multifunctional 
protein (alternative pathway), which are responsible for defence to infections/various danger 
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signals, clearance of apoptotic cells, and elimination of supernumerary synapses (synaptic 
pruning) (Mawuenyega et al. 2010).  
 
Fig. 2.2: An overview of the three complement activation pathways. Mannose-binding lectin = MBL, mannose-
associated serine protease 1, 2 = MASP-1, 2. Reproduced with permission from (Walport 2001), Copyright 
Massachusetts Medical Society. 
These three complement pathways converge at the formation of a C3 convertase, which cleaves a 
C3 protein into two fragments C3a and C3b. The activated C3b molecules can be sensed by 
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phagocytes through their surface CR1. Upon activation, the opsonin C3b labels the surface of 
pathogen, which is recognised by complement receptors of phagocytes resulting in their activation 
to the place of pathogen. Importantly, all pathways of complement activation involve the 
enzymatic cleavage of the C5 protein into the anaphylatoxin C5a and opsonin C5b followed by 
activation of the membrane attack complex (MAC). MAC consists of the complement proteins 
C5b, C6, C7, C8 binding to the outer surface of the target cell membrane, and numerous units of 
complement component 9 (C9) protein, which interact with each other to form a ring in the 
membrane. This ring structure creates a pore in the target cell membrane, which leads to their 
disrupted homeostasis and ultimately to the cell lysis (Bhakdi and Tranum-Jensen 1991). As a non-
lethal cell effect, the MAC deposits can stimulate the pro-inflammatory cellular cascade by 
promoting the IL-1β production through NLRP3 activation pathway (Laudisi et al. 2013; 
Triantafilou et al. 2013). The mechanism of this non-lethal MAC toxicity has been suggested by 
the finding showing that once the MAC pore is formed in the cell, there is an increased influx of 
Ca2+ ions into the cytosol followed by Ca2+ accumulations in the mitochondrial matrix (Morgan et 
al. 1986; Triantafilou et al. 2013). These intracellular Ca2+ deposits are in turn shown to induce 
the NLRP3 assembly, leading to caspase 1 activation and IL-1β secretion (Triantafilou et al. 2013).  
There is a line of evidence that a dysregulation of the classical complement pathway is implicated 
in the course of AD. The initial studies on complement activation in AD brains revealed that senile 
plaques, tangles and dystrophic neurites are immunopositive for the C1q, C3b, C4d, indicative of 
the classical complement cytolytic pathway activation, but immune-negative for the Bb fragment 
of Factor B and properdin, which are markers of the alternative pathway (McGeer et al. 1989; 
Rogers et al. 1992). Also, the C5b-9 representing the MAC, indicative of the full-blown 
complement activation, has been shown to stain only the dystrophic neurites of senile plaques as 
well as tangles (Rogers et al. 1992). More importantly, it has been speculated that Aβ peptide can 
self-activate the classical component cascade in an antibody-independent fashion (Rogers et al. 
1992), and therefore under the AD conditions characterised by the abundance of Aβ species can 
be considered as a reservoir of the chronic neurotoxicity for the AD brain tissue. Consistent with 
this hypothesis, in vitro studies showed that C1q can recognize fibrillar and aggregated forms of 
Aβ1–42 and Aβ1–40, but not the monomeric forms. Since the C1q receptor is expressed in microglia, 
there is a hope that the increased expression of this molecule in AD brains might modulate the Aβ 
phagocytosis (Meraz-Rios et al. 2013). Specifically, some studies in cell cultures and mouse 
models indicate the ability of C1q to block the interaction of Aβ with microglia possibly by the  
scavenger  receptor ligands polyinosinic  acid and maleylated-bovine serum albumin (BSA), and 
therefore inhibiting the phagocytosis of Aβ by microglia (Webster et al. 2000). Additionally, 
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microglia also produce C3 molecules. The study on an AD APP transgenic mice deficient for C3 
component revealed the beneficial role of C3 in the enhanced Aβ clearance and the ability to shift 
the pro-inflammatory M1 microglial response to M2 phenotype (Maier et al. 2008). 
2.2. State-of-the-art imaging techniques in the study of 
Alzheimer’s disease brains  
According to a hypothetical temporal model indicating 5 AD biomarkers (Jack et al. 2013), 
amyloid PET imaging of living human brains is the earliest clinical marker for AD diagnosis, 
classifying the deposition of Aβ in amyloid plaques as a first detectable event in AD 
pathogenesis (see Fig. 2.3 for details). 
 
Fig. 2.3: A hypothetical temporal model reporting 5 AD biomarkers. Reproduced from (Selkoe and Hardy 2016) 
under the terms of the CC BY 4.0 license. 
This in vivo imaging technique measures the uptake of amyloid PET tracers in brains, which are 
associated with fibrillar Aβ accumulations (Fleisher et al. 2011; Sojkova et al. 2011). The 
mechanism of the PET tracer (or radioactive isotope) usage to probe fibrillar Aβ burden in living 
brains can be explained as follows. Practically, two most common radionuclides with short half-
life time which is widely used in PET are fluorine-18 [18F] (~110 min) and carbon-11 [11C] 
(~20 min). 18F is an unstable radioactive isotope that decays to a stable oxygen-18 [18O] isotope, 
resulting in production of numerous positrons: 
 𝐹 → 𝑂 + 𝑒+ + 𝜈𝑒8
18
9
18  (2.1) 
Similarly, 11C decays to a stable boron-11 [11B] isotope: 
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 𝐶 → 𝐵 + 𝑒+ + 𝜈𝑒5
11
6
11  (2.2) 
These radioactive isotopes are used as a neuroimaging PET tracer designed to bind fibrillar 
amyloid in human brains, known as amyloid probe. In amyloid PET imaging, the amyloid probe 
is injected into the human body followed by brain incorporation, where the radioactive agent binds 
brain amyloid and undergoes transition to a stable form, resulting in positron 𝑒+ emission.  Then, 
the collision of the emitted positrons with electrons generates the bursts of γ-radiation, that are 
detected by PET scan. This principle is used for 3D PET image reconstruction, which retrieves 
amyloid concentration profiles in the brain. Although amyloid PET scan is a non-invasive 
technique that quantifies fibrillar amyloid burden in AD brains, it is a relatively expensive to 
perform: each PET scan costs $1000-1200 US dollars. 
In the model of 5 dynamic AD biomarkers (Jack et al. 2013), Aβ biomarkers measured by amyloid 
PET imaging are indicated as upstream, which permit the detection of the first pathological 
processes in AD human brains (see also Fig. 2.3 for details). Neurodegenerative biomarkers in 
turn are denoted as downstream, which can identify the signs of abnormal neuronal 
hypometabolism, triggered by progressive Aβ pathology and occurring roughly 10 years before 
the expected symptom onset (Bateman et al. 2012) (see Fig. 2.3 for details). Specifically, 
hypometabolism on [18F] fluorodeoxyglucose PET (FDG-PET) are used as a measure of 
neurodegeneration (Jagust et al. 2010). FDG PET neuroimaging postulates that high radioactivity 
is associated with brain activity. This is achieved by measuring the uptake of radioactively labelled 
glucose or oxygen by brain cells with FDG. Since neurodegenerative processes lead to reduced 
metabolism of glucose and oxygen in AD brains, FDG-PET can be used to differentiate AD from 
other types of dementia.  
Of other imaging tools available to detect pathological changes in AD brains, fluorescence 
microscopy identified the elevated accumulations of cholesterol in cores of mature Aβ 
plaques (Mori et al. 2001). However, this technique involves labelling the biomolecules of interest, 
and therefore is limited to study the chemical species, for which antibody is available. Furthermore, 
fluorescence microscopy does not allow to investigate the total chemical composition of the 
sample. Importantly, tagging can disturb the chemical structure of fragile lipids-amyloid co-
arrangements. Among spectroscopy techniques, Mass Spectrometry (MS) provides chemical 
information on a broad range of biomolecular constituents, but requires sample ionization, 
involving chemical extraction of lipids from tissue sample. For instance, Liquid Chromatography-
MS (LC-MS) revealed an increased level of diacylglycerol (+80%), glucosylceramide (+43%) and 
galactosylceramide (+33%), as well as decreased phosphatidylethanolamine (-25%) in the 
prefrontal cortex of AD human brains compared to controls. Furthermore, the entorhinal cortex of 
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AD individuals showed the elevated accumulations of  lysobisphosphatidic acid (+82%), 
sphingomyelin (+20%), ganglioside GM3 (ceramide-N-tetrose-N-acetylneuraminic acid) (+64%), 
and cholesterol esters (CEs) (+72%) in the form of CE-16:1, CE-16:0, and CE-18:1, associated 
with lipid droplets (Chan et al. 2012). In relation to MS-based imaging techniques, Matrix-
Assisted Laser Desorption Ionization (MALDI) and Secondary-Ion Mass Spectrometry (SIMS) 
have been applied to ex vivo imaging of lipid, proteins and metals in brains (Grasso 2011; Braidy 
et al. 2014). Note, MALDI is limited by low spatial resolution of about 30-50 µm, whereas SIMS 
allows to achieve sub-micron resolution.   However, both techniques are sample destructive, 
involving the partial degradation of a sample, and therefore cannot be applied to living brains. By 
detecting the intrinsic vibrations of chemical bonds in molecules, vibrational micro-spectroscopy 
techniques such as infrared absorption (Liao et al. 2013; Benseny-Cases et al. 2014) and Raman 
scattering microscopy (Diem 2015; Krafft et al. 2016) are non-invasive label-free chemically 
specific imaging approaches. However, infrared microscopy has limited spatial resolution due to 
the long wavelength of the infrared light. In contrast, Raman micro-spectroscopy can achieve sub-
micron spatial resolution by applying light source of the visible range. Notably, a non-linear 
version of Raman micro-spectroscopy, coherent Raman scattering (CRS) microscopy shows 
additional enhancement in 3D spatial resolution due the multiphoton nonlinearity as well as faster 
acquisition speed compared to spontaneous Raman, and has been recently applied to examination 
of post-mortem brain tissues (Freudiger et al. 2008; Kiskis et al. 2015; Lee et al. 2015). 
Specifically, coherent anti-Stokes Raman scattering (CARS) micro-spectroscopy has been 
recently utilized to investigate lipid-amyloid co-arrangements in AD human brains (Kiskis et al. 
2015). However, the spectral profiles measured by CARS do not resemble Raman spectra due to 
the interference between the vibrationally resonant and non-resonant parts of the third-order CARS 
susceptibilities, thus complicating their interpretation. Furthermore, the results on the chemical 
composition of brain tissues using CRS microscopy has been reported only in the CH-stretch 
vibrational region (2700-3100 cm−1), which contain more overlaid vibrational bands compared to 
the fingerprint region complicating their assignment and interpretation. In relation to confocal 
Raman micro-spectroscopy, several studies have recently reported the chemical profiles of AD 
brains (Michael et al. 2014; Michael et al. 2017), revealing the sensitivity of confocal Raman to 
detect the pathogenic β‐sheet chemical structure of amyloid fibrils and tau tangles both implicated 
in AD. Although these studies showed the spatial distribution of β-sheet structured protein of Aβ 
plaques by integrating Raman intensity of the amide-I peak in the range (1649, 1698) cm-1, such 
Raman imaging does not represent an individual chemical substance such as fibrillar amyloid.  
Altogether, Raman micro-spectroscopy is a useful technique complementary to the conventional 
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approaches for molecular characterization and chemical imaging of pathogenic proteins and lipids 
in AD brain tissues without any labelling and high spatial resolution.  
2.3. Multivariate unmixing analysis for micro-spectroscopy 
images 
Over the past few decades, the progress in multivariate image analysis methods allowed to 
efficiently quantify the biochemical information from spectroscopic images. Specifically, 
spontaneous Raman micro-spectroscopy data have been processed using multivariate image 
reconstruction methods (Miljkovic et al. 2010; Krafft et al. 2017), such as Principal Component 
Analysis (PCA), Hierarchical Cluster Analysis (HCA), and K-Means cluster 
Analysis (KMA) (Zhang et al. 2005; Filik and Stone 2008; Krafft et al. 2016; Czamara et al. 2017; 
Michael et al. 2017), aiming to separate the data into convoluted spatially resolved spectra that 
represents molecular vibrations from multiple species. However, the resulting images represent 
variance rather than the Raman intensities of individual biochemical compounds in the sample 
composition, making these methods less quantitative. 
Raman data have also been analysed using Vertex Component Analysis (VCA) (Hedegaard et al. 
2011) and Multivariate Curve Resolution (MCR) (Andrew and Hancewicz 1998; Zhang et al. 
2005; Piqueras et al. 2011; Vajna et al. 2012), which is also known as Non-negative Matrix 
Factorization (NMF) (Albuquerque and Poppi 2015). Compared to VCA requiring the presence of 
pixels with pure biochemical compounds, MCR/NMF does not imply this constraint, therefore 
providing broader chemical and biomedical applications.  
In relation to CRS micro-spectroscopy (Camp and Cicerone 2015; Cheng and Xie 2015), CARS 
and Stimulated Raman scattering (SRS) images have been analysed by PCA (Lin et al. 2011), 
cluster analysis based on spectral phasor approach (Fu and Xie 2014), MCR (Zhang et al. 
2013)  and NMF (Di Napoli et al. 2016) both based on the Alternating Non-negativity-constrained 
Least Squares algorithm (ANLS).   In contrast to PCA and HCA, MCR/NMF are more quantitative 
techniques, allowing to retrieve molecular fingerprints of physically meaningful chemical 
components in the sample composition. To note, CARS intensity spectra do not resemble in line-
shape Raman-like vibrational bands but rather contain maxima and minima of intensity due to the 
interference between the vibrationally resonant and non-resonant part of the third-order CARS 
susceptibilities (Diem 2015). Therefore, CARS data analysis requires appropriate computational 
methods (Liu et al. 2009) to extract the Raman line-shape spectra prior to application of 
multivariate hyperspectral unmixing approaches as documented above. 
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It is important to note that the widely used MCR-ANLS method (Jaumot et al. 2015) utilizes 
computationally inefficient realization of the non-negative least squares (NLS) algorithm, which 
performance can be orders of magnitude slower compared to the NMF method based on fast 
combinatorial non-negativity-constrained least squares (FC-NNLS) (Van Benthem and Keenan 
2004; Kim and Park 2007). This is because the conventional formulation of NLS 
algorithm (Lawson and Hanson 1995) is intended to work with a non-negative right hand-
side (RHS) vector. Therefore, the multiple-RHS problem should be split into several (equal to the 
number of RHS vectors) independent sub-problems. In practice, by alternative dividing of the 
hyperspectral data matrix into either columns representing wavenumbers or rows corresponding 
to pixels, one can apply the standard NLS algorithm to the divided data matrix resulting in the 
quantified chemical information in the hyperspectral image. While this approach is 
straightforward, it tends to be computationally inefficient, because it can result in redundant 
calculations, which is particularly important for large-scale data analysis. For example, careful 
analysis of a typical Raman data-set (≃ 50 × 50 × 103 matrix) using popular MCR-ANLS 
software (Jaumot et al. 2015) and involving investigation of its dependence on the number of 
components leads to processing time of several days as performed on a standard PC. This becomes 
even worse for large-scale data analysis of multi-set Raman images (≃ 103 × 103 × 103 matrix) 
resulting in extremely long computational times of years. Thus, the development of fast 
multivariate image unmixing methods, which shorten processing times of large-scale data analysis 
to hours without compromising the accuracy, is highly demanding.  
Aims of the PhD thesis: 
Consistent with a large body of evidence outlined in the literature review, the long-standing model 
for Aβ-related AD pathogenesis requires further consideration and investigation, which explore 
specific innate immunity and lipid pathways that might be activated in response to chronic Aβ 
aggregation and play a role in spreading AD pathology. Furthermore, the development of novel 
brain imaging biomarkers with illness-state dependence are highly desirable for the AD diagnosis. 
To identify specific inflammatory components of the innate immune system and lipid types 
involved in Aβ amyloidosis, I will study human brain slices from AD patients, together with a 
'control' cohort of elderly humans without AD using Raman micro-spectroscopy and high-
resolution fluorescence microscopy. Therefore, the general aim of my PhD thesis is the 
biomolecular characterization and chemical imaging of the AD tissues and non-demented controls, 
with a focus on imaging of Aβ plaques and their pathological biochemical microenvironment. 
According to this aim, the following research challenges can be outlined: 
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1. Label-free Raman micro-spectroscopy imaging of fixed paraffin-embedded brain slices from 
AD patients together with non-demented controls to show statistically significant changes in 
chemical composition of the diseased brain tissues compared to controls. Along with abundant 
Aβ deposits, I hypothesise the chemical composition of AD brains will be characterised by 
increased accumulations of specific types of lipids as well as biomarkers associated with 
neuroinflammation co-localising with Aβ plaques (Chapter 5). 
2. 3D Raman micro-spectroscopy imaging of unfixed frozen brain slices from AD patients 
together with non-demented controls to identify and demonstrate 3D distribution of key 
chemical components of diseased brains compared to controls as well as strengthen the 
findings received in the previous chapter (Chapter 6). 
3. Correlative fluorescence imaging of specific immunolabelled pathogenic proteins (ASC 
specks and Aβ1-42) and Iba-1-labelled microglia in fixed paraffin-embedded brain slices from 
AD patients to link amyloid aggregation and defective microglia-mediated Aβ clearance to 
specific inflammatory pathways (Chapter 7). 
4. Correlative fluorescence imaging of specific immunolabelled inflammatory markers (ASC 
specks and MAC) and Aβ1-42 in fixed paraffin-embedded brain slices from AD patients to 
better understand the mechanism how activated complement components can affect amyloid 
clearance (Chapter 8). 
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Chapter 3. Theoretical framework 
3.1. Formulation of hyperspectral image unmixing problem 
3.1.1. Forward scattering problem 
To introduce the hyperspectral image unmixing analysis, I will start with the presentation of 
forward scattering problem in this section, that can be formulated as the following research 
question.  Given the specimens consist of a mixture of 𝑁 pure chemical components with known 
individual Raman scattering cross-section spectra1 𝑆𝑖(𝜈), 𝑖 = 1,  2, … , 𝑁 and known spatial 
distributions of concentration 𝐶𝑖(𝐫), find a Raman intensity matrix 𝐼(𝐫; 𝜈) from 𝑆𝑖(ν) and 𝐶𝑖(𝐫). 
Here, ν represents a Raman shift and 𝐫 = (𝑥, 𝑦; 𝑟) is a radius vector indicating the image pixel 
with coordinates (𝑥, 𝑦) in the 𝑟th Raman image. 
Mathematically, this Raman intensity matrix 𝐼(𝐫; ν) can be represented as a superposition of the 
spatial distributions of concentration multiplied by corresponding pure spectra of the chemical 
constituents of the specimens: 
 
𝐼(𝐫; ν) = ∑ 𝐶𝑖(𝐫)𝑆𝑖(ν)
𝑁
𝑖=1
. (3.1) 
This equation gives the solution of the forward scattering problem, which can be calculated using 
basic approaches of linear algebra. 
3.1.2. Inverse scattering problem 
For a broad range of biomedical applications, it is necessary to identify the composition of samples 
without prior knowledge of their chemical content. Mathematically, this represents the inverse 
scattering problem, that can be formulated as follows. Given a Raman intensity matrix 𝐼(𝐫; ν), 
decompose it into N separate chemical components having individual Raman spectra 𝑆𝑖(ν) and 
spatial concentration 𝐶𝑖(𝐫) profiles. Additionally, if one or several Raman spectra 𝑆𝑖(ν) and/or 
concentration profiles Ci(r) are a priori known, this problem reduces to finding the rest of the 
spectral and concentration profiles of samples’ constituents. 
In typical point-scan Raman experiment, hyperspectral image is collected by raster scanning the 
sample through the focal point of the laser beam, and therefore the Raman dataset consists of the 
discrete coordinates 𝑥, 𝑦 and wavenumbers ν: 𝑥 = {𝑥𝑖:   𝑖 = 1,2, … , 𝑁𝑥(𝑟)}, 𝑦 = {𝑦𝑖:   𝑖 =
 
1 In the following, I will omit “scattering cross-section” for brevity 
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1,2, … , 𝑁𝑦(𝑟)}, ν = {ν𝑖:   𝑖 = 1,2, … , 𝑁𝑠}. Here, 𝑁𝑥(𝑟) and 𝑁y(𝑟) are a number of pixel points in 
the 𝑟th Raman image along 𝑥- and 𝑦-axes, respectively, and 𝑁𝑠 is a number of spectral points in 
this image. Also, a set of radius vectors 𝐫 = {𝐫𝑖:   𝑖 = 1,2, … , 𝑁𝑝}, where 𝑁𝑝 = ∑ 𝑁𝑥(𝐫)𝑁𝑦(𝐫)
𝑁𝑟
𝑟=1  
is a total number of pixel points and 𝑁𝑟 is a total number of hyperspectral images, can be created. 
This notation leads to the representation of the Raman intensity 𝐼(𝐫; 𝜈), spatial concentrations 
𝐶𝑖(𝐫) and spectra 𝑆𝑖(ν) as matrices 𝐼𝑖𝑗 = 𝐼(𝐫𝑖; ν𝑗), 𝐶𝑖𝑗 = 𝐶𝑖(𝐫𝑗), 𝑆𝑖𝑗 = 𝑆𝑖(ν𝑗), and expression 
Eq. (3.1) into the matrix form 
 𝐈 = 𝐂T𝐒, (3.2) 
where the superscript  T means matrix transpose. 
From here on, I will use both matrix and explicit forms of the Raman intensity, concentration, and 
spectra. 
Importantly, the inverse scattering problem aims to find unknown chemical composition from the 
Raman images using unsupervised hyperspectral image unmixing techniques, and therefore the 
problem of unknown image information retrieval is limited by the inability to detect the true 
concentrations of analytes.  However, such image analysis allows to determine the concentrations 
of analytes up to a constant factor, which can be measured in Raman experiment for each 
individual analyte. In particular, once the Raman spectrum 𝑆𝑖
0(ν) of pure chemical substance 
(identified as a component from the hyperspectral image unmixing analysis) with the known 
chemical concentration 𝑐𝑖 is measured, one could retrieve the chemical concentration of the analyte 
by multiplying its concentration profile 𝐶𝑖(𝐫) by a calibration factor 𝑐𝑖 ∫ 𝑆𝑖(ν)𝑑ν/ ∫ 𝑆𝑖
0(ν)𝑑ν. 
Therefore, in the course of my thesis, I will use the term “Raman concentration” instead of 
“chemical concentration”, because calibration factors were unknown for my Raman datasets. 
3.2. Singular Value Decomposition with Automatic Divisive 
Correlation (SVD-ADC) for noise filtering 
3.2.1. Formulation of SVD-ADC 
As documented in the literature, a standard formulation of Singular Value Decomposition (SVD) 
method (Golub and Van Loan 2013) applied to hyperspectral Raman images has been used to 
separate signal from noise by discarding small singular values and their corresponding singular 
vectors (scores and loadings) from further analysis (Uzunbajakava et al. 2003). Mathematically, 
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SVD algorithm in application to hyperspectral Raman intensity matrix 𝐈 projects the data into a 
new spatio-spectral orthonormal basis consisting of scores 𝐶𝑖(𝐫) and loadings 𝑆𝑖(ν) 
 𝐼(𝐫; ν) = ∑ 𝐶𝑖(𝐫)𝜆𝑖𝑆𝑖(ν)
𝑖∈𝑁
, (3.3) 
which is sorted by their descending singular values λ𝑖. 
Here, 𝑁 = {1,2, … ,rank(𝐈)} and 𝐶𝑖(𝐫) ⋅ 𝐶𝑗(𝐫) = 𝑆𝑖(𝜈) ⋅ 𝑆𝑗(𝜈) = 𝛿𝑖𝑗, where the dots indicate 
Euclidean scalar products. For this, I use the notation of Euclidean scalar product for two vectors 
𝑆𝑖(ν) and 𝑆𝑗(ν) (or 𝐶𝑖(r) and 𝐶𝑗(𝐫)) as follows: 
 
𝑆𝑖(ν) ⋅ 𝑆𝑗(ν) = ∑ 𝑆𝑖(ν𝑘)𝑆𝑗(ν𝑘)
𝑁𝑠
𝑘=1
 (3.4) 
 
𝐶𝑖(𝐫) ⋅ 𝐶𝑗(𝐫) = ∑ 𝐶𝑖(𝐫𝑘)𝐶𝑗(𝐫𝑘)
𝑁𝑝
𝑘=1
 (3.5) 
In a matrix form, Eqs. (3.4)-(3.5) can be rewritten as follows: 
 
𝑆𝑖(ν) ⋅ 𝑆𝑗(ν) = ∑ 𝑆𝑖𝑘
𝑁𝑠
𝑘=1
𝑆𝑗𝑘, (3.6) 
 
𝐶𝑖(𝐫) ⋅ 𝐶𝑗(𝐫) = ∑ 𝐶𝑖𝑘
𝑁𝑝
𝑘=1
𝐶𝑗𝑘 . (3.7) 
It is suggested that chemically meaningful components have significantly higher singular values 
than noisy ones (Uzunbajakava et al. 2003).  
However, sometimes, the meaningful chemical information is in the components with the smallest 
concentration, implying that selection of the optimum number of components is the main 
disadvantage of SVD. Such meaningful components might be colocalized in a small area of the 
image and therefore might correspond to small singular values that potentially will be filtered out 
during SVD leading to compromised results. It is therefore important that singular vectors (scores 
and loadings) with small singular values containing meaningful chemical information will be 
retained after SVD. As shown in (Lobanova and Lobanov 2019), such meaningful components 
appear to exhibit high values of autocorrelation function for small pixel shifts indicating that 
autocorrelation function provides more accurate sorting of the chemical information in the image. 
Altogether, selection of the optimum number of components in the SVD procedure should be 
considered very carefully. 
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As discussed in (Lobanova and Lobanov 2019), in case a chemical component is localised in a few 
pixels but exhibits distinct Raman spectral profile, which is equivalent to having a high value of 
spectral autocorrelation function, SVD might treat it as a singular component with small singular 
value and, therefore, this component will potentially be discarded from the further analysis. 
Therefore, autocorrelation function appears to be more reliable for assessing singular components 
than singular values.  
To overcome this limitation of conventional SVD, recently SVD in a new formulation, called SVD 
with Automatic Divisive Correlation (SVD-ADC), has been proposed (Lobanova and Lobanov 
2019). This method implements an additional step once SVD is performed, i.e.: for individual 
loadings 𝑆𝑖(ν) and scores 𝐶𝑖(𝐫) spectral 𝑅𝑖
𝑆and spatial 𝑅𝑖
𝐶 autocorrelation coefficients at one pixel 
shift are calculated 
 𝑅𝑖
𝑆 = 𝑅[𝑆𝑖(ν), 𝑆𝑖
δ(ν)], (3.8) 
 𝑅𝑖
𝐶 = max
𝛅
𝑅 [𝐶𝑖(𝐫), 𝐶𝑖
𝛅(𝐫)], (3.9) 
where 𝑅[… ] denotes correlation coefficient, which can be represented according to the following 
equations: 
 
𝑅[𝑆𝑖, 𝑆𝑖
δ] =
|∑ (𝑆𝑖𝑘 − 𝑆𝑖) (𝑆𝑖𝑘
δ − 𝑆𝑖
δ)𝑘 |
√∑ (𝑆𝑖𝑘 − 𝑆𝑖)
2
𝑘
√∑ (𝑆𝑖𝑘
δ − 𝑆𝑖
δ)
2
𝑘
, (3.10) 
 
𝑅[𝐶𝑖, 𝐶𝑖
𝛅] =
|∑ (𝐶𝑖𝑘 − 𝐶𝑖) (𝐶𝑖𝑘
𝛅 − 𝐶𝑖
𝛅)𝑘 |
√∑ (𝐶𝑖𝑘 − 𝐶𝑖)
2
𝑘
√∑ (𝐶𝑖𝑘
𝛅 − 𝐶𝑖
𝛅)
2
𝑘
, (3.11) 
where 𝑆𝑖
δ(ν) are loadings with “one” spectral point shift, i.e. 𝑆𝑖
δ(ν𝑘) = 𝑆𝑖(ν𝑘+δ), and 𝐶𝑖
𝛅(𝐫) – 
scores with one image pixel shift along 𝑥- [𝛅 = (δ𝑥, 0)] or 𝑦-axis [𝛅 = (0, δ𝑦)], i.e. 
𝐶𝑖
(δ𝑥,δ𝑦) (𝐫𝑘) = 𝐶𝑖(𝐫𝑘 + (δ𝑥, δ𝑦)). 
Therefore, SVD-ADC is intended to automatically sort the meaningful components from noise-
dominated ones (e.g.: shot noise, read noise, residual noise after cosmic ray removal, etc.). For 
this, by mapping spatial autocorrelation coefficients 𝑅𝑖
𝐶 against spectral ones 𝑅𝑖
𝑆 for individual 
scores/loadings, one discard the singular components corresponding to mean autocorrelation 
coefficient 𝑅𝑖 = (𝑅𝑖
𝐶 + 𝑅𝑖
𝑆)/2 lower than 𝑅thr = 50%. Then, by replacing the set 𝑁 in Eq. (3.3) 
by the new set 𝑁thr = {𝑖: 𝑅𝑖 > 𝑅thr} and performing the required summation, the Raman intensity 
matrix with reduced noise is found.  
47 
 
3.2.2. Validation of SVD-ADC 
In (Lobanova and Lobanov 2019), it has been verified that SVD-ADC with the 50% cut-off 
efficiently differentiates the meaningful components from the noise-dominated ones on one 
simulated and two biochemical Raman datasets:  
Dataset 1: a superposition of Gaussian functions resembling Raman-like signal superimposed by 
a background; 
Dataset 2: Raman spectra of known mixtures of 8 pure chemical compounds (sphingomyelin, β-
carotene, collagen, cholesteryl palmitate, elastin, iron transferrin, cholesterol, and iron (III) oxide) 
with simulated random spatial distribution of concentration superimposed by white Gaussian 
noise; 
Dataset 3: large-scale Raman hyperspectral images of human atherosclerotic aortic tissues and 
corresponding non-atherosclerotic controls, consisting of both high and low concentrated 
biochemical compounds. 
For Dataset 2, white Gaussian noise 𝐈n was added to the intensity matrix composed of the chemical 
mixture of pure Raman spectra 𝐈mR. Then, SVD-ADC filtering procedure with no input parameters 
was applied to the resulting matrix 𝐈 = 𝐈mR + 𝐈n. The results of this verification confirm that SVD-
ADC allowed to significantly remove noise from the Raman data and resulted in the denoised 𝐈R 
matrix with reduced noise by two orders of magnitude (NRF ≃ 0.01) as evident by Fig. 3.1A. 
Here, signal-to-noise ratio (SNR) and noise removal factor (NRF) were defined as follows: 
 
SNR =
‖𝐈mR‖F
2
‖𝐈n‖F
2  (3.12) 
 
NRF =
‖𝐈R − 𝐈mR‖F
2
‖𝐈n‖F
2  (3.13) 
The efficiency of SVD-ADC is also demonstrated in Fig. 3.1B by the distribution of spatio-spectral 
autocorrelation coefficients for singular vectors retrieved from SVD-ADC for SNR = 10. This 
autocorrelation map validates localization of singular vectors representing noise (cross signs) 
around the origin of coordinates in contrast to highly correlated singular vectors assigned to 
meaningful components (circled cross signs) located at the upper-right corner. Thus, the 
meaningful components are filtered from noise-dominated ones by the dashed diagonal line 
representing Rthr =  50%. 
Furthermore, the accuracy of SVD-ADC is confirmed by Fig. 3.1C, showing that the denoised 
Raman spectrum 𝐈R (red dashed line) is almost indistinguishable from the reference one 𝐈mR (grey 
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line), even when the noise in the input Raman spectrum (blue line) is comparable with the Raman 
signal. 
 
Fig. 3.1: Comparison of the SVD-ADC (A, blue line) method with MNF + S-G filtering (A, magenta line) using 
the Raman data of biochemical standard mixtures with white Gaussian noise (C, blue line), showing the efficiency 
of the SVD-ADC to reduce noise from the Raman data by 98% and resulting in denoised Raman spectra (C, red 
dashed line) to be almost identical to the reference one (C, grey line). The autocorrelation coefficients map of 
singular vectors received from SVD-ADC analysis of the given Raman data is shown in panel B. The green dashed 
diagonal line represents a decision line of a 50% cut-off for mean autocorrelation coefficients, that separates the 
coefficients above the line (circled cross signs – meaningful components) from those below it (cross signs – noise). 
Furthermore, SVD-ADC was compared with Maximum Noise Fraction (MNF) method (Green et 
al. 1988) combined with Savitzky-Golay (S-G) filtering (Savitzky and Golay 1964) as shown 
in (Lobanova and Lobanov 2019). In particular, Dataset 2 was processed using MNF and then N 
eigenimages ordered according to decreasing Signal-to-Noise Ratio (SNR) (or reducing image 
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quality) were used. The rest eigenimages were denoised using S-G filtering with two smoothing 
parameters: polynomial order and frame length. For this, optimization over these 3 parameters for 
each SNR, which minimizes denoising error, was performed. Finally, the application of inverse 
MNF to reduced noise eigenimages gives the resulting denoised data. As shown in Fig. 3.1A, both 
methods provide comparable NRF for noise-dominated data with SNR from the range (0.01,  1). 
However, when SNR is higher than 10, MNF allowed to reduce noise by just 80% (NRF = 20%), 
in contrast to SVD-ADC allowing to receive 98% of noise removal (NRF = 2%).  
Importantly, the selection of optimal parameters for MNF and S-G filtering is only achievable 
when the true solution is known. In contrast, SVD-ADC method provides autonomous reduction 
of noise from the hyperspectral Raman data with no input parameters. 
Altogether, the SVD-ADC approach, proposed in (Lobanova and Lobanov 2019), utilises 
autocorrelation coefficients of spatial and spectral singular vectors for noise filtering and allows 
to autonomously remove noise from Raman data with no input parameters. 
3.3. Bottom Gaussian Fitting (BGF) for background 
subtraction 
Raman spectra from tissue samples embedded on a standard glass slide typically exhibit an intense 
broad background associated with the fluorescence and amorphous scattering contributions from 
glass substrate and sample itself. Therefore, baseline correction algorithms via polynomial 
functions of different orders (Hirokawa 1980; Baek et al. 2009) and Asymmetric Least Squares 
(AsLS) method (Eilers 2003; Eilers 2004) are widely applied to hyperspectral image analysis for 
background correction (Peng et al. 2010; Piqueras et al. 2011; Albuquerque and Poppi 2015; 
Felten et al. 2015). 
However, polynomial baseline removal methods in application to hyperspectral Raman images 
might be limited by low reproducibility of the results and a large number of factors, which 
significantly affect accuracy (Jirasek et al. 2004). In contrast, AsLS is considered to be a relatively 
accurate and automated method for background correction of hyperspectral Raman data (Felten et 
al. 2015). 
It is important to note that the AsLS method involves the optimization over the smoothing λ and 
asymmetric 𝑝 parameters, which can result in a fluorescent background being higher than 
measured Raman intensity, ultimately leading to negative non-physical Raman signal. 
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3.3.1. Formulation of BGF 
In order to overcome the limitations of the AsLS method, a new algorithm, Bottom Gaussian 
Fitting (BGF), has been recently proposed and provides autonomous and accurate subtraction of a 
complex curved background from Raman micro-spectroscopy data (Lobanova and Lobanov 
2019). 
Compared to AsLS, BGF uses only one intuitive parameter, which has units of Raman 
wavenumbers (cm-1) and indicates minimum width of broad background features. 
The principles of this mathematical approach are proposed in (Lobanova and Lobanov 2019) and 
explained in the following. 
The principle of this method is to perform background removal procedure independently for each 
image pixel 𝑖. Therefore, I will present a brief theory of BGF using only the second index in the 
Raman intensity matrix 𝐈𝑖𝑗 labelling wavenumber, i.e. 𝐈𝑗 . 
The Raman intensity I can be split into two non-negative parts 
 I = IR + IB, (3.16) 
where IR represents Raman signal and 𝐈B is a fluorescent background. 
The method aims to find 𝐈B as a quasi-superposition of Gaussian functions with standard 
deviations (STD) larger than σ – the only one parameter that will be used for background 
subtraction. 
By fixing some Raman shift ν𝑗, one could find maximum possible background intensity at this 
point 𝐼𝑗
B. Fig. 3.2 illustrates the principle of this search for the case of one narrow Raman peak 
(STD<𝜎) superimposed by a broad fluorescent background (STD>𝜎) both modelled as a Gaussian 
function. The figure contains a series of Gaussian functions (green, red, and magenta lines) with 
varying amplitude 𝐴 and expectation value μ but fixed STD σ. Comparing values of these lines at 
the point 𝜈𝑗, one finds that magenta Gaussian function has maxim value at this point. However, 
this line cannot be used as a background because it crosses the Raman intensity I and, therefore, 
do not fit it from the bottom. The green line does not cross the Raman intensity I, but its value is 
not maximum at the point 𝜈𝑗. Only the red solid line tangents the Raman spectrum I (fits from the 
bottom) and appears to quantify the representative Raman intensity 𝐈R at the point ν𝑗. 
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Fig. 3.2: A schematic illustration showing a principle of BGF method used for background subtraction from Raman 
signal.  
Mathematically, since the background intensity 𝐈B tangents the Raman intensity 𝐈, it should be 
determined as a Gaussian function 𝐺σ(ν𝑗; ν𝑖, 𝐼𝑖, ν𝑘 , 𝐼𝑘) of STD σ, which goes through left- (ν𝑖 , 𝐼𝑖) 
and right-sided (ν𝑘, 𝐼𝑘) points of the Raman intensity 𝐈 corresponding to the considered Raman 
shift ν𝑗. 
Furthermore, the tangent background fit IB (red solid line) has minimum Raman intensity value at 
the point ν𝑗 compared to the red dotted and magenta lines. 
Therefore, the bottom Gaussian fit can be defined as 
 𝐼𝑗
𝐵 = min
𝑖≤𝑗≤𝑘
𝐺𝜎(𝜈𝑗; 𝜈𝑖, 𝐼𝑖, 𝜈𝑘, 𝐼𝑘), (3.17) 
where the Gaussian function 
 
𝐺σ(ν𝑗; ν𝑖 , 𝐼𝑖, ν𝑘, 𝐼𝑘) = 𝐴𝑒
−
(ν𝑗−μ)
2
2σ2  
(3.18) 
has amplitude 𝐴 and expected value μ, which are implicitly defined as follows: 
 
𝐴𝑒
−
(ν𝑖−μ)
2
2σ2 = 𝐼𝑖 , 𝐴𝑒
−
(ν𝑘−μ)
2
2σ2 = 𝐼𝑘. 
(3.19) 
Repeating the procedure in Eq. (3.17) for all Raman shifts ν𝑗, one can retrieve a quasi-smooth 
curve 𝐈B fitting the Raman signal 𝐈 from the bottom, so that the residual of these two curves (𝐈R =
𝐈 − 𝐈B) contains only sharp resonances representing Raman bands. 
Optionally, after the background-free Raman-like signal 𝐈R is found using BGF, the spatially-
resolved spectral auto-correlation coefficients for this matrix at one spectral point shift can be 
calculated. By discarding the spatial points, which have correlation values lower than 50%, from 
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the further analysis, one can achieve the partial elimination of spatial points, which are strongly 
distorted by noise due to dominated background, which might be orders of magnitude larger than 
the Raman signal. 
3.3.2. Validation of BGF 
In order to validate the accuracy of BGF, it was compared with AsLS algorithm (Eilers 2003; 
Eilers 2004) using Raman spectra 𝐈mR of biochemical mixtures with Gaussian background 
(Dataset 2) (Lobanova and Lobanov 2019). 
For this, the dependence of background removal relative error 
 
𝐸 =
max
𝑖𝑗
‖𝐼𝑖𝑗
R −𝐼𝑖𝑗
mR‖
max
𝑖𝑗
‖𝐼𝑖𝑗
mR‖
 (3.20) 
on the corresponding parameters of BGF (σ, red line with crosses) and AsLS (λ and fixed 𝑝 =
10−3, green line with pluses) has been investigated. The results show that BGF allows to achieve 
relative error of 7%, whereas AsLS provides 64% relative error (see Fig. 3.3A). Note, 𝐈R is a 
background-subtracted Raman signal found from BGF or AsLS. 
 
Fig. 3.3: Comparison of the BGF method with AsLS using the Raman data with known background (black dashed 
lines), showing the accurateness of the BGF to produce the true baseline (red lines) that subtract both low (B) and 
high (C) background. AsLS baselines are shown by green. 
Application of BGF to Raman spectra (blue lines) for two spatial pixels with low (B) and high (C) 
true background (black dashed lines) reveals that BGF performs equally accurate for low and high 
background (red lines), in contrast to AsLS, which might produce the baseline (green lines), 
significantly overfitting the original Raman signal and having non-physical negative values (see 
Fig. 3.3B-C). Note, Fig. 3.3B-C are demonstrated for the following optimal parameters found from 
Fig. 3A: σ = 449 cm-1 (BGF) and λ = 223, 𝑝 = 10−3 (AsLS). 
53 
 
Also, the BGF method has been verified on large-scale Raman micro-spectroscopy images from 
human tissues in atherosclerosis and simulated Raman data as described in (Lobanova and 
Lobanov 2019). 
3.4. Efficient Quantitative Unsupervised/Partially Supervised 
Non-negative Matrix Factorization (Q-US/PS-NMF) 
3.4.1. Formulation of Q-US/PS-NMF 
Applied to hyperspectral image analysis, NMF method (Paatero and Tapper 1994; Paatero 1997; 
Lee and Seung 1999; Lee and Seung 2001) is an unsupervised chemometric approach, allowing to 
factorise the spatially-resolved Raman intensity matrix 𝐈 into a superposition Eq. (3.2) of non-
negative spatial concentration 𝐂 multiplied by corresponding non-negative spectra 𝐒 of individual 
biochemical components of the samples’ composition. The aim of NMF is to find matrices 𝐂 and 
𝐒, which are unknown prior to factorization analysis. 
In (Lobanova and Lobanov 2019), NMF has been generalised to work as a partially supervised 
method, called Efficient Quantitative Unsupervised/Partially Supervised Non-negative Matrix 
Factorization (Q-US/PS-NMF). This development is beneficial for various biomedical 
applications, e.g. fixation of the spectrum of paraffin-wax compound during supervised NMF in 
the Raman intensity matrix measured on paraffin-embedded samples. This option allows to 
remove the contribution of paraffin-wax residues from the spectra of chemical components of 
actual samples’ composition.  
Mathematically, the problem can be formulated as follows. Assuming 𝑁𝑘 biochemical substances 
with Raman spectra 𝑆𝑖(ν), 𝑖 = 1, … , 𝑁𝑘 are known and I am aiming to find the rest 𝑁𝑢 = 𝑁 − 𝑁𝑘 
spectra 𝑆𝑖(ν), 𝑖 = 𝑁𝑘 + 1, … , 𝑁 together with the corresponding concentration profiles for both 
known and unknown components 𝐶𝑖(𝐫), 𝑖 = 1, 2, … , 𝑁. 
Let us denote known and unknown parts of the spectral matrix 𝐒 as 𝐒𝑘 and 𝐒𝑢, respectively. 
Corresponding parts of the concentration matrix 𝐂 can be also written as 𝐂𝑘 and 𝐂𝑢. Therefore, 
one can construct the following matrices 
 
𝐂 =  (
𝐂𝑘
𝐂𝑢
) , 𝐒 =  (
𝐒𝑘
𝐒𝑢
),  (3.14) 
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Mathematically, these matrices should satisfy Eq. (3.2). But, practically, the experimentally 
measured Raman intensity matrix 𝐈 can be decomposed with a residue E, known as a factorization 
error as follows 
  𝐈 − 𝐂T𝐒 = 𝐄. (3.15) 
The solution of this equation must minimise Frobenius norm of the residue ‖𝐄‖𝐹. In other words, 
the problem is reduced to finding two matrices 𝐂 and S which minimize the following function 
 
E(C, S) =
1
2
‖𝐈 − 𝐂TS‖𝐹
2  (3.16) 
subject to 𝐶𝑖𝑗 ≥ 0, 𝑆𝑖𝑗 ≥ 0. 
Since Eq. (3.16) has minimum at the point (𝐂, 𝐒), any deviation from this point must increase 
Frobenius norm of the residue, i.e. 𝐸(C+δC, S+δS) ≥ 𝐸(C, S) for any δC and δS subject to 𝐶𝑖𝑗 +
δ𝐶𝑖𝑗 ≥ 0 and 𝑆𝑖𝑗 + δ𝑆𝑖𝑗 ≥ 0. This means that variation of the factorization error 𝛿𝐸 ≡
𝐸(C+δC, S+δS) − 𝐸(C, S) at the point (𝐂, 𝐒) must be non-negative 
 
δ𝐸 = ∑ ∑
∂𝐸
∂𝐶𝑖𝑗
δ𝐶𝑖𝑗
𝑁𝑝
𝑗=1
𝑁
𝑖=1
+ ∑ ∑
∂𝐸
∂𝑆𝑖𝑗
δ𝑆𝑖𝑗
𝑁𝑠
𝑗=1
𝑁
𝑖=𝑁𝑘+1
≥ 0. (3.17) 
Furthermore, each term in Eq. (3.17) must be equal or greater than zero since variations δ𝐶𝑖𝑗 and 
δ𝑆𝑖𝑗 are arbitrary. 
In order to find a solution of Eq. (3.17), one can fix all elements in the matrices 𝐂 and 𝐒 except 
one element (for example, 𝐶12) and explore the dependence of the factorization error 𝐸(C, S) on 
this element (𝐶12). Fig. 3.4 shows the graph of this function which is parabola. Two possible cases 
are considered in Fig. 3.4. Specifically, blue parabola has a minimum at positive 𝐶12 in which its 
derivative is zero, i.e. ∂𝐸/ ∂𝐶12 = 0. Therefore, in order to satisfy Eq. (3.17), ∂𝐸/ ∂𝐶𝑖𝑗 must be 
zero for positive 𝐶𝑖𝑗. The green parabola has a minimum at negative 𝐶12, which is not permitted 
due to the non-negativity condition. Therefore, the constrained minimum must be translated to the 
nearest non-negative point, which is zero. Thus, ∂𝐸/ ∂𝐶𝑖𝑗 must be non-negative for 𝐶𝑖𝑗 = 0 in 
order to satisfy Eq. (3.17). 
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Fig. 3.4: Dependence of the factorisation error 𝛿𝐸(𝐶11, 𝐶12, 𝐶13, . . . , 𝑆11, 𝑆12, . . . ) on the element 𝐶12 for fixed other 
elements. 
These non-negativity requirements are known as the Karush-Kuhn-Tucker conditions (Lawson 
and Hanson 1995) 
  ∂𝐸/ ∂𝐶𝑖𝑗  =  0 if 𝐶𝑖𝑗 > 0, ∂𝐸/ ∂𝐶𝑖𝑗 ≥ 0 if 𝐶𝑖𝑗  =  0, (3.18) 
  ∂𝐸/ ∂𝑆𝑖𝑗  =  0 if 𝑆𝑖𝑗 > 0, ∂𝐸/ ∂𝑆𝑖𝑗 ≥ 0 if 𝑆𝑖𝑗  =  0. (3.19) 
Note, Eq. (3.19) must be fulfilled only for unknown spectra, i.e. 𝑖 > 𝑁𝑘. 
By differentiating Eq. (3.16), one can find partial derivatives required for solving Eqs. (3.18)-
(3.19) 
 ∂𝐸
∂C
= SSTC − S𝐈T, (3.20) 
 ∂𝐸
∂Su
= 𝐂𝑢𝐂𝑢
T𝑺𝑢 − 𝐂𝑢I + 𝐂𝑢𝐂𝑘
T𝐒𝑘, (3.21) 
Note, Eqs. (3.18)-(3.21) represent a system of non-linear equations and inequalities, which can be 
solved in an iterative manner. For this, one should fix one matrix (C or S𝑢) and find another one 
(S𝑢 or C, respectively) via NLS method (Lawson and Hanson 1995). This procedure can be done 
independently for each wavenumber if C is fixed or pixel if S𝑢 is fixed. However, this procedure 
is not computationally efficient. Therefore, another method was developed (Van Benthem and 
Keenan 2004; Kim and Park 2007; Lobanova and Lobanov 2019) allowing to achieve fast 
computational performance. The principle of this approach is based on the operation with the 
whole matrices instead of vectors. 
In order to quantitatively compare spatial Raman concentrations between samples, the 
normalisation conditions are required. As shown in (Lobanova and Lobanov 2019), the Q-US/PS-
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NMF method fulfils the following normalisation conditions. First, spectrum for each resolved 
component is normalised so that 
 
∫ 𝑑ν𝑆1(ν) = ∫ 𝑑ν𝑆2(ν) = ⋯ = ∫ 𝑑ν𝑆𝑁(ν). (3.22) 
Second, total mean concentration is normalized to be unity 
 
1
𝑁𝑝
∑ ∑ 𝐶𝑖(r𝑗)
𝑁
𝑖=1
𝑁𝑝
𝑗=1
= 1. (3.23) 
3.4.2. Validation of Q-US/PS-NMF 
To validate the accuracy of Q-US/PS-NMF, it was compared with the MCR-ALS (Jaumot et al. 
2015) and VCA (Nascimento and Dias 2005) methods using 8 pure Raman spectra of biochemical 
mixtures (Dataset 2, 32 × 32 × 804 data matrix) and large-scale Raman micro-spectroscopy 
images from human tissues in atherosclerosis (Dataset 3, ≃ 6 × 102 × 103 × 103 multi-image 
data matrix) as shown in (Lobanova and Lobanov 2019). 
For Dataset 2, it has been found that VCA was not able to find the original chemical components, 
providing the relative factorization error of 70%. In contrast, Q-US/PS-NMF allowed to achieve 
relative factorization error of 2.6%, 0.7%, and 0.5% for 1, 5, and 10 minutes of standard PC 
running times, respectively, and showed about 20 times more accurate results received for the 
same computational time compared to MCR-ALS (Lobanova and Lobanov 2019). 
For Dataset 3, it has been shown that Q-US/PS-NMF allowed to retrieve the composition of 
atherosclerotic tissues and non-atherosclerotic controls into a number of individual biochemical 
components with mean Raman concentration down to 1% as deduced from the analysis with 11 
components, providing 5% factorization error compared to 11% for VCA. Furthermore, compared 
to VCA, it has been demonstrated that Q-US/PS-NMF was able to detect additional chemical 
components, such as cholesterol and oxidatively-modified linoleic acid, which are well-established 
and important bio-markers of atherosclerosis (Lobanova and Lobanov 2019).  
3.5. Findings 
Collectively, three novel chemometric methods combined in the quantitative hyperspectral image 
unmixing Q-HIU methodology which is intended for the efficient quantitative analysis and 
decomposition of Raman micro-spectroscopy images were proposed in (Lobanova and Lobanov 
2019). The methods were compared and verified with existing state-of-the-art approaches: 
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• SVD-ADC was compared with MNF method combined with S-G filtering; 
• BGF was compared with AsLS method; 
• Q-US/PS-NMF was compared with VCA and MCR-ALS algorithm. 
These verifications with existing methods outlined above showed that the Q-HIU approach 
provides significantly more accurate results and efficient quantification with several orders of 
magnitude shorter computational time as testified on both simulated and real experimental Raman 
data (Dataset 1, 2 and 3).  Furthermore, Q-HIU was validated to identify and quantify the unknown 
biochemical composition of analytes from the hyperspectral Raman data. Therefore, the Q-HIU is 
a new unprecedented chemometric methodology, which is well-suited for the biomolecular 
characterization and quantitative imaging of individual biochemical components in chemical and 
biomedical samples of various complexity.  
In the course of my study chapters presenting the results on chemical composition of  AD brain 
tissues and corresponding non-demented controls (Chapter 5 and Chapter 6), I will utilise the Q-
HIU chemometric methodology for the simultaneous multi-set analysis of my hyperspectral 
Raman micro-spectroscopy images as discussed in this chapter and summarised in an overview 
flowchart of Fig. 3.5. In brief, I will analyse my biomedical Raman data in three steps as follows 
(see an overview flowchart of Q-HIU analysis in Fig. 3.5):  
1) Application of SVD-ADC, which autonomously filters spatially and spectrally 
uncorrelated noise from the Raman data;  
2) Application of BGF for a robust subtraction of fluorescent background from the data; 
3) Application of an efficient Q-US/PS-NMF via the FC-NNLS algorithm. I will use a 
partially supervised-NMF modality for my Raman data performed on paraffin-embedded 
brain samples (Chapter 5), where I will fix the known Raman spectrum of paraffin/wax 
compound in the factorizing Raman intensity matrix, which was measured on one of the 
brain samples. In Chapter 6, I will utilize an unsupervised-NMF for my Raman data 
acquired from frozen brain samples. 
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Fig. 3.5. Flowchart listing 3 main steps of the Q-HIU data analysis. 
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Chapter 4. Methodology 
Confocal Raman micro-spectroscopy is a widely used analytical approach providing a chemically 
specific imaging of biomedical samples in non-invasive and label-free manner (Movasaghi et al. 
2007; Krafft et al. 2016).  
Raman effect also known as inelastic scattering phenomena is originated from the interaction of 
laser light of a frequency in visible range with the molecules in a sample (Diem 2015). Such 
interaction with the laser light illuminated onto the sample induces the vibrations of chemical 
bonds in the molecules of the sample, leading to back scattering of the incident light with the 
shifted energy. On a quantum level, the incident laser light excites the molecules in the sample to 
a virtual state, from where they undergo a transition back to the corresponding vibrational states 
of specific molecular bonds with low energy, thus releasing the scattered photon of a red shifted 
energy (see Fig. 4.1). Here, the vibrational frequency of chemical bonds in the molecules is equal 
to the energy difference between incident laser and Raman scattered light. A series of molecular 
vibrational frequencies each corresponding to the unique chemical bonds of the sample compounds 
form a Raman spectrum.  
 
Fig. 4.1: Schematic energy diagrams representing spontaneous Raman scattering and fluorescence. 
However, the Raman effect is weak, resulting in only one in 108 of the incident photons being 
inelastically scattered (Butler et al. 2016). Nevertheless, these photons contain information about 
the vibrations of molecules and therefore the chemical structure of the sample constituents. 
Applied to the detection of pathogenic aggregated proteins implicated in a range of 
neurodegenerative diseases, it has been reported that amyloid fibrils exhibit a unique chemical 
structure enriched in β-sheet conformations compared to unaggregated native amyloid protein with 
α-helix structure (Kurouski et al. 2015; Ji et al. 2018). Generally, a typical Raman spectrum of the 
protein in the fingerprint region has dominant contributions from three vibrational modes, 
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originating from the polypeptide backbone (amide bands) and from aromatic/non-aromatic side 
chains of amino acid residue. The most diagnostic bands used to reveal protein backbone 
conformations are the amide I vibration (1640–1680 cm-1), which can be predominantly assigned 
to C=O stretching and a minor portion to out-of-phase C–N stretching; the amide II vibration 
(∼1550 cm-1), attributed to the coupled out-of-phase C–N stretching and N–H bending vibrations; 
and the amide III (1200–1340 cm-1), also associated with the C–N stretching and N–H bending 
motions (Rygula et al. 2013). Of these vibrational bands, the amide I band is well established to 
probe the changes in the protein secondary structure including Aβ peptide (Wang et al. 2013; Ji et 
al. 2018). It has been revealed that the polypeptide backbone conformation of protein determines 
the position of the amide I band: a β-sheet conformation corresponds to the amide I band in the 
vibrational range 1667–1672 cm-1, whereas α-helix structure is located in the 1655–1662 cm-1 
range. Applied to detection of Aβ aggregation using SRS microscopy, Aβ fibrils with 
predominantly the β-sheet structure have a 10 cm-1 higher Raman shift frequency of the Amide I 
band compared to a native Aβ peptide in the α-helix conformation (Ji et al. 2018). Interestingly, 
there is a line of evidence that parallel and antiparallel β-sheet conformation of Aβ fibrils can be 
distinguished by Raman micro-spectroscopy (Schweitzer-Stenner et al. 2006; Kurouski et al. 
2010; Schweitzer-Stenner 2012). It was suggested that anti-parallel β-sheet proteins have weaker 
peptide hydrogen bonding compared to those having parallel β-sheet structures, leading to a higher 
Raman shift of the amide I band for anti-parallel β-sheet proteins (Kurouski et al. 2015). However, 
comparison of the amide I band in the anisotropic Raman spectra for anti-parallel and parallel β-
sheets revealed that the number of strands affect the position of the amide I peak, thus complicated 
their assignment (Kurouski et al. 2015). Specifically, a reduction in the number of strands from 12 
to 1 induces a pronounced red-shift of the amide I band for the parallel β-sheets and only a slight 
peak shift for the anti-parallel β-sheets (Measey and Schweitzer-Stenner 2011). Therefore, the 
detection of parallel and anti-parallel β-sheet structure in Aβ fibrils based on the amide I Raman 
band is not possible. 
Instrumentally, confocal Raman spectrometers that are based on either upright or inverted 
microscopes are commonly utilised for collection of Raman spectra of biological tissues. A laser 
source of visible wavelength is widely used for generating light and sample illumination. In point-
scan Raman experiment, the Raman spectra also known as the multi-spectral hypercube is acquired 
by raster scanning the sample through the focal point of the laser beam. This multi-spectral 
hypercube consists of thousands discrete pixel points, each of which has individual Raman 
spectrum typically in a whole 50-4000 cm-1 spectral range with a high 5 cm-1 resolution. Schematic 
diagram of a conventional Raman setup can be found in Fig. 4.2. 
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Fig. 4.2: A typical Raman micro-spectroscopy setup. Reproduced from (Wu et al. 2011) with permission of PNAS. 
Fluorescence microscopy is the essential tool for numerous biomedical applications, including 
post-mortem histological examination of different types of tissues. Fluorescence microscopy is 
based on the absorption and subsequent emission of light by fluorophores, chemical dyes or auto-
fluorescent biochemical compounds. For this, the target biomolecule in a sample is attached with 
specific fluorophore conjugated antibody, which provides a fluorescent probe used for detection 
of the concentration of this fluorophore-bound target biomolecule. As can be explained by 
quantum theory, when the energy of the incident photon illuminating the fluorescently-labelled 
sample is equal to the energy of an electronic transition of the used fluorophore, the fluorophore 
molecule undergoes this transition occurring from the ground vibrational level of its electronic 
ground state to higher electronic and vibrational levels of the excited state. Then, this molecule 
rapidly relaxes to the lowest vibrational level of the excited state, from where it transits back to 
the electronic ground state, known as fluorescent emission of red-shifted photons (see Fig. 4.1). 
Compared to Raman effect, fluorescence has longer time scales ranging from nano- to micro-
seconds in duration versus femtoseconds for Raman. To note, when fluorescent emission lasts 
longer than micro-seconds after the radiation light has been switched off, this effect can be 
attributed to phosphorescence. 
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Chapter 5. Chemical imaging of formalin-fixed-
paraffin-embedded brain sections by point-scan 
Raman micro-spectroscopy 
5.1. Introduction 
Development of novel quantitative imaging biomarkers are of great interest for diagnosis and 
monitoring of AD (Jack et al. 2013). Complimentary to clinical imaging techniques such as PET 
and MRI, Raman micro-spectroscopy serves as a promising method for identification of new 
molecular markers of AD brains with quantitative chemical specificity, high spatial resolution, 
non-destructively and without the use of dyes or labels (Ryzhikova et al. 2014). In combination 
with advanced multivariate image analysis methods, Raman micro-spectroscopy shows a great 
potential for detection of early chemical changes of altered brain metabolism, so that AD brains 
could be differentiated from non-demented controls. Despite the significance of this research, a 
handful of Raman micro-spectroscopy studies in AD brain have been reported in the literature. 
Among them, the work presenting images of lipid-amyloid co-arrangements in AD human brains 
using a nonlinear version of Raman micro-spectroscopy, CARS, has been recently shown (Kiskis 
et al. 2015). However, in this study the spectral profiles of lipid deposits associated with the Aβ 
plaques have been extracted only in the CH-stretch vibrational region (2700-3100 cm−1), which is 
more congested due to overlap of the characteristic vibrational bands compared to the fingerprint, 
complicating the chemical interpretation of spectra. This research paper also suggested the 
mechanism for Aβ pathology spreading according which lipid vesicles continuously interact with 
the Aβ plaque by pulling out the oligomer fragments from its halo. Next, there could be two 
possible scenarios for these released oligomers. One possibility is that they can flow into synapses, 
disrupting the connections between neurons. Another possibility could be that the released 
oligomers build up, thereby seeding a new Aβ plaque assembly. Altogether, this hypothesis 
indicates lipids as a possible driver of Aβ pathology. In relation to confocal Raman micro-
spectroscopy, several studies have recently reported the chemical profiles of abnormal protein 
aggregates in AD brains (Michael et al. 2014; Michael et al. 2017), proving the sensitivity of 
confocal Raman to visualise the pathogenic β‐sheet chemical structure of Aβ plaques and tau 
tangles. This research study based on the idea that the Raman spectrum of misfolded Aβ in the 
plaque composition exhibits the strongly amplified amide I band due to a high content of β‐sheet 
structures (1667–1672 cm-1) (Ji et al. 2018). An unfortunate corollary of this approach is that such 
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Raman imaging does not distinguish a unique molecular fingerprint of fibrillar Aβ from other 
proteins in the β‐sheet conformation.  To overcome this limitation, hyperspectral image unmixing 
analysis that retrieve the whole individual spectral profiles of chemical components in the sample 
should be utilised (Piqueras et al. 2011). 
Comparison of spontaneous Raman and CARS micro-spectroscopy 
Spatially resolved spectra received from spontaneous Raman and CARS micro-spectroscopies 
contain chemical and structural information about functional, endogenous biomolecules of cells 
and tissues (Krafft et al. 2016).  However, CARS intensity spectra are complex in line-shape due 
to the interference between the vibrationally resonant and non-resonant part of the third-order 
CARS susceptibilities complicating their interpretation (Diem 2015). Therefore, CARS micro-
spectroscopy requires appropriate transformation methods for extraction of the imaginary part of 
the CARS susceptibility, similar to the spontaneous Raman spectra and linear in concentration of 
analytes (Liu et al. 2009). CARS imaging also suffers from low signal-to-noise ratio in the 
fingerprint region (700-1800 cm-1), that contains vibrational bands characteristic for the 
pathogenic conformation state of Aβ protein, making it important for investigation. As a 
consequence, all previous CARS micro-spectroscopy studies in brain tissue have been reported 
only in the CH-stretch region (2700-3100 cm-1) (Kiskis et al. 2015; Lee et al. 2015), which is less 
chemically specific. Despite these limitations, CARS benefits from high signal intensities, due to 
the constructive interference of Raman scattered photons from coherently driven identical 
chemical bonds in the molecules within the focal volume. It also exhibits high intrinsic 3D spatial 
resolution because of the multiphoton nonlinearity and has inherent immunity from sample 
autofluorescence. It is therefore a fast-high-resolution micro-spectroscopy technique invaluable 
for biomedical imaging of living cells and ex vivo tissues. Of note, in biological samples with high 
autofluorescence such as aged brain tissue containing high concentrations of yellow-brown 
lipofuscin pigment from old neurons, the normally weak two-photon fluorescence might transform 
to a significant blue-shifted (relative to the excitation wavelengths) signal which is superimposed 
on the CARS spectra. 
Spontaneous Raman spectra in turn consist of a series of vibrational bands representing unique 
molecular fingerprints of chemicals, making them easier to interpret. Furthermore, spontaneous 
Raman spectroscopy has a cheaper experimental set-up in terms of lasers and optics compared to 
the complex and expensive CARS optical system. It is important to note that a faster acquisition 
speed of Raman imaging could be achieved using a line-scan Raman modality by projecting the 
laser beam into a line rather than a point. With this set-up, the sample is scanned line by line rather 
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than pixel by pixel leading to a short image acquisition time of just several minutes. Better optical 
sectioning in turn could be gained using confocal microscopes.  
The aim of this chapter is to probe spatially resolved chemical composition of Aβ plaques and 
their microenvironment using spontaneous Raman micro-spectroscopy in unstained AD human 
brain samples with a particular focus on correlative imaging of individual chemical components 
of amyloid plaques. The use of confocal Raman micro-spectroscopy over CARS is chosen to be 
optimal for the study of AD brain tissue due to the biological importance of both the fingerprint 
and CH-stretch vibrational regions that contain chemical information about pathological protein 
and lipid signatures of abnormal brain function.  Sub-micron spatial resolution achieved with 
confocal Raman is well-suited for visualization of plaques which are typically 50 µm in size. 
Application of hyperspectral image unmixing analysis to acquired multi-set Raman images of AD 
brain tissues will be a useful toolbox for comprehensive visualization of three hallmarks of AD 
together: inflammation, Aβ, and lipids, that could shed the light on the significance of their 
association with the progression of AD. 
5.2. Method 
5.2.1. Human tissue samples and tissue preparation 
Human brain tissue was sourced from the Thomas Willis Oxford Brain Collection (TWOBC), 
which is part of the Medical Research Council (MRC) Brain Bank Network, with the ethical 
approval of the Research Tissue Bank provided by the Oxford Brain Bank (OBB) Access 
Committee. A total of 5 hippocampal and 6 cerebral cortex diseased samples were recruited from 
the hippocampus of five AD subjects and the frontal lobe of other six individuals, who at the time 
of death were affected by AD. As a control cohort, 2 hippocampal and 2 cerebral cortex control 
samples were collected from the corresponding brain regions of non-demented elderly subjects, 
which were not diagnosed with AD based on histological examination (see Table 5.1). The AD 
brain group received the neuropathologic diagnosis based on standard criteria for AD.  Brain 
sections were fixed with formalin, paraffin embedded, sectioned into 5 μm thick slices and 
mounted on standard glass slides. For Raman micro-spectroscopy measurements, formalin-fixed-
paraffin-embedded brain samples were prepared according to the following protocol: 
1. Formalin fixed brain tissue (5 μm thick) slides were deparaffinized using a standard 
dewaxing protocol consisting of three consecutive steps: 1) heating at 60-70 °C in a pre-
heated oven for 1h; 2) removing the paraffin in xylene (two cycles for 20 minutes each); 
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3) rehydrating in a sequence of 100%, 90% and 70% ethanol for 5 minutes each, followed 
by three times washing in distilled water for 5 minutes each.  
2. Brain slices were covered with 1X phosphate buffered saline (PBS) and a standard glass 
coverslip was attached on top followed by nail varnish sealing applied around the edges of 
the coverslip. 
3. After Raman measurements, the samples were reopened and stained with Thioflavin S (Th-
S) dye, which is a well-established indicator of Aβ plaque regions (Kelenyi 1967). For Th-
S staining, brain slides were incubated in 1x PBS/1 % (m/v) Th-S solution for 10 minutes, 
followed by differentiation cycles with 80%, 95% ethanol for 2 minutes each and 
subsequent three times washing in PBS for 5 minutes each. 
Table 5.1: Clinical characteristics of study participants. M = male; F = female, Control = non-demented control; AD 
= Alzheimer’s disease. 
 
Case 
Number 
 
Age in 
years 
 
Gender 
 
Neuropathological 
diagnosis 
The degree of 
Alzheimer’s disease pathology 
(Hyman et al. 2013) 
 
Brain region 
Ah1 92 F AD Severe Hippocampus 
Ah2 87 F AD Severe Hippocampus 
Ah3 73 M AD Moderate Hippocampus 
Ah4 70 M AD Mild/Moderate Hippocampus 
Ah5 85 F AD Moderate Hippocampus 
Ac1 75 M AD Moderate Frontal Lobe 
Ac2 82 F AD Severe Frontal Lobe 
Ac3 85 F AD Severe Frontal Lobe 
Ac4 80 M AD Moderate Frontal Lobe 
Ac5 76 M AD Moderate Frontal Lobe 
Ac6 77 M AD Moderate Frontal Lobe 
Ch1 59 M Control Normal Hippocampus 
Ch2 61 F Control Normal Hippocampus 
Cc1 64 M Control Normal Frontal Lobe 
Cc2 60 F Control Normal Frontal Lobe 
 
In the course of this study chapter, I refer to AD and non-demented control (C) samples, each of 
which represents an individual, as Ah1, ..., Ah5 and Ch1, Ch2, respectively, examined in the 
hippocampus; and as Ac1, ..., Ac6, and Cc1, Cc2, examined in the frontal lobe of the cerebral 
cortex. A total of 61 Aβ plaques were investigated: 30 in the five hippocampal brain samples and 
31 in the six cerebral cortex samples from the 11 AD individuals. Specifically, there were: 10, 9, 
5, 1, and 5 plaques in the Ah1, Ah2, Ah3, Ah4, and Ah5 hippocampal samples, respectively; and 
3, 13, 7, 2, 3, and 3 plaques in the Ac1, Ac2, Ac3, Ac4, Ac5, and Ac6 cortical samples. 
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5.2.2. Point-scan Raman micro-spectroscopy instrumentation 
Raman imaging was carried out using a home-built multimodal laser-scanning microscope based 
on an inverted Nikon Ti-U stand, coupled to a Horiba Jobin-Yvon iHR 550 imaging spectrometer 
(300 grooves/mm grating) and an Andor CCD Newton DU-971N-BV detector (1600 × 400 pixels, 
16 µm pixel size). A laser source (Laser Quantum GEM 532 nm, 2W) was used for excitation. The 
532 nm laser excitation was filtered by a Semrock LL01-532 clean-up filter and coupled into the 
microscope by a dichroic mirror (Semrock LPD01-532RS). Raman scattering was collected in epi-
direction, filtered with a long pass filter (Semrock BLP01-532R), and dispersed by the imaging 
spectrometer. The spectral resolution of the system was 4.9 cm-1 with 30 µm width of the 
spectrometer entrance slit, and the detector length enabled to cover a spectral range (330, 
4050) cm-1. Raman images (about 50×50 μm2) for all brain samples were collected by raster-
scanning the laser beam over a region of interest with a step size of 1 µm resulting in 50×50×1600 
points hyperspectral Raman image (see an illustration of the hyperspectral Raman data cube in 
Fig. 5.2A) with a 1 second exposure time per Raman spectrum. Most Raman images were taken 
with a nominal laser power of 50 mW at the sample. Note that during data processing each image 
was normalized according to its laser energy which is (the laser power) × (the exposure time), 
making the Raman intensities comparable between samples. All images were collected using a 
20× 0.75 NA dry objective (Nikon MRD00205) and a 1× tube lens. Confocal Raman imaging was 
provided by a horizontal slit (Thorlabs VA100), and the vertical input slit of the spectrometer. The 
estimated spatial resolution was 0.5 μm in-plane and 1 μm axially. 
Prior to Raman measurements, an overview image for each sample across 10.4 × 6 mm2, made of 
24 × 18 tiles with 0.43 × 0.33 mm2 tile size, was acquired using differential interference 
contrast (DIC) (see Fig. 5.1A for an example of such DIC image). In the DIC, a de-Senarmont 
compensator provided a phase offset of 20 degrees and a 0.72 NA dry condenser (Nikon 
MEL56100) with a DIC module (Nikon MEH52400) was used for illumination, combined with a 
matched DIC slider (Nikon MBH76220) in the objective, giving a shear of about 0.24 μm. A 
Hamamatsu ORCA 285 camera (1344 × 1024 pixels of 6.45 μm size) at 100 ms frame exposure 
time was used for detection at lowest gain (4.45 photoelectrons/count). 
For fluorescence imaging of the Th-S stained brain samples, wide-field epi-fluorescence was 
performed using the same microscope stand, a Prior Lumen 200 (standard) 200W fluorescence 
illuminator light source, and a filter set consisting of a single band exciter (Semrock FF01-370/36) 
transmitting 352-388 nm, a single band dichroic (Semrock FF409-Di03) at 409 nm, and a single 
band emitter  (Semrock FF02-447/60) transmitting 417-477 nm.  Each image was collected with 
200 ms exposure time and 10% lamp power. 
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5.2.3. Hyperspectral Image Unmixing analysis 
Hyperspectral Raman data were analysed using a Quantitative Hyperspectral Image 
Unmixing (Q-HIU) method, consisting of the following main steps (see Chapter 3 for details). 
Firstly, the data were noise-filtered using Singular Value Decomposition with Automatic Divisive 
Correlation (SVD-ADC), enabling to remove components which are identified as noise using 
Pearson’s auto-correlation coefficients for spatial and spectral singular vectors at one-pixel shift. 
Components with a mean Pearson’s auto-correlation coefficient less than 50% were assigned to 
noise and therefore filtered out. Secondly, broad features in the Raman spectra, which represent 
fluorescent background, were subtracted using Bottom Gaussian Fitting (BGF) with a standard 
deviation (STD) of 900 cm-1. Spatial points, for which the spectrally integrated background 
dominates (see Fig. A-22 and Fig. A-44 of Appendix A), were excluded from the analysis using 
the spatially-resolved Pearson’s auto-correlation coefficients for background-corrected Raman 
intensity at one spectral pixel shift. The spatial points with the Pearson’s coefficients less than 
50% were attributed to noise-dominated and discarded. Finally, the efficient quantitative 
unsupervised/partially supervised non-negative matrix factorization (Q-US/PS-NMF) method via 
a fast combinatorial alternating non-negativity-constrained least squares algorithm was applied to 
the noise-filtered background-subtracted data. This algorithm (Lobanova and Lobanov 2019) 
factorizes the spectrally and spatially resolved data into a linear superposition of direct products 
of non-negative spatial concentration maps (matrix 𝐂) and corresponding non-negative 
spectra (matrix 𝐒), representing biochemical components of the samples’ composition. For the 
reproducibility of the analysis, 20 repetitions with 20 000 iterations each were used during Q-
US/PS-NMF. Each repetition converged to a local minimum of the factorization error. The final 
factorization expansion was selected as a pair of matrices (𝐂 and 𝐒) with minimum factorization 
error over 20 repetitions. In the factorizations to be presented in this chapter, the relative 
factorization error was about 2%. In order to compare the Raman concentrations of different 
chemical species between samples, the component spectra were normalized to have equal 
integrals, having a value chosen to result in a sum of the spatial concentrations with a mean of one. 
In order to eliminate the contribution of wax residues to the spectral basis, the spectrum of the 
paraffin-wax compound, measured on one of the paraffin-embedded samples, was used as a fixed 
spectral component in the Q-US/PS-NMF. The Raman spectrum of wax is also shown in Appendix 
A (Fig. A-11and Fig. A-32), together with the results of hyperspectral image unmixing analysis of 
hippocampal and cortical brain tissues. 
To quantify the correlation of chemical components, received from the factorization analysis of 
Raman data, the Pearson's correlation coefficient R was calculated for spatial pixel concentrations 
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of each pair of individual components within each sample, representing a case subject. A 
significant correlation is considered with a p-value of <0.05. The pairwise difference in mean and 
median concentrations of each component (ℂ1…ℂ5) between AD and non-demented populations 
of the hippocampal or cortical brain regions was tested by the two-sample two-tailed t-test for 
unequal variances (for mean concentration) and the Wilcoxon rank sum test (for median 
concentration), respectively. A p-value of <0.05 was considered statistically significant. 
5.3. Results and discussion 
Label-free confocal Raman micro-spectroscopy was used to investigate the biochemical 
composition of Aβ plaques and their bioenvironment in human AD brain tissues from the 
hippocampus and frontal lobe. The Q-HIU data analysis was performed simultaneously on all data 
of a given type of brain region (i.e. hippocampus or cortex), providing a direct comparison of 
spatial concentration profiles of chemical components in diseased and control samples. The idea 
of decomposition of a typical Raman image with Aβ plaque into individual chemical components 
with spatially-resolved Raman concentration and spectral profiles using Q-HIU analysis is shown 
in Fig. 5.1C. 
To identify Aβ plaques, the brain samples were stained with Th-S (the well-established dye for 
identifying amyloid fibrils (Kelenyi, 1967)). To avoid the potential impact of the labelling artefacts 
and fluorescence background, the staining was performed after Raman imaging. To find potential 
areas containing plaques on label-free AD samples, I utilized large-scale DIC images (see example 
of this image in Fig. 5.1A). DIC contrast helped to identify potential Aβ plaques regions, which 
were used for the area selection for Raman measurements of label-free AD samples (see Fig. 5.1B). 
To validate that these regions are plaque-positive, I performed fluorescence microscopy of the 
measured areas on the same samples stained with the Th-S dye after Raman imaging on the label-
free samples. 
Intermediate steps of the Q-HIU data analysis on 38 Raman micro-spectroscopy images of cortical 
brain tissues in AD together with non-demented controls are shown in Fig. 5.2. Specifically, Fig. 
5.2D shows the autocorrelation coefficients map for singular vectors received from the SVD-ADC 
analysis of 38 Raman images, labelled according to the sample source. The dotted diagonal line 
represents a decision line of a 50% cut-off for mean autocorrelation coefficients, that separates the 
coefficients above the line (circled cross signs – meaningful components) from those below it 
(cross signs – noise) as shown in Fig. 5.2D. Note that read-noise and shot noise are localized 
around zero, whereas physically meaningful components show high mean autocorrelation. For this 
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data, SVD-ADC with a 50% cut-off of mean autocorrelation coefficients has defined an 
approximating matrix, consisting of 36 singular components. To verify this number, I consider the 
spatial distribution and corresponding spectra for two singular vectors with the autocorrelation 
coefficients 25% lower and higher of 50% value (Fig. 5.2E-F). For a pair of discarded singular 
vectors, corresponding to 45% mean autocorrelation, spatial maps do not show any recognised 
pattern, and spectrum resembles noise, whereas for a pair of meaningful singular vectors with 75% 
mean autocorrelation, spatial maps show some colocalized features, and spectrum exhibits several 
clear Raman bands. To show the accuracy of SVD-ADC, I give the results of this method for two 
points from a typical cortical sample with high (B) and low (C) fluorescent background in Fig. 
5.2B-C. As can be seen in the insets of Fig. 5.2B-C, SVD-ADC method allows to significantly 
reduce the noise from the image. 
 
Fig. 5.1. Large-scale DIC image of the hippocampus of sample Ah1 (A). The region of interest outlined by square 
(dashed line) measured by Raman micro-spectroscopy and post-proved to contain Aβ plaque (B). The chemical 
decomposition of this Raman image into individual chemical components with spatially-resolved Raman 
concentration and spectral profiles using the Q-HIU data analysis (C). 
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Also, Fig. 5.2B, C shows an example of BGF algorithm applied to the same Raman image, received 
from the SVD-ADC. The Raman spectra at two spatial pixels with high (B) and low (C) fluorescent 
background before (blue line) and after (green line) background removal with the representative 
bottom Gaussian fit (red line) are demonstrated in Fig. 5.2B-C. Similarly, as can be seen in the 
insets of Fig. 5.2B,C, the BGF algorithm allows to accurately subtract a fluorescent background 
from this image, even when a fluorescent background is about two orders of magnitude larger than 
the Raman signal (Fig. 5.2B). 
The final step of the Q-HIU data analysis is Q-US/PS-NMF. Applied to separate factorization 
analysis of the Raman images of a given type of brain region (i.e. hippocampus or cortex), I 
identified that all Raman images are well represented using 20 separate components. When 
selecting 19 components, the Q-US/PS-NMF algorithm was checked to show a higher 
factorization error, whereas for 21 components the Raman spectrum of an additional component 
appeared to be less meaningful spectrally representing the split protein component from the 
previous analysis with 20 components. For both analyses, the chemical components, which 
attribution has been identified, are summarised in Table 5.2. 
In the hippocampal brain regions, five of the 20 components were found to spatially colocalize 
with Aβ plaques, and exhibited spectra resembling those of known chemical species, which I will 
discuss in the course of this study chapter. In the cortical brain regions, four of these hippocampal 
components were reproduced, and furthermore a new component (ℂ7) colocalizing with plaques 
was observed. The other 15 components were found not to significantly colocalize with Aβ 
plaques. Their attribution is given as follows. Two components in both analyses were found to be 
correlated with the Raman spectra of chemical constituents of glass substrate, and one component 
was found consistent with the Raman spectrum of water using an ID expert tool of Bio-Rad’s 
KnowItAll Vibrational Spectroscopy software with Raman Spectral Libraries, where the degree 
of similarity between each component spectrum and corresponding reference spectrum is given by 
a correlation coefficient (R2) (in %). Note, to avoid contamination with meaningful chemical 
components, wax component was fixed prior to the Q-US/PS-NMF analysis. Its Raman spectrum 
was measured on one of the paraffin-embedded sample and verified to be consistent with the 
Raman spectrum of wax (ℂ11 in the hippocampus and ℂ10 in the frontal lobe, R2 = 99% for both 
analyses). Their Raman spectra and corresponding concentration profiles in the brain samples as 
retrieved from two separate Q-US/PS-NMF analyses with 20 components on Raman images from 
a given type of brain region (i.e. hippocampus or cortex) are given in Appendix A. In the course 
of the next sections, I will focus on the description and attribution of the chemical components, 
which are found to significantly colocalize with Aβ plaques. For the hippocampal brain regions, I 
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Fig. 5.2: Schematic of a hyperspectral Raman cube (A). The arrows with letters B and C mark two pixels, Raman 
spectra of which are shown on the panels B and C, respectively. The input Raman spectrum (blue line) before the 
SVD-ADC and the corresponding noise-filtered Raman spectrum (black line) after this procedure (B-C). The results 
of background subtraction using the bottom Gaussian fitting is shown by the green line: the bottom Gaussian fit (red 
dashed line) is subtracted from the noise-filtered Raman spectrum, giving background-free Raman spectrum. Spatio-
spectral autocorrelation coefficients map of singular vectors resulted from SVD-ADC (D). The dotted diagonal line 
represents a decision line of Rth = 50% cut-off for mean autocorrelation coefficients Ri, separating the coefficients 
above the line (circled cross signs – meaningful components) from those below it (cross signs – noise). The spatial 
distribution and corresponding spectra of two singular vectors with the mean autocorrelation coefficients with values 
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will examine in detail ℂ4, ℂ9, ℂ10, ℂ16, ℂ17. Similarly, for the cortical brain regions, I will discuss 
ℂ4, ℂ7, ℂ11, ℂ16, ℂ20. Note, in the following, I will sort these components by decreasing mean 
Raman concentration. 
Table 5.2. Chemical component attribution retrieved from two separate Q-US/PS-NMF analyses with 20 components 
on Raman images from a given type of brain region (i.e. hippocampus or cortex). 
Chemical component attribution 
R2 for component number ℂ# retrieved from the Q-US/PS-
NMF analysis with 20 components 
Hippocampus Frontal lobe 
glass 98% (ℂ1) 98% (ℂ2) 
BaO (glass) 98% (ℂ2) 92% (ℂ1) 
collagen (ℂ4) not found 
water 85% (ℂ6) 77% (ℂ9) 
Aβ1-42 fibrils + cholesteryl palmitate 84% - fingerprint (ℂ9) 78% - fingerprint (ℂ4) 
fibrin + arachidic acid 90% (ℂ10) 90% (ℂ11) 
β-carotene 82% (ℂ16) 86% (ℂ16), (ℂ13) 
Fe3O4 93% (ℂ17) 89% (ℂ20) 
calcium phosphate not found 93% (ℂ7) 
wax 99% (ℂ11) 99% (ℂ10) 
SiO2 89% (ℂ19) not found 
  
≅75% and ≅25% as indicated on the panel D (E-F). On both panels, 38 Raman images are labelled according to the 
sample source and represents cortical regions. 
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5.3.1. Chemical composition of hippocampal Aβ plaques: key 
chemical components  
Fig. 5.3 shows the Raman spectra of the 5 chemical components colocalized with Aβ plaques, as 
found from the Q-US/PS-NMF data analysis on 30 unstained hippocampal Aβ plaques (from 5 
AD patients) together with 10 control Raman maps (from 2 elderly humans without AD) in the 
fingerprint (736-1780 cm-1) and CH-stretch (2793-3122 cm-1) regions. The ranges below 736 cm-
1 and above 3200 cm-1 are dominated by fluorescence and Raman scattering from the glass 
slide/coverslip and Raman scattering from water, respectively, and therefore were excluded from 
the Q-US/PS-NMF analysis to avoid their interference with the chemical components, which are 
relevant for my study. For identification of chemical components’ assignments, I used Bio-Rad’s 
KnowItAll Vibrational Spectroscopy software with the Raman Spectral Libraries as a guide. Once 
I found the chemical assignment with this software, I compared the Raman spectra of the identified 
standards with the representative component spectra retrieved from my analysis using NLS 
algorithm as shown in Fig. 5.3. These comparisons revealed that 4 components can be spectrally 
assigned to a mixture of fibrillar Aβ1-42 and saturated lipids with cholesteryl derivatives such 
cholesteryl palmitate at a ratio of about 4:1 (ℂ9, R2 = 84%, Fig. 5.3B); a mixture of fibrin and 
arachidic acid at a ratio of about 4:1 (ℂ10, R2 = 90%, Fig. 5.3C); β-carotene (ℂ16, R2 = 82%, Fig. 
5.3D); Fe3O4 (ℂ17, R2 = 93%, Fig. 5.3E). 
In the following, I will discuss the characteristic Raman bands of the identified chemical 
components ℂ4, ℂ9, ℂ10, ℂ16 and ℂ17, which are found to be associated with the Aβ plaques 
regions in AD brains based on their spatial concentration profiles. The summary of key Raman 
vibrational bands, reflecting the presence of Aβ pathology and oxidative damage in AD human 
brains, as retrieved from this research study is given in Table 5.3.  
The spectrum of ℂ4 displays a numerical  number of characteristic bands, such the Raman bands 
at 1657 cm-1 (Amide I, α-helix), 1554 cm-1 (Amide II), 1338 cm-1 (CH2 wagging vibrations from 
glycine (Gly) backbone and proline (Pro) side chain), 1267 cm-1 (Amide III), 1206 cm-1 
(hydroxyproline (Hyp) and tyrosine (Tyr)), 1031 cm-1 (Pro), 1002 cm-1 (phenylalanine), 934 cm-1 
(C-C backbone), 852 cm-1 (Pro, Hyp, Tyr), which are all assigned to the Raman bands of 
collagen (Movasaghi et al., 2007). Additionally, the Raman spectrum exhibits a unique band at 
1705 cm-1, indicative for the C=O stretching vibration in amino acids. I suggest that this Raman 
band observed in ℂ4 spectrum might be originated from the Gly-Pro-X and Gly-X-Hyp sequence 
(where X is any amino acid), which are the most common motifs of collagen.  
Indeed, there are convincing data that senile plaques extracted from AD human brains contain 
CLAC component, which found to be associated with collagen XXV (Hashimoto et al. 2002). As 
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confirmed by in vitro studies, a collagen-like triple-helical peptide can attenuate the nucleation 
and fibril growth of the amyloidogenic peptide (Parmar et al. 2012). In relation to the C=O 
vibration observed in the Raman spectrum of ℂ4, the same study suggested that the C=O moieties 
in repeating Gly-Pro-Hyp sequences within the triple-helix collagen can bind to the backbone 
amides or to the glutamine/asparagine side chains of the amyloidogenic peptide and reduce its 
nucleation. The further link between collagen and amyloid has been indicated with the observation 
of the neuroprotective potential of collagen VI against Aβ neurotoxicity, which is able to inhibit 
the association of Aβ oligomers with neurons, protect Aβ plaques from dissolving into toxic 
amyloid species (Cheng et al. 2009). 
Table 5.3. The summary of key Raman vibrational bands indicative of Aβ pathology and oxidative damage resulting 
from the hyperspectral image unmixing analysis of Raman images of post-mortem AD human brains in the 
hippocampus and cortex. 
Raman 
shift, cm-1 
Molecular 
vibration 
Chemical assignments Potential role in AD 
pathogenesis, indicative of  
1673 
C=O (Amide I) β-sheet proteins pathogenic Aβ protein 
C=C cholesterol interaction with Aβ fibrils 
C=C 
E-unsaturated FAs in 
trans-configuration 
lipid peroxidation and induced 
pro-inflammatory cascade 
through ROS generation 
1705 C=O triple-helix in collagen binding site to Aβ 
peptide (attenuate nucleation) 
970 PO4
3- 
calcium phosphate 
crystals 
mitochondria damage, activation 
of the NLRP3 inflammasome 
1007, 1154 
1518 
C-CH3, C-C, C=C β-carotene inflammation and oxidative stress 
1320 Fe3O4 ferritin 
promotion of Aβ oligomer 
assembly and oxidative damage 
2884, 2852  
CH2 asymmetric 
and symmetric 
stretch 
FAs 
an acyl chain order (𝐼2884 𝐼2852⁄ ), 
pronounced for saturated lipids 
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Fig. 5.3: Raman spectra of the chemical components (blue solid lines) colocalizing with hippocampal Aβ plaques, obtained from 
the simultaneous Q-US/PS-NMF analysis of 30 hippocampal Aβ plaques (5 AD patients) together with 10 control Raman maps 
(2 elderly humans without AD). ℂ4 (A) has spectral characteristics resembling collagen XXV (see text). ℂ9 (B) is a mixture of 
aggregated Aβ1-42 peptides and saturated lipids with cholesteryl derivatives. ℂ10 (C) is a mixture of fibrin and arachidic acid. 
ℂ16 (D) is attributed to carotenoids. ℂ17 (E) is attributed to iron oxide. The chemical attribution of components ℂ9, ℂ10, ℂ16 
and ℂ17 is based on the comparison with analytical standard Raman spectra of pure chemical species. Fits are shown by the red 
dotted lines and found using NLS algorithm. Corresponding R2 are also indicated. The fit in (B) is a superposition of the Raman 
spectrum of synthetic Aβ1-42 fibrils (magenta line) and cholesteryl palmitate (green line); the contributions are separately shown 
in the inset for the fingerprint region. The fit in (C) is a superposition of fibrin (magenta line) and arachidic acid (green line); 
the contributions are shown in the inset. The red line in (D) is the Raman spectrum of β-carotene. The red line in (E) is the 
Raman spectrum of Fe3O4. 
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The spectra of ℂ9 and ℂ10 exhibit several bands in both the fingerprint and CH-stretch regions, 
which are assigned to a mixture of proteins and lipids with different molecular structure. 
Specifically, the fingerprint region of ℂ10 displays Raman bands at 1060, 1129, and 1293 cm-1, 
assigned to the C-C skeletal stretching vibrations, and the CH2 twisting mode of fatty acids, 
respectively (Krafft et al. 2005; Czamara et al. 2015). Its attribution to a saturated lipid in the solid 
phase is supported by co-presence of a strongly pronounced 2880 cm-1 band in the CH-stretch 
region, which is represented by the asymmetric CH2 stretch enhanced by the Fermi resonance 
interaction with the overtones of CH2 and CH3 deformations, compared with a relatively weak 
band around 2933 cm-1, which is attributed to a combination of CH3 and CH2 asymmetric 
vibrations enhanced by the broadening and shift of the CH deformations in the liquid phase 
(DiNapoli et al., 2014). These observations combined with the assignment with the Raman spectra 
of analytical standards using NLS fitting algorithm allowed me to assign the spectrum of ℂ10 to a 
mixture (red dotted line) of 79% fibrin (magenta line) (Jain et al. 2014) and 21% arachidic acid 
(green line) (Czamara et al. 2015) in both the fingerprint and CH-stretch regions. This assignment 
is consistent with the previous studies revealing deposition of fibrin in Aβ plaques of AD mouse 
brains (Paul et al. 2007). Furthermore, the same study has indicated that fibrin can promote 
neuroinflammation in AD brains, possibly accelerating neuronal damage. Similarly, my study 
reveals the co-presence of arachidic acid, indicative of oxidative damage in tissue, with fibrin 
within the Aβ plaque regions of human AD brains. 
I was able to identify an acyl chain order (i.e., an estimate of the lipid viscosity) in the Raman 
spectrum of ℂ9 according to the ratio between the intensity at 2884 cm-1 (the CH2 asymmetric 
stretch) and 2852 cm-1 (the CH2 symmetric stretch) (Kiskis et al. 2015).  I found that this ratio for 
ℂ9 was twice as high as that for ℂ10, thereby indicating a high proportion of saturated lipids in ℂ9. 
Importantly, Raman spectrum of ℂ9 has a strong band at 1673 cm-1, which can be assigned to the 
superposition of the C=O stretching vibration of the protein backbone (Amide I band) from a β-
sheet protein structure (Czamara et al. 2015), with the C=C stretching vibration of 
cholesterol (Krafft et al. 2005), and the FA chain of E-unsaturated FAs in trans-
configuration (Movasaghi et al. 2007). Interestingly, the generation of trans double 
bonds (near 1670 cm-1) occurs as a result of conversion of cis double bonds (near 1655 cm-1), that 
are not present in ℂ9, in the process of lipid peroxidation (Muik et al. 2005). Together with the 
assignment with the Raman spectra of analytical standards using NLS fitting algorithm, the Raman 
spectrum of ℂ9 in the fingerprint region can be well represented (red dotted line) by a mixture of 
81% synthetic Aβ1-42 fibrils (spectrum is available only in the fingerprint region (Dong et al. 
2003)), which is a well-known aggregated component of Aβ plaques with predominately β-sheet 
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protein structure (magenta line), and 19% cholesteryl palmitate (green line) (Czamara et al. 2015). 
For the CH-stretch region, the Raman spectrum of ℂ9 is found to be consistent with the reference 
spectrum of cholesteryl palmitate, which also conform with its high acyl chain order typical for 
saturated lipids as I showed above. Therefore, I assigned ℂ9 to a mixture of Aβ1-42 aggregated 
protein with a high-content of the β-sheet structures, and cholesteryl derivatives with saturated 
long-chain FA chains, representing lipid aggregates. The co-presence of pathogenic fibrillar Aβ1-42 
protein with saturated cholesteryl esters within one resolved chemical component might indicate 
the interaction of these species in AD brain tissues.  
The fingerprint region of ℂ16 exhibits three sharp bands at 1007 cm-1, 1154 cm-1, and 1518 cm-1, 
which can be attributed to the methyl rocking vibrational mode, C-C, and C=C in-phase stretch 
vibrations of the polyene chain, respectively, all indicative of carotenoids (Radu et al., 2016). 
Furthermore, the relative intensities of these Raman bands are similar to those for pure 
β-carotene (red dotted line), therefore confirming its attribution to β-carotene. It is important to 
note that this component is strongly pronounced in cortical plaques, as will be discussed in the 
next sections. According to the current stage of knowledge, average carotenoid concentrations in 
AD and non-demented control tissues from the frontal lobe and occipital cortex have been 
measured, and for β-carotene these concentrations were 4.5 ng/g in AD brains and 5.5 ng/g in 
normal elderly ones. However, the information about its spatial distribution and correlation with 
Aβ plaques is still missing. Furthermore, the ultimate role of β-carotene and other carotenoids in 
free radical-affected diseases, including AD has not yet been elucidated (Stocker and Keaney 
2004; Lloret et al. 2009). Despite being considered as a well-known anti-oxidant, in vitro studies 
reveal that β-carotene can show either anti- or pro-oxidant properties depending on its 
concentration and the oxygen partial pressure in tissue (Burton and Ingold 1983). 
The Raman spectrum of ℂ17 is found to be consistent with Fe3O4 (Glasscock et al., 2008) (see red 
dotted line). According to the literature, the redox metal ions including iron has been detected in 
AD brains (Ramos et al. 2014). Since metal ions are chemically overactive with other molecules, 
they make the tissues significantly predisposed to oxidative damage. Furthermore, the recent study 
using electron holography showed that iron nanoparticles colocalize with the Aβ plaque 
cores (Plascencia-Villa et al., 2016). Additionally, convincing data indicate a high binding affinity 
of metal ions to Aβ peptides (Zatta et al. 2009). This property of metal ions provides easy binding 
to Aβ species with formation of Aβ-metal complexes. Once the complex is generated,  the Aβ-
bound metal particles might influence the oligomerization of Aβ peptides (Zatta et al. 2009). 
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5.3.2. Spatial distributions of key chemical components in 
hippocampal Aβ plaques 
In this section, I inspect and compare Raman concentration maps of the chemical components (ℂ4, 
ℂ9, ℂ10, ℂ16 and ℂ17) across AD and non-demented patient groups in the hippocampal brain 
region. Fig. 5.4- Fig. 5.8 provide overview results of all unmixed Raman images, retrieved from 
the simultaneous Q-US/PS-NMF analysis of 30 hippocampal Aβ plaques (5 AD patients) together 
with 10 control Raman maps (2 elderly humans without AD). In order to investigate the spatial 
correlation of ℂ4, ℂ9, ℂ10, ℂ16 and ℂ17 in Aβ plaques of different morphologies together with 
controls, I show representative examples of Aβ plaques of the following types: fibrillar (Fig. 5.9A, 
70×70 μm2 from Ah1_001), cored neuritic (Fig. 5.9B, 60×60 μm2 from Ah2_001), core-only (Fig. 
5.9C, 40×40 μm2 from Ah3_001) and diffuse neuritic (Fig. 5.9D, 50×50 μm2 from Ah4_001) 
plaques, together with two control regions (Fig. 5.9E, 64×64 μm2 from Ch1_001, and Fig. 5.9F, 
50×50 μm2 from Ch2_001). Row 1 demonstrates fluorescence images acquired after staining with 
Th-S, and Row 2 shows DIC images of the same plaques collected before Raman measurements, 
with the white squares representing the areas of Raman imaging.  Rows 4 to 8 show the Raman 
concentration maps of ℂ4, ℂ9, ℂ10, ℂ16 and ℂ17, respectively, and Row 3 gives a blue-green-red 
overlay of the concentration maps of ℂ4, ℂ9, and ℂ10. Note, relative Raman concentrations are 
obtained from the Q-US/PS-NMF analysis, by applying the normalization such that the mean total 
concentration is equal to unity (see Section 5.2.3 and Section 3.4 (Chapter 3) for details).  
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Fig. 5.4: Spatial distributions of the Raman concentration and the corresponding component spectra of ℂ4 for the 
measured AD hippocampal brain regions together with controls (labelled according to the sample source as Ah1,..., 
Ah5, and Ch1, Ch2, respectively) on colour scales as indicated, retrieved from the simultaneous Q-US/PS-NMF 
unmixing analysis of 30 hippocampal Aβ plaques (5 AD patients) together with 10 control Raman maps (2 elderly 
humans without AD).  
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Fig. 5.5: Spatial distributions of the Raman concentration and the corresponding component spectra of ℂ9 for the 
measured AD hippocampal brain regions together with controls (labelled according to the sample source as Ah1,..., 
Ah5, and Ch1, Ch2, respectively) on colour scales as indicated, retrieved from the simultaneous Q-US/PS-NMF 
unmixing analysis of 30 hippocampal Aβ plaques (5 AD patients) together with 10 control Raman maps (2 elderly 
humans without AD). 
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Fig. 5.6: Spatial distributions of the Raman concentration and the corresponding component spectra of ℂ10 for the 
measured AD hippocampal brain regions together with controls (labelled according to the sample source as Ah1,..., 
Ah5, and Ch1, Ch2, respectively) on colour scales as indicated, retrieved from the simultaneous Q-US/PS-NMF 
unmixing analysis of 30 hippocampal Aβ plaques (5 AD patients) together with 10 control Raman maps (2 elderly 
humans without AD). 
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Fig. 5.7: Spatial distributions of the Raman concentration and the corresponding component spectra of ℂ16 for the 
measured AD hippocampal brain regions together with controls (labelled according to the sample source as Ah1,..., 
Ah5, and Ch1, Ch2, respectively) on colour scales as indicated, retrieved from the simultaneous Q-US/PS-NMF 
unmixing analysis of 30 hippocampal Aβ plaques (5 AD patients) together with 10 control Raman maps (2 elderly 
humans without AD). 
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Fig. 5.8: Spatial distributions of the Raman concentration and the corresponding component spectra of ℂ17 for the 
measured AD hippocampal brain regions together with controls (labelled according to the sample source as Ah1,..., 
Ah5, and Ch1, Ch2, respectively) on colour scales as indicated, retrieved from the simultaneous Q-US/PS-NMF 
unmixing analysis of 30 hippocampal Aβ plaques (5 AD patients) together with 10 control Raman maps (2 elderly 
humans without AD). 
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In general, the spatial concentration profiles indicate the increased accumulations of these 
components in the plaque areas compared to the control regions. 
Notably, CLAC (ℂ4) is found to be one of the main constituents of Aβ plaques with maximum 
concentrations of about 40%, 40%, 30%, and 20% for fibrillar, core-only, cored neuritic and 
diffuse neuritic plaques, respectively. This component is clustered in micro-domains of various 
sizes, which are linked to each other, forming one large structure of shape similar to the plaque. 
This can be clearly seen on the fibrillar plaque by comparing the concentration map of ℂ4 (Fig. 
5.9A4) with the fluorescence image of this plaque (Fig. 5.9A1). Notably, this collagen component 
is not observed in the oligomeric halo of the cored neuritic plaque, as seen by the void areas in its 
concentration map (Fig. 5.9B4). Similarly, fibrillar Aβ1-42 species and saturated lipids with high 
cholesteryl ester content, representing ℂ9, are observed to be packed in multi-clusters, which in 
turn are bundled to each other, forming macro-aggregate, templating fibrillar plaque (Fig. 5.9A5-
D5) (Kiskis et al. 2015). This amyloid/lipid compound is another main constituent of Aβ plaques 
with maximum concentrations of about 35%, 30%, 25%, and 20% for fibrillar, core-only, cored 
and diffuse neuritic plaques, respectively. ℂ10, which is assigned to a mixture of fibrin and 
arachidic acid, is found to be specific to Aβ plaques in AD samples (Fig. 5.9A6-D6), since it is not 
observed for any control region corresponding to non-demented elderly brains (Fig. 5.9E6, F6). 
This protein-lipid component is strongly present in fibrillar and core-only plaques, where it 
accounts for 25% maximum concentration, compared to cored and diffuse neuritic plaques, where 
its concentration exhibits a peak of 15% just in a few pixels. As can be visually observed for the 
fibrillar plaque (Fig. 5.9A6), this mixed component is assembled in multi-domains, which co-
localise with the plaque. β-carotene component (ℂ16), in turn, accumulates in micro-scale clusters 
throughout the entire core-only (Fig. 5.9C7) and diffuse neuritic plaques (Fig. 5.9D7) only, where 
it accounts for about 25% and 15% maximum concentrations, respectively, compared to negligible 
concentrations for control regions (Fig. 5.9E7, F7). As can be seen from the concentration maps 
of iron oxide (ℂ17) in fibrillar (Fig. 5.9A8) and core-only plaques (Fig. 5.9B8), this component is 
accumulated in uni-clusters (~2 µm in size), which are more pronounced at the outer rim of Aβ 
plaque. 
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Fig. 5.9: Images of hippocampal Aβ plaques with different morphologies and non-demented control regions shown 
in jet colour scale: the fibrillar (A), cored neuritic (B), core-only (C) and diffuse neuritic (D) plaques referring to 
AD samples, labelled as Ah1_001, Ah2_001, Ah3_001, Ah4_001, respectively, and two control regions (E,F), 
corresponding to non-demented elderly individuals marked as Ch1_001, Ch2_001. Rows 1-2: the regions of Raman 
measurements, indicated by white square and visualized by DIC microscopy of the unlabelled samples (A2-F2) and 
by fluorescence microscopy of the plaque areas (A1-D1) after staining with Th-S. Row 3: pseudo-colour images 
for the Aβ plaques and control regions using ℂ4 (collagen XXV) as blue, ℂ9 (a mixture of fibrillar Aβ1-42 and 
saturated cholesteryl esters) as green, and ℂ10 (a mixture of fibrin and arachidic acid) as red, scaled to saturate at 
25% of maximum colour channel. Rows 4-8: spatial concentration profiles of the selected components, on colour 
scales as indicated. The Raman concentrations in panel D4, D5 is rescaled by a factor of two for visibility. The 
corresponding component spectra are indicated as white lines in the first column (see also Fig. 5.3). Scale bars: 
10 µm. 
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A pseudo-color image encoding the concentrations of ℂ4 in blue, ℂ9 in green, and ℂ10 in red 
provides a good rendering of the components’ correlation in plaques of different morphologies, as 
shown in Fig. 5.9 (row 3). For example, each of these components colocalize with the fibrillar core 
of Aβ plaque, but there is a lack of fibrin-arachidic acid structures (ℂ10) at the outer rim (Fig. 
5.9A3) of the fibrillar plaque. On the other hand, the oligomeric halo of Aβ plaque is found to be 
enriched in Aβ-saturated cholesteryl ester domains (ℂ9), which can be clearly observed for the 
cored neuritic plaque (Fig. 5.9B3). 
To investigate the significance of the received concentration levels, I have statistically analysed 
the mean (see Fig. 5.10) and median (Fig. 5.11) concentrations of ℂ4, ℂ9, ℂ10, ℂ16, and ℂ17 found 
from AD and control populations over the imaged regions. For each component, the mean (or the 
median) and the STD are given separately for AD and control groups, and a t-test (or the Wilcoxon 
rank sum test) was used to determine the significance of the observed differences. The probability 
of the null-hypothesis, revealing whether the statistical distributions corresponding to diseased and 
control samples are significantly different, which will be reflected by the small p-values. For both 
mean and median concentrations of ℂ4, ℂ9, ℂ10 and mean concentration of ℂ16, ℂ17, I found p-
values below a few percent, which confirms a significant increase in the levels of these components 
in plaque regions of AD tissues compared to the control group. However, the difference in median 
 
Fig. 5.10: A scatter plot of the sample mean concentrations is given for 30 hippocampal Aβ plaques (5 AD patients) 
and 10 control (2 elderly humans without AD) Raman images versus component number (ℂ4, ℂ9, ℂ10, ℂ16, and 
ℂ17). The mean and standard deviation of each cohort are indicated by the error bars. The significance in pairwise 
difference in the concentration levels between AD and control groups was determined by two-sample two-tailed t-
test with unequal variances. *p < 0.05, ***p < 0.001, ****p < 0.0001, *****p < 0.00001. Here, AD = Alzheimer’s 
disease; C = control. 
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concentration for ℂ16 and ℂ17 between diseased and control cohorts was found insignificant as 
reflected by the p-values higher than a 5% (Fig. 5.11). It is important to note that the distribution 
of ℂ16 and ℂ17 for the AD group appears to be shifted to higher levels of median concentration 
for 3 diseased samples as could be clearly observed for ℂ16 in Fig. 5.11, implying the high 
variation and heterogeneity in the concentration of these components from patient to patient. 
Fig. 5.12 demonstrates the colocalization histograms for the concentration distributions of ℂ9 - 
ℂ10 (top row) and ℂ9 - ℂ4 (bottom row) for AD and control groups, representing the statistics on 
10, 9, 5, 1, 5 plaques from Ah1, Ah2, Ah3, Ah4, Ah5, and 6, 4 control Raman images from Ch1, 
Ch2 individuals, respectively. A typical size of each Raman image was about 50×50 μm2. The 
Pearson's correlation coefficients R for each case subject are also shown in Fig. 5.12, indicating a 
positive linear correlation between concentration distributions of the selected paired components, 
except for the pair ℂ9 - ℂ10 from subject Ah5. The colocalization histogram for Ah4 sample 
representing a Raman image of just one measured plaque is also given. These histograms show a 
significant difference in the concentration distributions of collagen, Aβ1-42 fibrils-saturated 
cholesteryl ester and fibrin-arachidic acid complexes between AD and control groups, and 
therefore might be beneficial for the discrimination of patients’ classes. Specifically, a cut-off of 
concentration levels at 15%, 5%, and 15%, 28% for components 9, 10 (top row) and components 
9, 4 (bottom row) in the colocalization histograms of Fig. 5.12, respectively, results in only the 
 
Fig. 5.11: A scatter plot of the sample median concentrations is given for 30 hippocampal Aβ plaques (5 AD 
patients) and 10 control (2 elderly humans without AD) Raman images versus component number (ℂ4, ℂ9, ℂ10, 
ℂ16, and ℂ17). The median of each cohort is indicated by the plus sign. The significance in pairwise difference in 
the concentration levels between AD and control groups was determined by the Wilcoxon rank sum test. ***p < 
0.001, ****p < 0.0001, *****p < 0.00001. Here, AD = Alzheimer’s disease; C = control. 
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histograms for the AD cohort exhibiting concentrations higher than these levels. Therefore, I have 
been able to separate hippocampal AD samples from the non-AD controls using the information 
from the components’ concentration distributions of unmixed Raman images, which is in line with 
the results using the mean concentration (Fig. 5.10). 
 
Fig. 5.12: Colocalization histograms of concentration (%) for ℂ9 - ℂ10 (upper row) and for ℂ9 - ℂ4 (lower row) for 
each diseased (5 AD patients) and control (2 individuals) hippocampal samples, which refer to AD and non-
demented elderly individuals, labelled as Ah1 (A), Ah2 (B), Ah3 (C), Ah4 (D), Ah5 (E) and Ch1 (F), Ch2 (G). 
Statistics on these samples was determined by the analysis of 10 (from Ah1), 9 (from Ah2), 5 (from Ah3), 1 (from 
Ah4), 5 (from Ah5) plaques, and 6 (Ch1), 4 (Ch2) control regions with a typical size of each Raman image of about 
50×50 μm2. The Pearson's correlation coefficients R for each case subject are shown. 
5.3.3. Chemical composition of cortical Aβ plaques: key chemical 
components 
Similar to the hippocampal brain region, I have measured 31 unstained cortical Aβ plaques from 
6 AD patients, and 7 control regions from 2 elderly humans without AD. The same framework of 
the Q-HIU analysis as for the hippocampus samples was applied. The results of this analysis reveal 
five key chemical components found colocalizing with cortical Aβ plaques, with four of these 
exhibiting Raman spectra similar to ℂ9, ℂ10, ℂ16, and ℂ17 found in the hippocampus and sorted 
by their mean concentration, from largest to smallest. These are: a mixture of fibrillar Aβ1-42 and 
saturated lipids with cholesteryl derivatives (ℂ4, R2 = 78%), a mixture of fibrin and arachidic acid 
(ℂ11, R2 = 90%), β-carotene (ℂ16, R2 = 86%) and Fe3O4 (ℂ20, R2 = 89%) (see Table 5.2 on 
components’ attribution). Importantly, collagen component (ℂ4 in the hippocampus) was not 
found in the cortical plaque regions, whereas a new component appears, in spectral characteristics 
resembling calcium phosphate crystals (ℂ7, R2 = 93%) (see Fig. 5.13). Specifically, the spectrum 
of this component has a very strong Raman band near 970 cm-1, attributed to the symmetric 
stretching mode of the phosphate group, indicative of whitlockite (Haskin et al. 1997).  
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Fig. 5.13:  Raman spectra of the chemical components (blue solid lines) colocalizing with cortical Aβ plaques, obtained from 
the simultaneous Q-US/PS-NMF analysis of 31 cortical Aβ plaques (6 AD patients) together with 7 control Raman maps (2 
elderly humans without AD). ℂ4 (A) is a mixture of Aβ1-42 fibrils and saturated lipids with cholesteryl derivatives.  ℂ7 (B) is 
assigned to calcium phosphate crystals. ℂ11 (C) is a mixture of fibrin and arachidic acid. ℂ16 (D) is attributed to carotenoids. 
ℂ20 (E) is attributed to iron oxide. The chemical attribution of components ℂ4, ℂ7, ℂ11, ℂ16 and ℂ20 is based on the comparison 
with analytical standard Raman spectra of pure chemical species. Fits are shown by the red dotted lines and found using NLS 
algorithm. Corresponding R2 are also indicated. The fit in (A) is a superposition of the Raman spectrum of synthetic Aβ1-42 
fibrils (magenta line) and cholesteryl palmitate (green line); the contributions are separately shown in the inset for the fingerprint 
region.  The red line in (B) is the Raman spectrum of calcium phosphate. The fit in (C) is a superposition of fibrin (magenta 
line) and arachidic acid (green line); the contributions are shown in the inset. The red line in (D) is the Raman spectrum of β-
carotene. The red line in (E) is the Raman spectrum of Fe3O4. 
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5.3.4. Spatial distributions of key chemical components in cortical Aβ 
plaques 
In this section, I examine and compare the spatial concentration profiles of the 5 components, 
identified in the previous section over AD and non-demented populations in the frontal cortical 
brain region. Similarly to the hippocampal brain region, I show an overview results of all unmixed 
Raman images, as retrieved from the simultaneous Q-US/PS-NMF analysis of unstained 31 
cortical Aβ plaques (6 AD patients) together with 7 control Raman maps (2 elderly humans without 
AD) in Fig. 5.14-Fig. 5.18. 
In order to examine in detail the spatial correlation of ℂ4, ℂ7, ℂ11, ℂ16 and ℂ20 in the cortical Aβ 
plaques of various types, I show the spatial concentration profiles of the plaques with three 
different morphologies (see rows 4-8 of Fig. 5.19), namely two neuritic (40×40 μm2 from 
Ac1_001, 64×64 μm2 from Ac2_001), core-only (55×55 μm2 from Ac2_007) and cored neuritic 
(64×64 μm2 from Ac3_001) plaques supplemented by two control regions (64×64 μm2 from 
Cc1_001, and 32×32 μm2 from Cc2_001).  The DIC and fluorescence images of the same plaque 
and control areas are given in row 1 and 2 of Fig. 5.19, where white squares indicate the regions 
of Raman measurements. To note, white areas in panels B4-B8 represent pixels, which were 
excluded from the analysis as noise-dominated (see Section 5.2.3 for details). 
By examining Fig. 5.19, I found that the spatial concentration profiles of ℂ4 (the Aβ fibrils and 
saturated lipids with high cholesteryl ester content) (Fig. 5.19A4-D4) and ℂ7 (calcium phosphate) 
(Fig. 5.19A8-D8) in the plaque areas mimic the contours of Th-S stained plaques in the 
corresponding fluorescence images (Fig. 5.19A1-D1). In particular, ℂ4 and ℂ7 (indicative of 
calcium mineralization) accumulate throughout the Aβ plaque areas tending to have higher 
concentrations at the core of plaques and lower ones at the plaque periphery, except for the cored 
neuritic plaque (the upper one only, Fig. 5.19D8). Also, the concentration images of ℂ11 (a mixture 
of fibrin and arachidic acid), ℂ16 (β-carotene) and ℂ20 (Fe3O4) reveal the increased micro-
accumulations of these species in Aβ plaques. Notably, β-carotene component is clustered within 
the plaques and tends to wrap their core. It appears that the smaller the plaque the higher its 
coverage by β-carotene. Similarly, iron oxide (ℂ20) shows clear specks observed inside the 
plaques, whereas a fibrin/arachidic acid complex accumulates not only inside but also outside of 
plaque regions. 
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Fig. 5.14: Spatial distributions of the Raman concentration and the corresponding component spectra ℂ4 for the 
measured AD cortical brain regions together with controls (labelled according to the sample source as Ac1,...,Ac6, 
and Cc1, Cc2, respectively) on colour scales as indicated, retrieved from the simultaneous Q-US/PS-NMF 
unmixing analysis of 31 cortical Aβ plaques (6 AD patients) together with 7 control Raman maps (2 elderly humans 
without AD). 
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Fig. 5.15: Spatial distributions of the Raman concentration and the corresponding component spectra ℂ7 for the 
measured AD cortical brain regions together with controls (labelled according to the sample source as Ac1,...,Ac6, 
and Cc1, Cc2, respectively) on colour scales as indicated, retrieved from the simultaneous Q-US/PS-NMF 
unmixing analysis of 31 cortical Aβ plaques (6 AD patients) together with 7 control Raman maps (2 elderly humans 
without AD). 
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Fig. 5.16: Spatial distributions of the Raman concentration and the corresponding component spectra ℂ11 for the 
measured AD cortical brain regions together with controls (labelled according to the sample source as Ac1,...,Ac6, 
and Cc1, Cc2, respectively) on colour scales as indicated, retrieved from the simultaneous Q-US/PS-NMF 
unmixing analysis of 31 cortical Aβ plaques (6 AD patients) together with 7 control Raman maps (2 elderly humans 
without AD). 
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Fig. 5.17: Spatial distributions of the Raman concentration and the corresponding component spectra ℂ16 for the 
measured AD cortical brain regions together with controls (labelled according to the sample source as Ac1,...,Ac6, 
and Cc1, Cc2, respectively) on colour scales as indicated, retrieved from the simultaneous Q-US/PS-NMF 
unmixing analysis of 31 cortical Aβ plaques (6 AD patients) together with 7 control Raman maps (2 elderly humans 
without AD). 
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Fig. 5.18: Spatial distributions of the Raman concentration and the corresponding component spectra ℂ20 for the 
measured AD cortical brain regions together with controls (labelled according to the sample source as Ac1,...,Ac6, 
and Cc1, Cc2, respectively) on colour scales as indicated, retrieved from the simultaneous Q-US/PS-NMF 
unmixing analysis of 31 cortical Aβ plaques (6 AD patients) together with 7 control Raman maps (2 elderly humans 
without AD). 
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Fig. 5.19: Images of cortical Aβ plaques with different morphologies and non-demented control regions shown in 
jet colour scale: the neuritic (A, B), core-only (C) and cored neuritic (D) plaques referring to AD samples, labelled 
as Ac1_001, Ac2_001, Ac2_002, Ac3_001, respectively, and two control regions (E,F), corresponding to non-
demented elderly individuals marked as Cc1_001, Cc2_001. Rows 1-2: the regions of Raman measurements, 
indicated by white square and visualized by DIC microscopy of the unlabelled samples (A2-F2) and by fluorescence 
microscopy of the plaque areas (A1-F1) after staining with Th-S. Row 3: pseudo-colour images for the Aβ plaques 
and control regions using ℂ4 (a mixture of fibrillar Aβ1-42 and saturated cholesteryl esters) as blue, ℂ20 (iron oxide) 
as green, and ℂ11 (a mixture of fibrin and arachidic acid) as red, scaled to saturate at 25% of maximum colour 
channel. Rows 4-8: spatial concentration profiles of the selected components, on colour scales as indicated. The 
corresponding component spectra are indicated as white lines in the first column (see also Fig. 5.3). Scale bars: 
10 µm. 
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A statistical analysis of all cortical samples reveals the statistically significant changes (p-value 
less than 5%) in the mean concentration levels of ℂ7, ℂ11, ℂ16, and ℂ20, but not for ℂ4, found 
from two-sample two-tailed t-test with unequal variances as evident from Fig. 5.20. Additional 
consideration of the median concentration for the same components (see Fig. 5.21) and their 
comparison with the corresponding mean values revealed the skew statistical distribution in 
individual component concentrations for the AD patient group (see, for example, the distribution 
of ℂ16 in Fig. 5.21) reflected by the significant changes in p-values between the median and mean 
concentrations levels. The significance in pairwise difference for the median concentration levels 
between AD and control groups was determined by the Wilcoxon rank sum test (Fig. 5.21). 
 
Fig. 5.20: A scatter plot of the sample mean concentrations is given for 31 cortical Aβ plaques (6 AD patients) and 
7 control (2 elderly humans without AD) Raman images versus component number (ℂ4, ℂ7, ℂ11, ℂ16, and ℂ20). 
The mean and standard deviation of each cohort are indicated by the error bars. The significance in pairwise 
difference in the concentration levels between AD and control groups was determined by two-sample two-tailed t-
test with unequal variances. *p < 0.05, **p < 0.01, *****p < 0.00001. Here, AD = Alzheimer’s disease; C = control. 
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Fig. 5.21: A scatter plot of the sample median concentrations is given for 31 cortical Aβ plaques (6 AD patients) 
and 7 control (2 elderly humans without AD) Raman images versus component number (ℂ4, ℂ7, ℂ11, ℂ16, and 
ℂ20). The median of each cohort is indicated by the plus sign. The significance in pairwise difference in the 
concentration levels between AD and control groups was determined by the Wilcoxon rank sum test. *p < 0.05, 
**p < 0.01. Here, AD = Alzheimer’s disease; C = control. 
Fig. 5.22 shows the colocalization histograms for the concentration distributions of ℂ16 (β-
carotene) and ℂ20 (iron oxide) of each diseased (4 AD patients) and control (2 elderly individuals 
without AD) samples, using data came from 3, 13, 7, 2, 3 and 3 plaques corresponding to Ac1 (A), 
Ac2 (B), Ac3 (C), Ac4 (D), Ac5 (E), and Ac6 (F) samples as well as 4, 3 control regions 
representing Cc1 (G), Cc2 (H) individuals. Each Raman image was about 50×50 μm2 in size. The 
inspection of the distribution histograms reveals significant changes in the concentration levels of 
these components between AD and control groups, indicating their potential to be utilized for the 
patients’ classes differentiation, similar to what observed for the hippocampal regions. 
Specifically, the cut-off value of the colocalization histograms at 5% and 3% Raman concentration 
levels for ℂ16 and ℂ20, respectively, results in only the AD group having Raman concentrations 
higher than these values, therefore implying the differentiation of the AD samples from the non-
demented controls. 
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Fig. 5.22: Colocalization histograms of concentration (%) for ℂ20 - ℂ16 for each diseased (6 AD patients) and 
control (2 individuals) samples in the cortex, which refer to AD and non-demented individuals, labelled as Ac1 (A), 
Ac2 (B), Ac3 (C), Ac4 (D), Ac5 (E), Ac6 (F) and Cc1 (G), Cc2 (H). Statistics on these samples was determined by 
the analysis of 3 (from Ac1), 13 (from Ac2), 7 (from Ac3), 2 (from Ac4), 3 (from Ac5), 3 (from Ac6) plaques, and 
4 (Cc1), 3 (Cc2) control regions with a typical size of each Raman image of about 50×50 μm2. The Pearson's 
correlation coefficients R for each case subject are shown. 
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5.4. Findings 
In this chapter, I reported the chemical composition of label-free Aβ plaques in the hippocampus 
and the frontal lobe regions of AD human brains using point-scan confocal Raman micro-
spectroscopy. I showed that Raman micro-spectroscopy allowed to resolve and quantify 
pathogenic Aβ1-42 chemical component of plaques from completely label-free samples. Strikingly, 
these Aβ1-42 fibrils are found to form a co-aggregate with saturated lipids of high cholesteryl ester 
content, that spatially colocalize with the plaque core and spectrally representing one chemical 
component. This finding points to the close interaction between aggregated Aβ and cholesteryl 
derivatives with long-chain saturated FAs. Along with amyloid-lipid complex, the Aβ cores of AD 
human brains are observed to contain another mixed component, spectrally assigned to a 
combination of fibrin and arachidic acid, both indicative of tissue inflammation. As other 
important neuroinflammatory markers, β-carotene and iron oxide are found strongly colocalizing 
with Aβ aggregates and forming distinct multiple clusters within plaque regions. As a signature of 
cell damage, cortical plaque core is found to accumulate excessive amounts of calcium phosphate 
crystals, that might indicate about complete cellular membrane rupture due to neurotoxic Aβ 
interaction with lipid membranes of human cortical neurons. Collectively, the identified 
inflammatory markers found colocalizing with Aβ plaques and exhibiting significantly increased 
levels in AD tissues might suggest a conserved pattern of chronic immune system activation in 
response to Aβ neurotoxicity. Therefore, a detailed characterization of immunological pathways 
followed by accumulation of pro-inflammatory components in close proximity to Aβ plaque 
regions might provide new insight into Aβ amyloidosis implicated in human AD brains (Stefani 
2012). To address this, Chapter 7 and Chapter 8 will be devoted to the fluorescence imaging of 
specific inflammatory markers in Aβ plaques of human AD brains with a focus on the investigation 
of Aβ colocalization with them. 
In response to potential clinical application, the results of Raman micro-spectroscopy in the 
hippocampal and frontal lobe brain regions show a proof-of-principle for the biomolecular 
characterization and quantitative imaging of individual biochemical components of diseased 
tissues compared to non-diseased controls. Importantly, these identified components are found to 
exhibit significantly different Raman concentrations between AD and non-demented brains, 
highlighting their potential use as characteristic biomarkers of AD, beneficial for the disease 
diagnosis. 
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Chapter 6. Three-dimensional chemical imaging of 
thick frozen brain sections by line-scan Raman 
micro-spectroscopy 
6.1. Introduction 
My previous study chapter shows a proof of concept for Raman micro-spectroscopy combined 
with efficient multivariate hyperspectral image unmixing analysis to simultaneously detect 
individual spectral profiles and spatial distributions of three hallmarks of AD brains: Aβ fibrils, 
saturated lipids and inflammatory components of prolonged immune system activation (iron oxide, 
calcium crystals, β-carotene and fibrin) all colocalizing in the Aβ plaque. That study was 
performed on thin formalin-fixed-paraffin-embedded brain sections mounted on a standard glass 
slide, which is the gold standard for histological tissue examination used in research and clinical 
setting. However, it has been inferred from the previous study chapter that Raman imaging on this 
type of samples have three disadvantages due to (1) significant contribution of fluorescence and 
Raman scattering from the glass slide/coverslip to the Raman spectra of tissues complicating the 
extraction of relevant chemical information; (2) contribution of wax residuals to the Raman spectra 
of dewaxed tissues requiring a digital fixation of this component during analysis to avoid 
interference with meaningful components; (3)  potential effects of dewaxing and paraffin wax 
itself on preservation of actual bio-chemical content of tissues. It is worth mentioning that based 
on my experience of work with paraffin brain sections these samples preserve good tissue 
architecture and solid structure after dewaxing making them easy to handle for Raman imaging 
and post-examination with fluorescence microscopy without destroying the sample. 
In balance, this study chapter will present the spatially resolved chemical composition of frozen 
brain tissues without chemical fixatives and mounted on fluorescence-free CaF2 Raman windows 
for Raman imaging. Furthermore, in this study chapter, 3D Raman imaging will be performed on 
thick brain sections using an advanced version of Raman micro-spectroscopy, line-scan Raman, 
(pros: improved scanning speed and smooth image distribution by scanning the laser beam over a 
region of interest line by line) coupled with an oil immersion objective of a higher 
magnification (pros: higher spatial resolution and better 3D sectioning). 
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6.2. Method 
6.2.1. Human tissue samples and tissue preparation 
As in Chapter 5, human brain tissue was sourced from the Thomas Willis Oxford Brain 
Collection (TWOBC), which is part of the Medical Research Council (MRC) Brain Bank 
Network, with the ethical approval of the Research Tissue Bank provided by the Oxford Brain 
Bank (OBB) Access Committee. A total of 4 hippocampal diseased samples were recruited from 
the hippocampus of three AD subjects, who at the time of death were affected by AD. As a control, 
1 hippocampal control sample was investigated from the corresponding brain region of non-
demented elderly subject, which was not diagnosed with AD based on histological tissue 
examination. Source brain sections arrived unfixed frozen and were packed in a box with a dry 
ice, that upon arrival were placed and kept in the freezer at -80 °C for later cryostat sectioning. 
Prior to cryostat sectioning, fresh brain block was removed from the freezer and immediately 
placed into a cryostat at -20 °C (thereby preventing tissue thawing), followed by a mounting of the 
tissue block in freezing media (that was pre-applied on top of a specimen disk (chuck)).  Next, the 
chuck with the mounted cold brain block was positioned onto a specimen holder with a cutting 
blade in place. Then, a section of interest was sliced into adjusted thickness (in a range 20-40 µm) 
and quickly caught with the brush, followed by its transfer to a CaF2 window (25 mm in diameter 
and 0.5 mm in thickness) by sticking to the glass surface. To confirm the disease status by 
histochemistry, one additional tissue section adjacent to each brain slice to be imaged with Raman 
micro-spectroscopy was always cut and mounted on standard glass slide. Subsequently, these 
sections were stained with Th-S dye as described in Section 5.2.1 and tested for the presence of 
plaques via fluorescence microscopy (see Section 5.2.2). Immediately after cryostat sectioning, 
the mounted fresh brain samples were air dried for about 30 minutes at room temperature, and then 
were placed in a holder with another CaF2 coverslip on top of the sample, in which the brain tissue 
stayed intact.  Finally, the holder with the mounted brain section was transferred and kept in a 
freezer at -80 °C for further use. For Raman imaging, unfixed frozen brain samples were removed 
from the freezer and from the holder, and the sample was allowed to thaw at room temperature for 
10 minutes. For Aβ fibril visualization, 35 μl of a mixture solution consisting of a 10-4 % Th-S in 
D2O diluted in a 2% low melting point agarose liquid at 9:1 was pipetted into the sample mounted 
on CaF2 window and another CaF2 coverslip of the same size was attached on top. This sandwiched 
structure was squeezed and gripped between two plastic chambers. Similarly, control sample of a 
non-demented subject was stained with Th-S following the procedure above. To control the 
potential artefacts of staining on the chemical composition of brain, one AD sample was prepared 
completely label-free and covered with just D2O.  
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6.2.2. Line-scan Raman micro-spectroscopy instrumentation 
As in Chapter 5, Raman imaging was carried out using a home-built multimodal laser-scanning 
microscope based on an inverted Nikon Ti-U stand, coupled to a Horiba Jobin-Yvon iHR 550 
imaging spectrometer (300 grooves/mm grating) and an Andor CCD Newton DU-971N-BV 
detector (1600 × 400 pixels, 16 µm pixel size). A laser source (Laser Quantum GEM 532 nm, 2W) 
was used for excitation. The 532 nm laser excitation was filtered by a Semrock LL01-532 clean-
up filter and coupled into the microscope by a dichroic mirror (Semrock LPD01-532RS). Raman 
scattering was collected in epi-direction, filtered with a long pass filter (Semrock BLP01-532R), 
and dispersed by the imaging spectrometer. The spectral resolution of the system was 4.9 cm-1 
with 20 µm width of the spectrometer entrance slit, and the detector length enabled to cover a 
spectral range (330, 4050) cm-1. For line-scan Raman imaging, all brain samples were collected 
by scanning the laser beam line by line (129 µm in length) over a region of interest with a step size 
of 0.64 µm in y-direction resulting in a 129×129×1600 points hyperspectral Raman with typically 
a 5 second exposure time per line. A z-stack Raman image was acquired by sequential scanning 
of each focal plane with a step size of 3 µm. All Raman images were taken with a nominal laser 
power of 1W at the sample. Note that during data processing each image was normalized according 
to its laser energy which is (the laser power) × (the exposure time), making the Raman intensities 
comparable between samples. All images were collected using a 40× 1.15 NA oil objective and a 
1× tube lens. Line-scan confocal Raman imaging was provided by a cylindrical lens allowing to 
project the laser beam into a line subsequently coupled with the vertical input slit of the 
spectrometer, and a horizontal slit (Thorlabs VA100), that was widely open (set at nominal 0.8 
units in width) enabling to transfer the whole laser line containing Raman signal for detection. The 
estimated spatial resolution was 0.5 μm in-plane and 1 μm axially. 
6.2.3. Hyperspectral Image Unmixing analysis 
As in Chapter 5, I used the same approach (see a flowchart of the Q-HIU data analysis 
methodology in Fig. 3.5) for the unsupervised hyperspectral image analysis of the biomedical 
Raman data from frozen unfixed AD brain samples together with non-demented controls to be 
investigated in this study chapter. Like in Chapter 5, all acquired images were analysed together, 
enabling the comparison of the unmixing biochemical content between samples. As detailed in 
Section 5.2.3 and Chapter 3, the analysis to be presented in this chapter consisted of 3 major 
consecutive steps: (1) subtraction of a short noise from the data using the SVD-ADC method with 
the 50% cut-off for scores and loadings; (2) removal of a broad background from the denoised 
data using the BGF method with a STD of 900 cm-1; (3) hyperspectral image unmixing for 
chemical composition retrieval from the noise-filtered background-subtracted data using the 
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efficient quantitative unsupervised/partially supervised non-negative matrix factorization (Q-
US/PS-NMF) method via a fast combinatorial alternating non-negativity-constrained least squares 
algorithm. The Q-US/PS-NMF algorithm (Lobanova and Lobanov 2019) factorizes the spectrally 
and spatially resolved data into a linear expansion of direct products of non-negative spatial 
concentration (matrix 𝐂) and corresponding non-negative spectral (matrix 𝐒) profiles, resolving 
the individual biochemical components of the samples’ composition. For analysis reproducibility, 
2 repetitions with 20 000 iterations each were utilised during Q-US/PS-NMF. Each repetition 
converged to the same local minimum of the factorization error. The final factorization expansion 
was selected as a pair of matrices (𝐂 and 𝐒) with minimum factorization error. In the factorizations 
to be presented in this chapter, the relative factorization error was about 2%. To compare the 
Raman concentrations of resolved chemical components between samples, I normalize each 
component spectrum and concentration map in such a way that mean spectra of the chemical 
components are equal and the total mean spatial concentration is one. 
It is important to note that, unlike the analysis for paraffin-embedded samples investigated in 
Chapter 5, the analysis of the unfixed frozen tissues was fully unsupervised, i.e. the composition 
of frozen brain tissues was retrieved without any prior information of its biochemical content.  
Of note, from experimental point of view, correlative Raman imaging of Aβ plaques using frozen 
brain sections is a challenging task due to the lack of contrast in these wet tissues with DIC 
microscopy and inability to reopen the sample for histochemical examination of the areas imaged 
with Raman without destroying the tissues. To help with Aβ plaque identification, the brain 
samples were stained with Th-S (the well-established dye for identifying amyloid fibrils (Kelenyi, 
1967)) of a very low concentration (10-4 % m/v Th-S solution) prior Raman measurements. To 
avoid the washing out of the lipid content, ethanol washing cycles were not used during the 
procedure. To check whether the staining with a very small concentrated Th-S dye affects the 
Raman biochemical composition of the brain samples, one completely label-free sample covered 
with water was participated in this study for comparison. For the final results, 3D Raman images 
acquired from the label-free sample and shown spectrally and spatially resembling the Aβ plaque 
were included in the analysis of all tissues. In the analysis, the Raman images of the hippocampal 
brain samples from 3 AD individuals and 1 non-demented control (C) individual are named as 
AD1_01z1-z3 (label-free sample from AD patient AD1), AD1_02z1-z7 (Th-S stained sample from 
AD patient AD1), AD2_01z01-z11 (Th-S stained sample from AD patient AD2), AD3_01z1-z5 
(Th-S stained sample from AD patient AD3) and C1_01z01-z10 (Th-S stained sample from 
control subject C1 without AD). All z-stacks were acquired sequentially with a 3 µm step in z-
direction except for AD1_01z1-z3 stack, where a 5 µm step was used. 
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6.3. Results 
Confocal Raman micro-spectroscopy was used to investigate the biochemical composition and 3D 
spatial distribution of Aβ plaques and their bioenvironment in frozen human AD brain tissues from 
the hippocampus. Compared to formalin-fixed-paraffin-embedded brains studied in the previous 
study chapter, the frozen brain samples were prepared without chemical fixative and paraffin 
preservation, which allows to study the actual content of brain tissues. The Q-HIU data analysis 
was performed simultaneously on all data, allowing a direct comparison of spatial concentration 
profiles of chemical components in diseased and control samples.  
Intermediate steps of the Q-HIU data analysis on acquired Raman micro-spectroscopy images of 
hippocampal brain tissues in AD together with non-demented controls are shown in Fig. 6.1. 
Specifically, Fig. 6.1D shows the autocorrelation coefficients map for singular vectors received 
from SVD-ADC analysis of all Raman images, labelled according to the sample source and 
representing consequent planes of the representative z-stack composite image as z1, z2 and etc. 
The dotted diagonal line represents a decision line of a 50% cut-off for mean autocorrelation 
coefficients, that separates the coefficients above the line (circled cross signs – meaningful 
components) from those below it (cross signs – noise) as shown in Fig. 6.1D. Note that read-noise 
and shot noise are localized around zero, whereas physically meaningful components show high 
mean autocorrelation. For these data, SVD-ADC with a 50% cut-off of mean autocorrelation 
coefficients has defined an approximating matrix, consisting of 40 singular components. To verify 
this number, I consider the spatial distribution and corresponding spectra for two singular vectors 
with the autocorrelation coefficients that are lower and higher 50% (Fig. 6.1E-F). For a pair of 
discarded singular vectors, corresponding to 28% mean autocorrelation, spatial maps do not show 
any recognised pattern, and spectrum resembles noise, whereas for a pair of meaningful singular 
vectors with 80% mean autocorrelation, spatial maps show some colocalized features, and 
spectrum exhibits several clear Raman bands. To show the accuracy of SVD-ADC, I give the 
results of this method for two points from a Raman image of Aβ plaque (AD1_01z1) with 
low (right) and high (left) fluorescent background in Fig. 6.1B-C. As can be seen in detail in the 
inset of Fig. 6.1B, SVD-ADC method allows to significantly reduce the noise from the image. 
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Fig. 6.1: Schematic of a hyperspectral Raman cube (A). The arrows with letters B and C mark two pixels, Raman 
spectra of which are shown on the panels B and C, respectively. The input Raman spectrum (blue line) before the 
SVD-ADC and the corresponding noise-filtered Raman spectrum (black line) after this procedure (B-C). The results 
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of background subtraction using the bottom Gaussian fitting is shown by the green line: the bottom Gaussian fit 
(red dashed line) is subtracted from the noise-filtered Raman spectrum, giving background-free Raman spectrum. 
Spatio-spectral autocorrelation coefficients map of singular vectors resulted from SVD-ADC (D). The dotted 
diagonal line represents a decision line of Rth = 50% cut-off for mean autocorrelation coefficients Ri, separating the 
coefficients above the line (circled cross signs – meaningful components) from those below it (cross signs – noise). 
The spatial distribution and corresponding spectra of two singular vectors with the mean autocorrelation 
coefficients with values ≅80% and ≅28% as indicated on the panel D (E-F). On both panels, Raman images are 
labelled according to the sample source and represents hippocampal regions. 
 
Also, Fig. 6.1B, C show an example of BGF algorithm applied to the same Raman image, received 
from the SVD-ADC. The Raman spectra at two spatial pixels with high (Fig. 6.1B) and low (Fig. 
6.1C) fluorescent background before (blue line) and after (green line) background removal with 
the representative bottom Gaussian fit (red line) are demonstrated in Fig. 6.1B-C. A zoom of the 
amide I, II bands of the Raman spectrum in Fig. 6.1B shows that the BGF algorithm allows to 
accurately subtract a fluorescent background from the spectra. 
The final step of the Q-HIU data analysis is Q-US/PS-NMF. Applied to factorization analysis of 
the acquired Raman images of frozen brain tissues, I identified that all Raman images are well 
represented using 11 separate components giving a factorization error of 2.36%. When selecting 
12 components, the Q-US/PS-NMF analysis was checked to show a similar factorization error of 
2.22% and retrieved a significantly modified key component of Aβ pathology lesions exhibiting a 
noisy spatial distribution and significantly less meaningful Raman spectrum (R2 = 80%) compared 
to that for 11 components’ analysis that was assigned to a mixture of saturated CEs and fibrin 
protein (R2 = 92%). Similarly, the same component in the analysis using 10 components with a 
factorization error of 2.72% shows a Raman spectrum that significantly less resembles the 
chemical signatures of proteins and lipids, and spatial distributions having a high background 
concentration.  As deduced from the 11 components’ analysis, the chemical components, which 
attribution has been identified, are summarised in Table 6.1. 
The results reveal that one component exhibiting spectrum that resemble a specific type of lipid, 
whereas another component can be attributed to a cytoskeleton protein. Other 2 components are 
observed to contain a series of Raman bands characteristic of both proteins and lipids. Three of 
these four assigned components are found significantly localizing with Aβ plaques. The other 7 
components were found not significantly colocalizing with Aβ plaques or their chemical 
attribution has not been established based on available spectral databases. Of identified 
components, ℂ3 was found consistent with the Raman spectrum of water (R2 = 97%) using an ID 
expert tool of Bio-Rad’s KnowItAll Vibrational Spectroscopy software with Raman Spectral 
Libraries. The Raman spectra and corresponding concentration profiles of all 11 components in 
the brain samples as retrieved from the Q-US/PS-NMF analysis are given in Appendix B. In the 
course of the next sections, I will focus on the description and attribution of the chemical 
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components, which are found significantly colocalizing with Aβ plaques. Specifically, I will 
examine in detail ℂ1, ℂ2, ℂ6, ℂ9. Note, in the following, I will sort these components by decreasing 
mean Raman concentration. 
Table 6.1: Chemical component attribution retrieved from the Q-US/PS-NMF analysis with 11 components on Raman images of  
frozen brain tissue. 
Chemical component attribution 
R2 for component number ℂ# retrieved from the Q-US/PS-
NMF analysis with 11 components 
phosphatidylcholine 93% (ℂ1) 
actin 76% (ℂ2) 
water 97% (ℂ3) 
 fibrin + cholesteryl palmitate 92% (ℂ6) 
Aβ1-42 fibrils + oxidized arachidonic 
acid in trans configuration 
76% (ℂ9) 
6.3.1. Chemical composition of frozen human brain tissues in 
Alzheimer’s disease: key chemical components 
Fig. 6.2 shows the Raman spectra of the 4 chemical components colocalized with Aβ plaques, as 
obtained from the Q-US/PS-NMF data analysis of AD human brain tissues together with non-
demented controls in the fingerprint (736-1780 cm-1) and CH-stretch (2793-3122 cm-1) regions. 
The range above 3200 cm-1 is dominated by Raman scattering of water, and therefore was excluded 
from the Q-US/PS-NMF analysis to avoid its interference with the chemical components, which 
are relevant for my study. To identify chemical components’ assignments, I used Bio-Rad’s 
KnowItAll Vibrational Spectroscopy software with the Raman Spectral Libraries as a guide. Once 
I found the chemical attribution with this software, I compared the Raman spectra of the identified 
standards with the representative component spectra retrieved from my analysis using NLS 
algorithm as shown in Fig. 6.2. These comparisons revealed that 4 components can be spectrally 
assigned to phosphatidylcholine (PC) (ℂ1, R2 = 93%, Fig. 6.2A); actin (ℂ2, R2 = 76%, Fig. 6.2B); 
a mixture of fibrin and saturated CEs such as cholesteryl palmitate at a ratio of about 1:1 (ℂ6, 
R2 = 92%, Fig. 6.2C); a mixture of fibrillar Aβ1-42 and oxidized polyunsaturated acid in 
trans chemical configuration such as trans isomer of arachidonic acid (AA) at a ratio of about 1:1  
(ℂ9, R2 = 76%, Fig. 6.2D). The summary of key Raman vibrational bands, reflecting the presence 
of Aβ pathology and oxidative stress implicated in AD human brains, as retrieved from this 
research study is given in Table 6.2. 
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Table 6.2. The summary of key Raman vibrational bands indicative of Aβ pathology and oxidative stress resulting 
from the hyperspectral image unmixing analysis of Raman images of frozen AD human brains in the hippocampus. 
Raman 
shift, cm-1 
Molecular vibration Chemical assignments 
Potential role in AD 
pathogenesis, indicative 
of 
1668 
C=O (Amide I) stretch  β-sheet proteins pathogenic Aβ protein 
C=C stretch  
E-unsaturated FAs in 
trans-configuration 
oxidation of lipid 
membranes by free 
radicals, triggering the 
pro-inflammatory 
cascade and pyroptotic 
cell death 
548, 703, 
1700 
C=C stretch  cholesterol interaction with Aβ 
fibrils 
1740 C=O stretch cholesteryl ester 
718, 875  
N+(CH3)3 symmetric and 
asymmetric stretch 
phosphatidylcholine 
a major constituent of 
the grey matter of 
healthy brain tissue 
(30%)  
1068, 1088, 
1132, 1177  
C-C stretch saturated FAs 
a pronounced feature of 
AD brain tissues, 
diagnostic of oxidative 
modification of lipid 
membranes 
3004 =CH stretch unsaturated FAs 
a lacking feature of AD 
brain tissues, diagnostic 
of oxidative 
modification of lipid 
membranes 
To further justify the chemical components’ assignments, I characterised the marker Raman bands 
of the identified chemical components ℂ1, ℂ3, ℂ6 and ℂ9, that were found in a good agreement 
with the assignments using the respective Raman spectra of analytical standards based on NLS 
fitting algorithm. In particular, the attribution of ℂ1 (Fig. 6.2A) to PC was confirmed by the 
presence of two marker bands at 718 cm-1 and 875 cm-1 assigned to the symmetric and asymmetric 
stretching modes of the choline N+(CH3)3 (Krafft et al. 2005; Czamara et al. 2015). Of the FA 
content, the presence of the unsaturated carbon (C=C) chains and cis conformation of lipid ℂ1 is 
indicated by the characteristic Raman bands at 1268 cm-1 and 1662 cm-1, respectively (Krafft et 
al. 2005; Czamara et al. 2015).  
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Fig. 6.2: Raman spectra of the chemical components (blue solid lines) colocalizing with hippocampal Aβ plaques, obtained from 
the Q-US/PS-NMF analysis of AD human brain tissues together with non-demented controls. ℂ1 (A) has spectral characteristics 
resembling phosphatidylcholine. ℂ2 (B) resembles actin. ℂ6 (C) is attributed to a mixture of fibrin and saturated lipids with 
cholesteryl derivatives. ℂ9 (E) can be represented as a mixture of aggregated Aβ peptide and trans lipids such as a trans isomer of 
arachidonic acid.  The chemical attribution of components ℂ1, ℂ2, ℂ6 and ℂ9 is based on the comparison with analytical standard 
Raman spectra of pure chemical species. Fits are shown by the red dotted lines and found using NLS algorithm. Corresponding R2 
are also indicated. The fit in (A) is the Raman spectrum of phosphatidylcholine. The fit in (B) is the Raman spectrum of actin. The 
fit in (C) is a superposition of fibrin (magenta line) and cholesteryl palmitate (green line); the contributions are shown in the separate 
figure D. The fit in (E) is a superposition of the Raman spectrum of synthetic Aβ1-42 fibrils (magenta line) and arachidonic 
acid (green line); the contributions are separately shown in the figure F for the fingerprint region.  
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The Raman spectrum of ℂ6 exhibits the several diagnostic bands of cholesterol (CHL) backbone 
and CEs. Specifically, the presence of the CHL backbone is indicated by the co-occurrence of 
distinct hallmark bands at 548 cm-1, 703 cm-1 and 1670 cm-1 (the C=C stretch of the cholesterol 
ring) (Krafft et al. 2005; Czamara et al. 2015). CE attribution is confirmed by the appearance of 
characteristic small-intensity band centred at 1740 cm-1 assigned to the C=O stretching vibrations 
of the ester group (Krafft et al. 2005). The dominated presence of saturated FAs chains in the 
composition of ℂ6 is reflected by the occurrence of high/medium intensity bands at 1068, 1088, 
1132 and 1177 cm-1 due to the C-C stretching vibrations that are profound for saturated FAs, 
compared to a relatively low intensity band at 1271cm-1 and an apparently small shoulder 
at 3013 cm-1, that are both characteristic features of unsaturated FAs (Krafft et al. 2005; Czamara 
et al. 2017). The presence of protein in the composition of ℂ6 is indicated by the occurrence of the 
amide-like shoulder band at 1665 cm-1 typical for the α-helix structured proteins such as collagen 
and fibrin combined with the band at 2942 cm-1 assigned to the CH3 stretching vibrations of 
proteins. Possibly, fibrin protein can be present in the chemical composition of ℂ6, which Raman 
spectrum shows a good similarity in both the positions and shapes of the bands with its pure 
chemical reference based on NLS algorithm reflected by a high correlation similarity coefficient 
as well as the presence of characteristic vibrational bands of α-helix structures as discussed above.  
For ℂ9 (Fig. 6.2D), the structural hallmark of aggregated amyloid peptide assembled into the 
cross-β structured fibrils is confirmed by the profound high intensity amide band at 
1668 cm-1 (Kiskis et al. 2015), assigned to the C=O stretching vibrations of the protein backbone, 
and the missing shoulder located between 1662–1655 cm-1, characteristic of the α-helix structured 
proteins (Rygula et al. 2013). For the lipid content, Raman spectrum of ℂ9 spectrally resembles 
that of AA, which is an essential polyunsaturated FA in the composition of cellular membranes 
accounting for about 15% of total polyunsaturated FAs content of the phospholipid membranes in 
brain grey matter (Crawford and Sinclair 1971). Related to disease-associated pathology, AA has 
been suggested to maintain the fluidity of the cellular membranes (Tremi et al. 2018). Importantly, 
presence of polyunsaturated fats in the trans isomerization in ℂ9, known to be massively generated 
during oxidation of lipid membranes by free radicals (Tremi et al. 2018), is indicated by the high 
intensity band at 1668 cm-1 assigned to the C=C stretching vibrations of FAs in the trans 
isomerization (Sadeghi-Jorabchi et al. 1991) combined with the lack of the neighbouring band 
near 1656 cm-1 originated from the C=C stretch of FAs in the cis configuration (Czamara et al. 
2015).  The oxidation modification of polyunsaturated acid in the composition of ℂ9 is also 
reflected by the missing band around 3004 cm-1, that is a diagnostic band of unsaturated FAs 
originated from the =CH stretching vibrations (Krafft et al. 2005).  Together with the spectral 
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assignments to a superposition of fibrillar Aβ1-42 and AA, my findings suggest the attribution of 
ℂ9 to a mixture of Aβ1-42 fibrils and oxidized trans isomer of AA (ox-trans-AA). 
6.3.2. Spatial distributions of key chemical components in frozen 
human Alzheimer’s disease brains 
In this section, I analyse the spatial concentration profiles of the chemical components (ℂ1, ℂ2, ℂ6 
and ℂ9) across AD and non-demented patient groups in the hippocampal brain region. Fig. 6.3- 
Fig. 6.6 show overview results of all unmixed 3D Raman images, retrieved from the simultaneous 
Q-US/PS-NMF analysis that allowed to retrieve the chemically specific 3D concentration maps of 
AD human brain tissues affected by Aβ pathology and non-demented controls. In order to illustrate 
3D distribution of ℂ1, ℂ2, ℂ6 and ℂ9 in human brains, each unmixed z-stack composite has been 
imaged into the representative planes as AD1_01z1, AD1_01z2, AD1_01z3;…; C1_01z01-z10 
(see Section 6.2 for details on the acquired images) for each resolved component as shown in Fig. 
6.3 - Fig. 6.6. A typical step between neighbour planes was 3 µm, except for the AD1_01z1-z3 
stack, where a 5 µm step was used. Note, relative Raman concentrations are obtained from the Q-
US/PS-NMF analysis, by applying the normalization such that the mean total concentration is 
equal to unity (see Section 6.2.3 and Section 3.4 (Chapter 3) for details). 
In general, the spatial concentration profiles of unmixed Raman images revealed the high lipid 
content of the human brain tissues distributed throughout the brain regions. In particular, ℂ1, 
representing unsaturated PC-rich lipid bodies, is found to be one of the main constituents of the 
hippocampus (see Fig. 6.3). Its representative concentration maps show a rather uniform 
distribution over the human non-demented brains that remind the cell morphology (see the 
C1_01z01-z10 images in Fig. 6.3) compared to a more dispersed spatial pattern for the AD tissues 
with distinct accumulations of individual lipid droplets as clearly observed from the AD1_02z1-
z4 images of Fig. 6.3. Another lipid-rich component (ℂ6), representing a lipoprotein with a high 
CE content, appears to be the plaque-associated one that tightly envelopes the plaque core as 
visually observed from the spatial distribution of the AD1_01z1 image in Fig. 6.5.  
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Fig. 6.3: 3D spatial distributions of the Raman concentration and the corresponding component spectra of ℂ1 from 
the measured AD hippocampal brain regions and non-demented controls labelled according to the sample source 
as AD1, AD2, AD3, and C1 on colour scales as indicated, retrieved from the simultaneous Q-US/PS-NMF 
unmixing analysis of 3D Raman images of the human AD tissues affected by Aβ pathology together with non-
demented control regions. 3D distribution is shown by a sequential representation of each image plane of a 
representative z-stack as AD1_01z1, AD1_01z2, AD1_01z3;…; C1_01z01-z10. A typical step between neighbour 
planes was 3 µm, except for the AD1_01z1-z3 stack, where a 5 µm step was used. In all panels, a typical image 
size is 127×127 µm2, except for the AD1_02z1-z7 images of a 127×98 µm2 in size. 
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Fig. 6.4: 3D spatial distributions of the Raman concentration and the corresponding component spectra of ℂ2 from 
the measured AD hippocampal brain regions and non-demented controls labelled according to the sample source 
as AD1, AD2, AD3, and C1 on colour scales as indicated, retrieved from the simultaneous Q-US/PS-NMF 
unmixing analysis of 3D Raman images of the human AD tissues affected by Aβ pathology together with non-
demented control regions. 3D distribution is shown by a sequential representation of each image plane of a 
representative z-stack as AD1_01z1, AD1_01z2, AD1_01z3;…; C1_01z01-z10. A typical step between neighbour 
planes was 3 µm, except for the AD1_01z1-z3 stack, where a 5 µm step was used. In all panels, a typical image 
size is 127×127 µm2, except for the AD1_02z1-z7 images of a 127×98 µm2 in size. 
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Fig. 6.5: 3D spatial distributions of the Raman concentration and the corresponding component spectra of ℂ6 from 
the measured AD hippocampal brain regions and non-demented controls labelled according to the sample source 
as AD1, AD2, AD3, and C1 on colour scales as indicated, retrieved from the simultaneous Q-US/PS-NMF 
unmixing analysis of 3D Raman images of the human AD tissues affected by Aβ pathology together with non-
demented control regions. 3D distribution is shown by a sequential representation of each image plane of a 
representative z-stack as AD1_01z1, AD1_01z2, AD1_01z3;…; C1_01z01-z10. A typical step between neighbour 
planes was 3 µm, except for the AD1_01z1-z3 stack, where a 5 µm step was used. In all panels, a typical image 
size is 127×127 µm2, except for the AD1_02z1-z7 images of a 127×98 µm2 in size. 
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Fig. 6.6: 3D spatial distributions of the Raman concentration and the corresponding component spectra of ℂ9 from 
the measured AD hippocampal brain regions and non-demented controls labelled according to the sample source 
as AD1, AD2, AD3, and C1 on colour scales as indicated, retrieved from the simultaneous Q-US/PS-NMF 
unmixing analysis of 3D Raman images of the human AD tissues affected by Aβ pathology together with non-
demented control regions. 3D distribution is shown by a sequential representation of each image plane of a 
representative z-stack as AD1_01z1, AD1_01z2, AD1_01z3;…; C1_01z01-z10. A typical step between neighbour 
planes was 3 µm, except for the AD1_01z1-z3 stack, where a 5 µm step was used. In all panels, a typical image 
size is 127×127 µm2, except for the AD1_02z1-z7 images of a 127×98 µm2 in size. 
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As for the amyloid component, ℂ9 that is assigned to a mixture of fibrillar Aβ1-42 species and 
oxidized polyunsaturated trans lipids is observed to form the highly concentrated plaque core with 
condensed, densely packed content of these co-aggregated components (see Fig. 6.6). For 
example, the spatial distribution of this component for the images the AD1_01z1-z3 representing 
AD group shows the classical morphology of the so-called “dense core Aβ plaque” (D’Andrea and 
Nagele 2010). This type of plaque is believed to have an increased ability to attract immune cells 
such as microglia compared to other ones (D’Andrea and Nagele 2010). As an example of 
intracellular Aβ deposits, the concentration maps of ℂ9 for the images AD1_02z1-z7 show 
significant accumulations of these amyloid-lipid species apparently within the cell bodies of 
neurons. In the supplementary material I included a 3D volume view of  chemical ℂ9 (red) and ℂ1 
(blue) generated based on the AD1_02z1-z7 Raman images, projecting the spatial volumeric 
distribution of intracellular Aβ protein aggregated with oxidised polyunsaturated trans lipids (ℂ9) 
within the neuronal cells that colocalize with the phosphatidylcholine-rich lipid droplets (ℂ1).  
In the non-demented control regions, the concentration map of this mixed component (ℂ9) show 
some non-zero Raman concentrations (see the C1_01z01-z10 images in Fig. 6.6) which values are 
comparable to that for the AD3 sample. This might be due to a dominated content of the oxidized 
lipids in a mixed ℂ9 for the non-demented control sample compared to the amyloid fraction. 
Therefore, the Raman concentrations observed in the control sample represent largely the 
accumulations of lipids. Furthermore, these oxidized polyunsaturated lipid domains in the 
composition of ℂ9 show granular distribution that is colocalized to the cellular membranes 
outlining the cell shape as can be deduced from the C1_01z03 image in Fig. 6.6. Of note, these 
evident changes observed as amyloid-lipid micro-domains deposited in the cells of the non-
demented tissues might possibly indicate early signs of AD pathology, that can be important for 
early diagnosis of AD.  
For ℂ2, found to be rich in actin, the spatial distributions of this component across AD and non-
demented tissues exhibit relatively uniform spatial pattern of Raman concentrations (Fig. 6.4). 
Interestingly, the concentration maps of this component for the AD1_02z1-z7 images show the 
significant accumulations of actin that form the ellipsoid-shape cloud of possibly cell lysis 
material, surrounding the Aβ-positive neurons. This accumulation material of actin content might 
be originated from the dead cells that underwent the pro-inflammatory programmed cell 
death (pyroptosis) involving the release of lytic cellular content. 
To show colocalization of the Aβ and lipid components with the pro-inflammatory ones in human 
AD brain tissues, I show absolutely label-free Raman image, encoding the concentrations of ℂ9 
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(Aβ species co-aggregated with oxidized trans isomers of AA) in green and ℂ6 (the CE-rich 
lipid domains) in red, in comparison to the high-resolution fluorescence images of the Aβ 
stained (green) plaques co-labelled for either microglia (Iba1, blue) and gasdermin 
D (GSDMD) (red) (see Fig. 6.7A) or ASC specks (red) (see Fig. 6.7C). The inspection of these 
images together indicates that the CE-rich lipid bodies in the label-free Raman image localize to 
the pro-inflammatory microglia that tightly envelop the plaque core. Together with colocalization 
to the microglial processes, the CE halo is observed spatially correlating with the accumulations 
of the pore-forming GSDMD, characteristic of cell pyroptosis, and ASC specks, indicative of the 
canonical inflammasome activation such as NLRP3, both colocalizing to the microglial 
membranes. These observations indicate the link between the abnormal accumulations of CE lipids 
around the plaque core and the pro-inflammatory processes both induced by the Aβ pathology in 
human AD brains. 
 
Fig. 6.7: Unmixed label-free Raman image of the plaque composition (B) in human AD brains: the core enriched 
with Aβ fibrils and oxidized trans polyunsaturated lipids such as AA (green) and the surrounding halo composed 
of lipoproteins with high CEs content (red). Combined fluorescence images of Aβ-stained (green) plaques co-
labelled for GSDMD (red) and microglia (blue) (A) as well as ASC specks (red) (C), showing the localization of 
ASC specks and pore-forming GSDMD (indicated by white square) to the microglial membranes all correlated to 
the sites of the CE-rich plaque halo in the representative Raman image (B), indicating pyroptotic cell death of 
highly inflammatory immune response around the plaque. In panel B, Ox-trans-AA = oxidized trans isomer of 
arachidonic acid. 
6.4. Findings 
Frozen human brain tissues in AD were investigated using label-free confocal Raman micro-
spectroscopy. 3D Raman images of Aβ deposits surrounded by lipidomic environment were 
measured and chemically unmixed to retrieve individual biochemical profiles of the pathological 
brain composition. In relation to extracellular amyloid, my results revealed that the plaque core 
mainly consists of a mixture of aggregated Aβ1-42 protein and oxidatively-modified arachidonic 
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acid in the trans isomerization, representing one component.  Similarly, my analysis allowed to 
resolve the accumulations of intracellular Aβ1-42 aggregates co-depositing with oxidised 
polyunsaturated trans lipid bodies within the cell bodies of neurons. Also here, Raman imaging 
enabled to distinguish the ellipsoid-shaped cloud surrounding the Aβ-positive neurons consisting 
of actin, possibly representing the lytic material of dead cells underwent the programmed pro-
inflammatory cell death (pyroptosis). 
Importantly, co-deposition of Aβ1-42 fibrils with oxidised polyunsaturated lipids in one component 
possibly indicate a close interaction between these two. Importantly, oxidation status of the lipids 
within the Aβ aggregate is confirmed by the presence of the enhanced Raman band at 1668 cm-1, 
implicated during lipid peroxidation (Muik et al. 2005), combined with the lack of the Raman band 
around 3004 cm-1, indicative of unsaturated FAs or the loss/absence of C=C double 
bonds (Brozek-Pluska et al. 2012), occurring during oxidation with generation of saturated lipid 
bio-products. The significant accumulations of the oxidatively-modified arachidonic acid with 
pathogenic Aβ fibrils shown in this study might point to unresolved neuroinflammation and 
oxidative damage implicated in human AD brains in response to the chronic Aβ deposition. It is 
important to note that the results showing the accumulation of the oxidation lipid products derived 
from AA colocalizing with the aggregated Aβ protein within the plaque core and neuronal cell 
bodies, revealed the strong dysregulation of AA lipid pathways previously documented to be 
implemented in the AD pathogenesis. Indeed, a natural cis isomer of AA is known as a key 
component of phospholipid cellular membranes that maintains their fluidity and integrity whereas 
the trans configuration of AA embedded into the cell membranes was suggested to cause the 
decreased membrane fluidity and permeability with a more rigid packing, that might be detrimental 
for the cell survival (Tremi et al. 2018). In the healthy brain, AA shows anti-oxidative properties 
by activating a peroxisome proliferator-activated receptor gamma (Wang et al. 2006) and a 
syntaxin-3 (STX-3) protein implicating in the neuron growth and repair (Darios and Davletov 
2006). To that end, the disturbance of AA pathways possibly through peroxidation induced by 
toxic Aβ accumulation in the human brain might trigger the AD pathogenesis, which is consistent 
with my findings.  
The halo of the plaque is revealed to consist of predominantly lipids in spectral characteristics 
resembling CEs, that tightly envelope the Aβ core.  Using high-resolution fluorescence microscopy 
in combination with confocal Raman micro-spectroscopy, I demonstrate that the CE-rich lipid 
aggregates localize to the pro-inflammatory microglia processes surrounding the plaque core and 
are found to spatially correlate with numerous pore-forming GSDMD, indicative of pyroptosis, 
and ASC specks, reflecting the canonical inflammasome activation such as NLRP3, both 
colocalizing to the microglial membranes. This finding of the significant accumulation of CE lipids 
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within microglia colocalizing with pro-inflammatory oligomerized proteins such as GSDMD and 
ASC specks around the plaque core might point to a cross-talk between these neuroinflammatory 
cell death-inducing proteins and aberrant lipid aggregates together able to strongly amplify 
neuroinflammation and oxidative damage in human AD brains, ultimately causing 
neurodegeneration. One possible mechanism of their relationship might be suggested, representing 
the hypothetic chronic cycle of AD pathogenesis. To begin with, it is widely accepted that AD 
pathogenesis started from the deposition of aggregated Aβ proteins, that are sensed by the NLRP3 
inflammasome as a pathogenic danger signal (Halle et al. 2008). Indeed, the receptors of the innate 
immune system have been evolutionally programmed to sense surface amyloid, that is abundant 
in many bacteria (Sleutel et al. 2017). Applied to AD-associated amyloidosis, assembly of the 
NLRP3 inflammasome triggered by pathogenic Aβ leads to accumulation of pro-inflammatory 
cytokines, that are believed to shift a microglia state to the pro-inflammatory one with decreased 
phagocytic capacity (Cherry et al. 2014). Consequently, this results in impaired Aβ clearance by 
these pro-inflammatory microglia processes, that significantly contribute to accumulation of 
damage-associated molecular patterns (DAMPs) signals and lysosomal damage (evident by 
aberrant intracellular lipid build-up of lysosomal membrane oxidation material), that are in turn 
able to further alarm the NLRP3 inflammasome and therefore amplify neuroinflammation (Sarlus 
and Heneka 2017). Here, the unresolved neuroinflammation represent a conserved pattern of Aβ-
induced toxicity, which all together lead to neurodegeneration. It is also important to note that the 
mechanism of neuronal cell death implicated in AD pathogenesis possibly can be driven by 
lysosomal membrane rupture (Aits and Jaattela 2013), evident by aberrant intracellular build-up 
of lipids from oxidised lysosomal membranes within enlarged, swollen neurons and immune 
cells (Jerome et al. 1998). Lysosomal membrane oxidation can be in turn initiated through either 
the interaction of Aβ oligomers with lipid cellular membranes or the Aβ-induced inflammatory 
bio-products such as ROS with lysosomal membranes (Oku et al. 2017). To that end, the distinct 
CE lipid halo around the Aβ core revealed by label-free Raman micro-spectroscopy in this chapter 
colocalizing with strongly activated pro-inflammatory components of human AD brains might 
reflect lysosomal membrane oxidation of surrounding the plaque cells, leading to their death and 
contributing to unresolved neuroinflammation. To link Aβ accumulation to specific inflammatory 
pathways my next two study chapters will present the results of correlative fluorescence imaging 
of immuno-stained inflammatory components in Aβ plaques of post-mortem human AD brains. 
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Chapter 7. Correlative fluorescence imaging of 
amyloid-β with ASC speck and microglia in human 
Alzheimer’s disease brains: inflammatory response 
to amyloid-β aggregation 
7.1. Introduction 
Despite the long-standing model for Aβ-associated pathogenesis in AD, inflammatory and 
immunological processes are considered by many of not just mere bystanders but the central 
players in the initiation and progression of AD (Weiner and Frenkel 2006).   
The innate immune response to accumulation of pathogenic Aβ protein in AD brain begins with 
activation of resident phagocytic cells such as microglia (Sarlus and Heneka 2017). To induce 
phagocytosis of misfolded Aβ aggregates, microglia express a variety of cellular PRRs including 
but not limited to cytosolic NOD-like receptors such as NLRP3 (Halle et al. 2008; Heneka et al. 
2013). On molecular level, the recognition of amyloid-β by the NLRP3 domain induce its assembly 
with ASC and pro-caspase-1 proteins into the large protein complex called the NLRP3 
inflammasome (Latz 2010). NLRP3 activation initiates processing of pro-caspase-1 into active 
caspase-1 through interaction with ASC filaments. Active caspase-1 in turn cleaves pro-IL-1β and 
pro-IL-18 into the mature cytokines known as key mediators of neurotoxicity in “inflamed” 
brain (Latz 2010). Caspase-1 activation also produces a fragment of pore-forming gasdermin D 
that enables the release of the mature IL-1β, IL-18 and ASC specks through the gasdermin pores 
in the membrane of affected cells in the process of a pyroptotic cell death (Shi et al. 2015). In the 
extracellular space, ASC specks preserve their capability to mature pro-IL-1β following their 
ingestion by macrophages, from where ASC specks initiate a pro-inflammatory cascade (Franklin 
et al. 2014). Therefore, targeting molecules of the innate immune system that are involved in the 
regulation of the pro-inflammatory cascade are of great interest to therapy, as that could shift the 
immune response into the neuroprotective one preventing neurodegeneration.  
Not only do ASC specks responsible for caspase-1 activation during the NLRP3 inflammatory 
signalling serve as a key regulator of inflammatory responses but they are also believed to promote 
Aβ aggregation. Recent discovery using an AD mouse model (Venegas et al. 2017) proposed a 
new model of AD pathogenesis according which extracellular ASC micro-domains spread Aβ 
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toxicity by seeding a new Aβ nucleation.  The consistence with this hypothesis has been shown in 
the same study demonstrating the effectiveness of anti-ASC speck immunotherapy tested in the 
FAD mice for blockage of Aβ pathology spreading.  
The aim of this chapter is to link Aβ pathology spreading and defective microglial Aβ phagocytosis 
to specific inflammatory pathways in human AD brains. Spatial colocalization and 3D distribution 
patterns of the three AD hallmarks at the sites of Aβ plaques will be examined and quantified using 
high-resolution fluorescence microscopy. For this, co-immunostaining of the ASC speck 
neuroinflammatory complex, pathogenic Aβ protein and microglia will be performed in post-
mortem human AD brain and non-demented control to determine the significance of a pro-
inflammatory microglia phenotype in the areas of Aβ pathology and a degree of colocalization of 
ASC specks with Aβ.  
7.2. Method 
7.2.1. Human tissue samples  
Human brain tissue was sourced from the Thomas Willis Oxford Brain Collection (TWOBC), 
which is part of the Medical Research Council (MRC) Brain Bank Network, with the ethical 
approval of the Research Tissue Bank provided by the Oxford Brain Bank (OBB) Access 
Committee. Formalin-fixed-paraffin embedded brain slices of 5 μm thickness were participated in 
this study. The diseased cohort was represented by the samples of two brain regions (hippocampus 
and frontal lobe) collected from 5 AD patients. For control experiment, the non-demented control 
samples from the subjects without AD were also included in the study. 
7.2.2. Immunohistochemistry 
For immunofluorescent staining of formalin-fixed-paraffin-embedded brain sections, the 
following protocol has been used: 
1. Formalin fixed brain tissue (5 μm thick) slides were deparaffinized using a standard 
dewaxing protocol consisting of three consecutive steps: 1) heating at 60-70 °C in a pre-
heated oven for 1 hour; 2) removing the paraffin in xylene (two cycles for 20 minutes 
each); 3) rehydrating in a sequence of 100%, 90% and 70% ethanol for 5 minutes each, 
followed by three times washing in distilled water for 5 minutes each.  
2. Heat-induced epitope retrieval in boiling DAKO solution: deparaffinized brain sections 
were transferred to 1X DAKO/PBS (pH 6.2) target retrieval solution (REF S1699 – 1OX 
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concentrate) and then incubated in a preheated to and maintained at 90 °C water-bath for 
45 minutes, followed by cooling down in the solution for 20 minutes; 
3. Sections were washed three times for 5 min each in 1X PBS (pH 7.4) and blocked in 1X 
PBS/1% BSA/0.1% Triton X-100 (or 0.1% Saponin) (Blocking Buffer) for 30 min 
followed by 2 hours incubation with all primary antibodies in Blocking Buffer. 
4. Sections were washed three times in 1X PBS/0.1% Triton X-100 (Wash Buffer), and 
incubated with Alexa- 488, 546 and 633 conjugated donkey secondary antibodies 
(Invitrogen, 1:400, 5 μg/ml) diluted in Blocking Buffer for 90 min, followed by three times 
washing in Wash Buffer for 5 min each.  
5. Sections were mounted using Immu-Mount (Thermo).  
The following combination of primary antibodies for triple immunofluorescence staining of Aβ, 
ASC speck and Iba-1 was used with respective concentrations:  
• mouse monoclonal anti-Aβ (6E10, BioLegend Catalog# 803004, 1:200, 5 μg/ml) 
• rabbit polyclonal anti-ASC (AL177, AdipoGen, 1:200, 5 μg/ml),  
• goat monoclonal anti-Iba1 (AIF-1/Iba1, Novus Biologicals, 1:200, 2.5 μg/ml) 
7.2.3. Laser-scanning confocal fluorescence microscopy 
instrumentation 
High-resolution fluorescence microscopy was performed on a LSM 710 inverted confocal laser 
scanning microscope (Zeiss) using 100X/ NA 1.46 oil objective (0.23 μm lateral resolution at λ = 
0.550 μm). Images were acquired with an 8-bit colour depth, a view of 512×512 pixels, and 0.17 
µm pixel size, which results in an 85×85 µm2 image size. All images were taken using a z-stack 
mode with a step of 0.5 µm in z-direction. Emission of fluorescently labelled antibodies were 
acquired sequentially.  
7.2.4. Analysis 
Z-stack images were processed using Zen 2.5 lite imaging software. The regions of Aβ, microglial 
processes and ASC speck immunoreactivity were determined using a threshold at 20% value of 
the deviation from a representative exponentially decaying distribution histogram of Aβ, microglia 
and ASC speck fluorescence intensities. For comparison of results, the threshold at 3 STD, 1.5 
STD and 3 STD of Aβ, microglia and ASC speck total distribution histograms, respectively, were 
used as described in (Condello et al. 2015). The results of both methods are checked to produce 
124 
 
equivalent results. The example of the areas representing the plaque core and halo, determined as 
a difference of the whole plaque and its core diameters, for one cortical and one hippocampal 
plaque is shown in Fig. 7.1A, B.  The images of the thresholded Aβ, microglia and ASC speck 
fluorescence intensities for the same plaques are also given in Fig. 7.1. 
 
Fig. 7.1: Individual and merged channels fluorescence images of the thresholded Aβ, microglia and ASC speck 
fluorescence intensities for one cortical (A) and one hippocampal (B) plaques. In all panels, the white circles of 
smaller and larger radius indicate the area of plaque core and halo, respectively, selected for the quantification. 
For AD group of samples, the relative volume of antibody reactivity inside the whole 
plaque/plaque core or its halo was determined as a sum of the representative pixel intensities above 
the threshold within the corresponding plaque area divided by this area were calculated. For non-
demented hippocampal controls, the equivalent approach was used. The comparison of the relative 
volumes between AD and non-demented samples was performed through quantification of plaque 
(AD) versus non-plaque control (non-AD) regions using two-sample two-tailed t-test with unequal 
variances. To examine correlation/colocalization of the immunolabelled Aβ, ASC specks, and Iba-
1-labeled microglia, the following quantities were calculated for each plaque region: 
1. As a measure of how Aβ plaques are covered by microglia processes, the volume of the 
Aβ covered by microglia within the whole plaque, the plaque core and its halo normalised 
on the microglia-positive volume in the corresponding region (𝑉microglia+A𝛽
𝑝𝑙𝑎𝑞𝑢𝑒 𝑉microglia
𝑝𝑙𝑎𝑞𝑢𝑒⁄ ) 
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versus the volume of the Aβ un-covered by microglia within the same area normalised on 
the microglia-negative volume within this area (𝑉A𝛽−microglia
𝑝𝑙𝑎𝑞𝑢𝑒 1 − 𝑉microglia
𝑝𝑙𝑎𝑞𝑢𝑒⁄ ). 
2. As a measure of ASC speck colocalization with Aβ, the volume of the ASC specks 
colocalizing with Aβ within the whole plaque, the plaque core and its halo normalised on 
the Aβ-positive volume in the corresponding region (𝑉ASC+A𝛽
𝑝𝑙𝑎𝑞𝑢𝑒 𝑉A𝛽
𝑝𝑙𝑎𝑞𝑢𝑒⁄ ) versus the volume 
of the ASC specks non-colocalizing with Aβ within the same area normalised on the Aβ-
negative volume within this area (𝑉ASC−A𝛽
𝑝𝑙𝑎𝑞𝑢𝑒 1 − 𝑉A𝛽
𝑝𝑙𝑎𝑞𝑢𝑒⁄ ). 
3. As a measure of Aβ colocalization with ASC specks, the volume of the Aβ colocalizing 
with Aβ within the whole plaque, the plaque core and its halo normalised on the ASC 
speck-positive volume in the corresponding region (𝑉ASC+A𝛽
𝑝𝑙𝑎𝑞𝑢𝑒 𝑉ASC
𝑝𝑙𝑎𝑞𝑢𝑒⁄ ) versus the volume 
of the Aβ non-colocalizing with Aβ within the same area normalised on the ASC speck-
negative volume within this area (𝑉A𝛽−ASC
𝑝𝑙𝑎𝑞𝑢𝑒 1 − 𝑉ASC
𝑝𝑙𝑎𝑞𝑢𝑒⁄ ). 
4. As a measure of correlation/colocalization among microglia, Aβ and ASC specks: 
correlation coefficient of microglia-Aβ-ASC specks colocalization within the selected 
region according to the formula: 𝑉microglia+A𝛽+ASC
𝑝𝑙𝑎𝑞𝑢𝑒 √𝑉microglia
𝑝𝑙𝑎𝑞𝑢𝑒 𝑉A𝛽
𝑝𝑙𝑎𝑞𝑢𝑒𝑉ASC
𝑝𝑙𝑎𝑞𝑢𝑒3⁄ . 
5. As a measure of a shifted microglia state to the pro-inflammatory phenotype with 
decreased phagocytic capacity (i.e. the reduced Aβ clearance function): (1) the volume of 
microglia processes colocalized with Aβ and ASC specks within the whole plaque, the 
plaque core and its halo divided by the volume of microglia colocalized with Aβ in the 
same area (indicative of pro-inflammatory phenotype), determined as 
𝑉microglia+A𝛽+ASC
𝑝𝑙𝑎𝑞𝑢𝑒 𝑉microglia+A𝛽
𝑝𝑙𝑎𝑞𝑢𝑒⁄ , 𝑉microglia+A𝛽+ASC
𝑐𝑜𝑟𝑒 𝑉microglia+A𝛽
𝑐𝑜𝑟𝑒⁄  and 
𝑉microglia+A𝛽+ASC
ℎ𝑎𝑙𝑜 𝑉microglia+A𝛽
ℎ𝑎𝑙𝑜⁄ . 
To confirm the statistical significance of the observed effect, the representative quantities has been 
investigated between the hippocampal versus cortical plaque regions of AD brain tissues. A total 
of 42 cortical and 61 hippocampal plaques from four AD patients were included in the 
quantification. As a control group, 13 fluorescence images of the hippocampus from one non-
demented control subject were also included in the analysis. 
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7.3. Results  
In general, the Aβ plaque regions of the human AD brain tissues are found to be enveloped by 
activated microglia processes, which are strongly correlated with the co-deposits of the Aβ-ASC 
specks of about 4 μm average size within the microglial soma (see Fig. 7.2, for example).  
 
Fig. 7.2: Individual and merged channels fluorescence images of activated microglia (Iba1, blue) and ASC specks 
(AL177, red) around Aβ plaque (6E10, green) in the frontal lobe brain region of a patient with AD. Colocalization 
of anti-Aβ/ASC specks within Iba1-positive microglia supports the hypothesis of inflammasome activation in 
response to Aβ aggregation. Scale bars, 10 µm. 
In particular, activated microglia found in a close proximity to the Aβ plaque regions contain 
numerous assembled ASC (see Fig. 7.3), therefore indicating that the microglial phagocytosis of 
Aβ aggregates triggers the inflammasome activation within the microglia in the human AD brains, 
involving the formation of the ASC specks in their soma.  
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Fig. 7.3: Representative fluorescence image of co-deposition of Aβ with ASC speck-positive microglia in the 
hippocampal brain region of a patient with AD. The zoom of the outlined image area is shown on the right and 
indicates the inflammasome activation within microglia in close proximity to the Aβ plaque resulting in the distinct 
ASC speck formations. Scale bars, 20 µm. 
The cores of Aβ plaques appear to contain multiple micro-scale clusters of the ASC specks of 
various sizes, which are integrated into the plaque core and surrounded by the Aβ fibrils (see Fig. 
7.4A-C). 
To quantify the observed effects, the comparisons of the relative microglia, ASC speck and Aβ-
positive volumes within the plaque core, halo and whole plaque for cortical versus hippocampal 
plaques of AD human brains are performed using histogram distributions (upper panels) and two-
sample two-tailed t-test with unequal variances (Fig. 7.5A-C). The results of t-test represented as 
mean ± the standard error of mean (SEM) are shown in the lower panels of Fig. 7.5A-C. The 
significant difference of each antibody reactivity for hippocampal plaque (AD) versus non-
demented control (non-AD) regions is also demonstrated in Fig. 7.5A-C (lower panels) indicated 
by p-values of  2.1 ∙  10−10, 9.7 ∙  10−11 and  1.6 ∙  10−13 for microglia, ASC speck and Aβ 
channels, respectively. The analysis was based on the quantification of 42 hippocampal and 61 
cortical plaques from four AD patients. Control regions were represented by 13 fluorescence 
images from one non-demented control subject. As can be deduced from Fig. 7.5, cortical plaques 
have significantly more compact core and a stronger activation of microglia processes and ASC 
specks in the halo compared to the hippocampal plaques. However, the microglial coverage 
throughout Aβ plaque regions is found to be extremely low accounting for about 5% and 4.5% in 
the core and 8% and 5% in the halo in average for the cortical and hippocampal plaques, 
respectively (see Fig. 7.5A). 
128 
 
 
Fig. 7.4: Individual and merged channels fluorescence images of ASC specks (AL177, red) integrated into the Aβ 
cores and microglia (Iba1, blue) around in the frontal lobe (A) and hippocampal (B, C) brain regions of two patients 
with AD. Scale bars, 10 µm in all panels. 
To elucidate the degree of Aβ-microglia and Aβ-ASC speck colocalization in hippocampal and 
cortical plaques regions, I compared (i) the relative volume of Aβ covered versus uncovered by 
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microglia processes (Fig. 7.6A), (ii) the relative volume of ASC specks colocalizing versus non-
colocalizing with Aβ (Fig. 7.6B), and (iii) the relative volume of Aβ colocalizing versus non-
colocalizing with ASC specks (or in other words, in regions containing and non-containing ASC 
specks) (Fig. 7.6C) within the core, halo and whole plaque. The quantification using t-test reveals 
that microglia is significantly colocalized with Aβ in the plaque halo and core, except hippocampal 
plaques with a relatively high proportion of microglia-uncovered Aβ cores, indicative of inefficient 
microglial Aβ phagocytosis in these locations. As evident from Fig. 7.6B for the plaque core and 
halo, the volume of free ASC specks, which do not colocalize with Aβ, is negligible compared to 
the ASC volume bound to Aβ. Furthermore, according to Fig. 7.6C, about 80% of ASC specks is 
bound with Aβ in average for both hippocampal and cortical plaques, whereas the amount of Aβ 
non-colocalizing with ASC specks accounts for less than 35% and 15% for the hippocampal and 
cortical plaques in average. Altogether, these observations might indicate that the interaction of 
ASC with Aβ at the sites of plaque core and halo is a statistically significant process for both 
hippocampal and cortical Aβ plaques. 
To elucidate to what extent the pro-inflammatory microglia activation associated with the Aβ 
accumulations and diverse for different brain regions with AD pathology, the activated pro-
inflammatory microglial state was quantified within the plaque areas in the hippocampus and 
cortex, by calculating the volume ratio of microglia processes colocalized with Aβ and ASC 
specks in this area to that colocalized with Aβ. The results are shown in Fig. 7.7A.  Specifically, 
the distribution histograms testifying the shifted microglia phenotype reveals that the cortical 
plaques are characterized by microglia processes containing both Aβ and ASC specks and 
statistically showing that ASC specks are present in about 90% of Aβ-positive microglia in 
average, therefore indicating a significant upregulation of the pro-inflammatory microglial 
phenotype in response to aggregated Aβ in the cortical plaques of human AD brains. In contrast, 
the hippocampal plaque cores appear to be associated with the less reactive microglial state, which 
does not accumulate the significant amounts of ASC specks in their somas compared to the cortical 
plaque ones (𝑝  =  6.2 ∙  10−11). 
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Fig. 7.5: (A-C) Quantification of relative microglia, ASC speck and Aβ-positive volumes within the plaque core, 
halo and whole plaque for cortical versus hippocampal plaques of AD human brains. Data are represented as 
histogram distributions (top panels) and mean ± SEM (bottom panels). The examination of each antibody reactivity 
for hippocampal plaque (AD) versus non-demented control (non-AD) regions is also given, confirming a 
statistically significant increase of microglia, ASC and Aβ immunoreactivity in plaque regions.  
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Fig. 7.6: Quantification of cortical and hippocampal plaques revealing a high degree of the Aβ-microglia (A) 
and Aβ-ASC speck (B) colocalization in the plaque core, halo and whole plaque, except hippocampal core with 
a statistically non-significant microglial Aβ coverage. Data are represented as mean ± SEM. 
 
 
132 
 
  
 
Fig. 7.7: (A-B) Quantification of the Aβ-ASC speck-microglia immunolabelled fluorescence images revealing a 
significant shift of the microglial activation to the pro-inflammatory state in the cortical plaque cores compared to 
the hippocampal ones. Data are represented as mean ± SEM. 
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7.4. Findings 
The analysis of correlative fluorescence images of the immunolabelled with Aβ/ASC 
specks/microglia AD brain sections and corresponding non-demented controls shows that ASC 
specks strongly colocalize with Aβ in the plaque cores of AD human brains and the statistical 
significance of this effect has been demonstrated. As shown in this chapter, the relative volume of 
the microglia-associated Aβ, indicative of microglial Aβ phagocytosis, is found to be similar 
between the cortical and hippocampal Aβ plaques accounting for about 50% in average for both 
plaque core and halo.  However, the quantification reveals that the cores of hippocampal plaques 
contain significant amount of Aβ accumulations, which are not covered by microglia processes. 
Furthermore, colocalization of the Aβ-ASC specks within microglia, that might be a hallmark of 
a pro-inflammatory microglial Aβ phagocytosis, is found to be high for the sites of plaque halos. 
The extent of this colocalization is more pronounced for the cortical plaques accounting for about 
65% average correlation value. In contrast, the pro-inflammatory microglial Aβ phagocytosis in 
the Aβ core is several times less efficient compared to that in the halo as evident from a 2- and 5-
fold decrease in microglia-Aβ-ASC speck correlation value for the cortical and hippocampal core, 
respectively. Importantly, the cortical plaques are observed to be associated with a significantly 
upregulated pro-inflammatory microglia phenotype containing the largely increased 
accumulations of ASC specks compared to the hippocampal plaques. The degree of this effect is 
markedly greater for the Aβ plaque cores as evident by a surprisingly small p-value (𝑝  =  6.2 ∙
 10−11). My findings suggest that the microglial phagocytosis of Aβ aggregates triggers the 
inflammasome activation within microglia in the human AD brains, resulting in the formation of 
the ASC specks in their soma. Then, the ASC specks possibly undergo the release from the 
microglia to the extracellular space, where they promote Aβ oligomer assembly. Possibly, 
accumulations of pro-inflammatory cytokines, resulted from the inflammasome activation within 
microglia, in the place of intensive Aβ aggregation polarize the microglial phenotype to a pro-
inflammatory state with impaired phagocytic capacity of aggregated Aβ.  
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Chapter 8. Correlative fluorescence imaging of 
amyloid-β with ASC speck and complement 
component 9 in human Alzheimer’s disease brains: 
inflammatory response to amyloid-β aggregation 
8.1. Introduction 
It has been reported that the activation of the complement system pathway in response to Aβ 
aggregation results in the reduction of Aβ plaque burden in AD brains. Specifically, the studies in 
AD transgenic mouse models have found that the treatment with transforming growth 
factor β1 (TGF-β1), stimulating upregulation of the complement C3 (Hogasen et al. 1995) protein, 
enhances the microglial phagocytosis of C3b-opsonized Aβ deposits, resulting in a 50% reduction 
of the Aβ plaque burden (Wyss-Coray et al. 2001; D’Andrea et al. 2004). Thus, it is not far-fetched 
to hypothesize that MAC can also possibly help to clear Aβ load by creating MAC pores on the 
Aβ plaque surface containing lipid vesicles, that are shown to be a major component of the Aβ 
plaque (see Chapter 5-6), thereby facilitating the MAC incorporation. Upon assembly of MACs 
on the amyloid-lipid plaque complex, they might destabilise the plaque chemical structure and 
induce its dissociation into less toxic forms that are more sensitized for brain phagocytic cells of 
the innate immune system. On the other hand, the recent studies in human lung epithelial cells 
show that accumulation of MAC pores in the cell membranes disturb calcium homeostasis 
resulting in Ca2+ efflux in the mitochondrial matrix, that in turn induces the NLRP3 activation, 
thereby initiating a pro-inflammatory response and cell apoptosis (Triantafilou et al. 2013). 
Applied to AD brains, the detrimental pro-inflammatory role of MAC on adjacent to plaque 
neuronal cells might be also associated with the activated NLRP3 inflammasome and formation 
of ASC specks. It is important to note that chronic Aβ aggregation occurring in the course of AD 
results in an excessive generation of the NLRP3 pathway products including ASC specks, leading 
to unresolved inflammation with fatal consequences for the activated cells and surrounding tissues. 
In response to NLRP3 activation by Aβ pathogen, gasdermin D of the NLRP3 inflammatory 
signalling induces the pyroptosis of activated cell (Shi et al. 2015), allowing the release of ASC 
specks into extracellular space (Latz 2010). As identified by recent in vitro studies, extracellular 
ASC specks play an important role in Aβ pathology spreading due to their unique ability to seed 
Aβ oligomer assembly (Venegas et al. 2017). This finding is also in line with the results of the 
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previous chapter, where I showed the significance of the ASC speck incorporation into the Aβ 
plaque cores.  
The aim of this chapter is to better characterise lethal and pro-inflammatory effects of the MAC 
complex of the late stage complement cascade on Aβ clearance and the propagation of 
neuroinflammation in human AD brains. Quantification and correlation of spatial distribution 
patterns of the three AD hallmarks at the sites of Aβ plaques will be investigated using high-
resolution fluorescence microscopy. For this, co-immunostaining of the ASC speck (indicative of 
the NLRP3 inflammasome assembly), pathogenic Aβ protein and the complement component 9 
of MAC pores will be performed in post-mortem human AD brain and non-demented control to 
determine the significance of the inflammasome activation effect in conjunction with activated 
MAC pores in the areas of Aβ pathology and access a potential capability of MAC pores to 
facilitate Aβ clearance. 
8.2. Method 
8.2.1. Human tissue samples  
As in Chapter 7, human brain tissue was obtained from the Thomas Willis Oxford Brain 
Collection (TWOBC), which is part of the Medical Research Council (MRC) Brain Bank 
Network, with the ethical approval of the Research Tissue Bank provided by the Oxford Brain 
Bank (OBB) Access Committee. Correlative fluorescence imaging study of this chapter was 
performed on formalin-fixed-paraffin embedded brain slices of 5 μm thickness. The diseased 
group is originated from the samples of two brain regions (hippocampus and frontal lobe) coming 
from 5 AD patients. For control experiment, the non-demented control cohort of samples from the 
individuals without AD were also participated in the study. 
8.2.2. Immunohistochemistry 
For immunofluorescent staining of the formalin-fixed-paraffin-embedded tissue brain sections, the 
following protocol has been used: 
6. Formalin fixed brain tissue (5 μm thick) slides were deparaffinized using a standard 
dewaxing protocol consisting of three consecutive steps: 1) heating at 60-70oC in a pre-
heated oven for 1 hour; 2) removing the paraffin in xylene (two cycles for 20 minutes 
each); 3) rehydrating in a sequence of 100%, 90% and 70% ethanol for 5 minutes each, 
followed by three times washing in distilled water for 5 minutes each.  
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7. Heat-induced epitope retrieval in boiling DAKO solution: deparaffinized brain sections 
were transferred to 1X DAKO/PBS (pH 6.2) target retrieval solution (REF S1699 – 1OX 
concentrate) and then incubated in preheated to and maintained at 90 °C water-bath for 45 
minutes, followed by cooling down in the solution for 20 minutes; 
8. Sections were washed three times for 5 min each in 1X PBS (pH 7.4) and blocked in 1X 
PBS/1% BSA/0.1% Triton X-100 (or 0.1% Saponin) (Blocking Buffer) for 30 min 
followed by 2 hours incubation with the primary antibodies in Blocking Buffer. 
9. Sections were washed three times in 1X PBS/0.1% Triton X-100 (Wash Buffer), and 
incubated with Alexa- 488, 546 and 633 conjugated donkey secondary antibodies 
(Invitrogen, 1:400, 5 μg/ml) diluted in Blocking Buffer for 90 min, followed by three times 
washing in Wash Buffer for 5 min each.  
10. As an indicator of Aβ plaque regions, Th-S dye was used for detection in green channel. 
For Th-S staining, after immunofluorescent labelling or prior mounting with an anti-fade 
media, brain slides were incubated in 1x PBS/0.01 % Th-S solution for 20 minutes, 
followed by differentiation cycles with 80%, 95% ethanol for 2 minutes each and 
subsequent three times washing in PBS for 5 minutes each. 
11. Sections were mounted using Immu-Mount (Thermo).  
The following combination of primary antibodies were used with respective concentrations for 
triple immunofluorescence staining of Aβ, ASC speck and C9/C5b-9 of the MAC complex: 
• Aβ (Th-S dye, 0.01 % (m/v) solution in PBS) 
• rabbit polyclonal anti-ASC (AL177, AdipoGen, 1:200, 5 μg/ml),  
• mouse C9 neoantigen (mAb WU13-15, Hycult Biotech, 1:25, 4 μg/ml) or mouse 
monoclonal anti-C5b-9 (ab66768, Abcam, 1:50, 20 μg/ml). 
8.2.3. Laser-scanning confocal fluorescence microscopy 
instrumentation 
As in Chapter 7, high-resolution fluorescence microscopy was performed on a LSM 710 inverted 
confocal laser scanning microscope (Zeiss) using 100X/ NA 1.46 oil objective (0.23 μm lateral 
resolution at λ = 0.550 μm). Images were acquired with an 8-bit colour depth, a view of 512×512 
pixels, and 0.17 µm pixel size, which results in an 85×85 µm2 image size. All images were taken 
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using a z-stack mode with a step of 0.5 µm in z direction. Emission of fluorescently labelled 
antibodies were acquired sequentially.  
8.2.4. Analysis 
Similar to Chapter 7, z-stack images were processed using Zen 2.5 lite imaging software. The 
regions of Aβ, microglia processes and ASC speck immunoreactivities were determined using a 
threshold at 20% value of the deviation from a representative exponentially decaying distribution 
histogram of Aβ, C9 and ASC speck fluorescence intensities. For comparison of results, the 
threshold at 3 STD, 1.5 STD and 3 STD of Aβ, C9 and ASC speck total distribution histograms, 
respectively, were used as described in (Condello et al. 2015). The results of both methods are 
checked to produce equivalent results. The example of the areas representing the plaque core and 
halo, determined as a difference of the whole plaque and its core diameters, for one hippocampal 
and one cortical plaque is shown in Fig. 8.1.  The images of the thresholded Aβ, C9 and ASC 
speck fluorescence intensities for the same plaques are also given in Fig. 8.1. 
 
Fig. 8.1: Individual and merged channels fluorescence images of the thresholded Aβ, C9 and ASC speck 
fluorescence intensities for one cortical (A) and one hippocampal (B) plaques. In all panels, the white circles of 
smaller and larger radius indicate the area of plaque core and halo, respectively, selected for the quantification. 
As in Chapter 7, an equivalent methodology was used for the analysis of C9-ASC speck-Aβ 
labelled fluorescence images of Aβ plaques in hippocampal and frontal lobe regions of AD human 
brains. The comparison of the fluorescence images between the hippocampal plaques (AD 
patients) and control regions (non-AD subjects) was also included. Characteristic quantities were 
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calculated using the same approach as for microglia-ASC speck-Aβ labelled fluorescence images. 
A total of 35 cortical and 43 hippocampal plaques from four AD patients were included in the 
quantification. As a control group, 16 fluorescence images of the hippocampal regions of brain 
from one non-demented control subject were also participated in the analysis. Two-sample two-
tailed t-test with unequal variances was used to demonstrate the significance of the observed effect. 
To examine correlation/colocalization of the immunolabelled ASC specks, C9 and Th-S stained 
Aβ, the following quantities were calculated for each plaque region: 
1. As a measure of C9-Aβ colocalization: (1) the volume of C9 colocalizing with Aβ within 
the whole plaque, the plaque core and its halo normalised on the Aβ-positive volume in the 
corresponding region (𝑉C9+A𝛽
𝑝𝑙𝑎𝑞𝑢𝑒 𝑉A𝛽
𝑝𝑙𝑎𝑞𝑢𝑒⁄ ) versus the volume of the C9 non-colocalizing 
with Aβ within the same area normalised on the Aβ-negative volume within this area 
(𝑉C9−A𝛽
𝑝𝑙𝑎𝑞𝑢𝑒 𝑉1−𝐴𝛽
𝑝𝑙𝑎𝑞𝑢𝑒⁄ ); (2) correlation coefficient of C9-Aβ colocalization within the selected 
region according to the formula: 𝑅 =  𝑉𝐶9+A𝛽
𝑝𝑙𝑎𝑞𝑢𝑒 √𝑉𝐶9
𝑝𝑙𝑎𝑞𝑢𝑒𝑉A𝛽
𝑝𝑙𝑎𝑞𝑢𝑒⁄ . 
2. As a measure of ASC-Aβ colocalization: (1) the volume of Aβ colocalizing with ASC 
specks within the whole plaque, the plaque core and its halo divided by the ASC-positive 
volume in the same area (𝑉ASC+A𝛽
𝑝𝑙𝑎𝑞𝑢𝑒 𝑉ASC
𝑝𝑙𝑎𝑞𝑢𝑒⁄ ) versus the volume of the Aβ non-colocalizing 
with ASC within the same area normalised on the ASC-negative volume within this area 
(𝑉A𝛽−ASC
𝑝𝑙𝑎𝑞𝑢𝑒 1 − 𝑉ASC
𝑝𝑙𝑎𝑞𝑢𝑒⁄ ). 
3. As a measure of C9-ASC speck colocalization: the volume of ASC specks colocalizing 
with C9 within the whole plaque, the plaque core and its halo divided by the C9-positive 
volume in the same area (𝑉C9+ASC
𝑝𝑙𝑎𝑞𝑢𝑒 𝑉C9
𝑝𝑙𝑎𝑞𝑢𝑒⁄ ) versus the volume of the ASC specks non-
colocalizing with C9 within the same area normalised on the C9-negative volume within 
this area (𝑉ASC−C9
𝑝𝑙𝑎𝑞𝑢𝑒 1 −  𝑉𝐶9
𝑝𝑙𝑎𝑞𝑢𝑒⁄ ). 
4. As a measure of potential difference between Aβ areas colocalizing with C9 compared to 
that with ASC, possibly testifying the significance of the neuroprotective effect of MAC 
pores on the shrinkage of the Aβ plaque area versus the neurotoxic effect of ASC on the 
Aβ plaque growth: the volume of Aβ colocalized with C9 within the whole plaque, the 
plaque core and its halo divided by the Aβ-positive volume in the same area 
(𝑉𝐶9+𝐴𝛽
𝑝𝑙𝑎𝑞𝑢𝑒 𝑉𝐴𝛽
𝑝𝑙𝑎𝑞𝑢𝑒⁄ ) versus the volume of the Aβ colocalized with ASC within the same area 
normalised on the Aβ-positive volume within this area (𝑉𝐴𝑆𝐶+𝐴𝛽
𝑝𝑙𝑎𝑞𝑢𝑒 𝑉𝐴𝛽
𝑝𝑙𝑎𝑞𝑢𝑒⁄ );  
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To confirm the statistical significance of the observed effect, the representative quantities has been 
investigated in the hippocampal and cortical plaque regions of AD brain tissues using two-sample 
two-tailed t-test with unequal variances.  
To check whether C9 and Aβ levels are inversely correlated at the sites of plaque cores, I used 
Pearson’s correlation coefficient (R) calculated for the core areas and determined according to the 
formula:  
 𝑅 =  
cov (IC9,IAβ)
σ(IC9)σ(IAβ)
, (8.1) 
where 𝑐𝑜𝑣 is the covariance and σ(IC9), σ(IAβ) are the standard deviation of the fluorescence 
intensities of C9 (IC9) and Aβ (IAβ), respectively. 
In this quantification, the pixels with ‘zero’ fluorescence intensity of Aβ or C9 were excluded from 
the analysis. For each plaque with the negative correlation of C9 with Aβ, the dependence of the 
Aβ intensities from the C9 ones within the plaque core was investigated. For this, one plane from 
a z-stack fluorescence image of Aβ plaque was used. The data were represented as mean ± SEM.  
8.3. Results 
To investigate the balance between potential neuroprotective and neurotoxic role of MAC against 
plaque toxicity, the confocal fluorescence images of the anti-Aβ-stained plaques co-
immunolabelled for C9 and ASC specks in AD human brains of two regions (hippocampus and 
frontal lobe) together with non-demented controls were examined. The co-immunofluorescence 
images show that MAC components appear to create multiple pores within the Aβ plaque core by 
arranging in deposits of small (colocalized with the Aβ core in the centre) and large (colocalized 
with the inner perimeter of the Aβ core in the ring) diameters. MAC accumulations of larger 
diameter tend to form the ring-shaped accumulations within the Aβ core (Fig. 8.3), whereas the 
smaller-scale MAC deposits appear to colocalize with the Aβ core in the centre (Fig. 8.2). The 
presence of the MAC deposits inserted into the Aβ plaque core (Fig. 8.2, Fig. 8.4) might suggest 
that the MAC pores formed during the Aβ aggregation. 
140 
 
 
Fig. 8.2: Individual and merged channels fluorescence images of the MAC pores (C9, blue) integrated into the Aβ  
core (Th-S, green) and ASC specks (AL177, red) around in the hippocampal brain region of AD patient. Scale bars, 
10 µm. 
The inspection of the MAC-ASC speck correlation reveals the accumulation of numerous ASC 
speck deposits, indicative of NLRP3 inflammasome activation, around the MAC pores at the sites 
of Aβ plaque cores (Fig. 8.2-Fig. 8.7), and therefore reflecting the MAC as a possible driver of the 
pro-inflammatory inflammasome activation in response to Aβ aggregation in human AD brains.  
It has been observed that the spatial distribution of the ASC specks in some MAC-positive plaque 
cores tend to be more uniform (Fig. 8.2 and Fig. 8.3), whereas other plaque cores accumulate 
district ASC specks and MAC pores both co-localizing to the apoptotic cell membrane (Fig. 8.5 
and Fig. 8.7). 
141 
 
 
Fig. 8.3: Individual and merged channels fluorescence images showing the ring-shaped deposits of MAC pores 
(C9, blue) within the Aβ  core (Th-S, green) and ASC specks (AL177, red) around in the hippocampal brain region 
of AD patient. Scale bars, 10 µm. 
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Fig. 8.4: Individual and merged channels fluorescence images revealing the presence of MAC pores (C9, blue) 
within the Aβ core (Th-S, green) with ASC specks (AL177, red) around in the hippocampal brain region of AD 
patient. Scale bars, 10 µm. 
To elucidate the degree of cross-correlation of C9, ASC specks and Aβ species, I compared (i) the 
relative volumes of C9 colocalizing versus non-colocalizing with Aβ (Fig. 8.9B), (ii) the relative 
volume of Aβ colocalizing versus non-colocalizing with ASC specks (Fig. 8.10A) as well as 
(iii) the relative volume of ASC specks colocalizing versus non-colocalizing with C9 complex 
(Fig. 8.10B) within the core, halo and whole plaque. The correlation coefficient for C9-Aβ 
complex has been also examined in Fig. 8.9A. In general, quantification of cortical and 
hippocampal plaques reveals a high degree of a pairwise colocalization of the investigated species 
within Aβ plaque cores, implying a direct link between these three. Analysis of Aβ-C9 correlation 
in both cortical and hippocampal plaques reveals that the pore-forming C9 strongly colocalize with 
Aβ at the sites of plaque cores as indicated by a high correlation value (Fig. 8.9A) and significant 
volume of C9-Aβ co-arrangements (Fig. 8.9B) within the Aβ-positive plaque regions. This 
observation implies the significance of MAC pore deposition within the Aβ plaque cores. 
Additionally, this effect is found to be strong at the sites of plaque halos, however it is less 
profound compared to the core based on p-values. 
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Fig. 8.5: Activation of the NLRP3 inflammasome and ASC speck assembly are triggered in response to sublytic 
MAC deposition in AD human brains. Figure shows the colocalization of the MAC (С-9, blue) and ASC specks 
(AL177, red) to the membranes of apoptotic cells activated within the core of the Aβ plaque (Th-S, green) in the 
hippocampal brain region of AD patient 5. Scale bars, 10 µm.  
In relation to Aβ-ASC speck quantification (Fig. 8.10A), almost all ASC specks are found to 
colocalize with Aβ fibrils at the sites of plaques (𝑉ASC+A𝛽
𝑝𝑙𝑎𝑞𝑢𝑒 ≈ 𝑉ASC
𝑝𝑙𝑎𝑞𝑢𝑒
), indicating their interaction. 
Furthermore, the ASC specks are observed to colocalize with MAC pores (C9) at the sites of 
plaque core and halo, except the cortical plaque core, where the colocalization of ASC with C9 is 
found to be non-significant (Fig. 8.10B).  
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Fig. 8.6: Individual and merged channels fluorescence images showing the co-accumulation of MAC pores (C5b-
9, blue) and ASC specks (AL177, red) throughout the cortical Aβ plaque (Th-S, green) in the frontal lobe brain 
region of AD patient 4. Scale bars, 10 µm. 
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Fig. 8.7: Individual and merged channels fluorescence images showing the significant accumulations of MAC 
pores (C9, blue) and ASC specks (AL177, red) in the cortical Aβ plaque (Th-S, green) of the hippocampal brain 
region of AD patient 2. Scale bars, 10 µm.  
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Fig. 8.8: (A-C) Quantification of relative C9, ASC speck and Aβ-positive volumes within the plaque core, halo and 
whole plaque for cortical versus hippocampal plaques of AD human brains. Data are represented as histogram 
distributions (top panels) and mean ± SEM (bottom panels). The examination of each antibody reactivity for 
hippocampal plaque (AD) versus non-demented control (non-AD) regions is also given, confirming a statistically 
significant increase of C9, ASC and Aβ immunoreactivity in plaque regions and the specificity of the used 
antibodies. 
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Further examination of plaques regions reveals the subpopulation of the cortical plaques (15 
plaques from a total population) that is characterized by the downregulated ASC activation and 
inverse correlation of C9 with Aβ levels at the sites of plaque core (see Fig. 8.11A,C,E). 
Specifically, colocalization histograms testifying the dependence of Aβ from C9 immunoreactivity 
reveals a marked reduction of Aβ-positive area of the plaque core, where C9 is upregulated (see 
Fig. 8.11B,D,F). Therefore, this observation might indicate that MAC clustering within the Aβ 
plaque cores can potentially stimulate the local clearance of Aβ burden in AD brains.  
Collectively, my data show that the increased coverage of Aβ plaque cores by MAC pores might 
be associated with enhanced microglial Aβ phagocytosis lowering the local Aβ concentrations. In 
 
Fig. 8.9: (A-B) Quantification of cortical and hippocampal plaques revealing a high degree of the Aβ-C9 
colocalization in the plaque core, halo and whole plaque that indicate the significance of the pore-forming C9 
accumulation within the core and halo of the Aβ plaques. Data are represented as mean ± SEM. The histogram 
distributions of the correlation value for C9-Aβ complex (𝑅C9+A𝛽) are also included (A, top panel). For the 
hippocampal region, a comparison of 𝑅𝐶9+𝐴𝛽  between plaques and normal control regions coming from non-AD 
patients is given. 
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contrast, the increased coverage of Aβ plaque cores with ASC specks has been shown in the 
previous chapter (Section 7.3) to be linked to the increased ASC-associated pro-inflammatory 
microglia phenotype that might lead to Aβ pathology spreading (Venegas et al. 2017). 
 
Fig. 8.10: Quantification of cortical and hippocampal plaques revealing a colocalization of ASC specks with Aβ 
(A) and C9 (B) in the plaque core, halo and whole plaque, except the cortical plaque core. (C) Quantification 
indicating the significance of the neuroprotective MAC effect on Aβ plaque shrinkage compared to the neurotoxic 
effect of ASC on Aβ plaque growth exclusively in the cortical plaque core. Data are represented as mean ± SEM. 
Therefore, the difference of relative MAC and ASC specks volumes colocalizing with Aβ within 
the plaque cores (𝑉C9+A𝛽
𝑐𝑜𝑟𝑒  versus 𝑉ASC+A𝛽
𝑐𝑜𝑟𝑒 ) can possibly reveal whether the MAC-mediated Aβ 
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clearance is a more significant effect of AD brains compared to the ASC-induced Aβ assembly 
and toxicity. The results of this quantification confirm the significance of the pro-phagocytic effect 
of MAC pores on the shrinkage of the Aβ plaque area versus the neurotoxic effect of ASC on the 
Aβ plaque growth observed as a prominent feature of the cortical plaque core only (Fig. 8.10C). 
 
Fig. 8.11: Quantification of the C9-ASC-Aβ-stained cortical plaques revealing an inverse correlation of C9 with 
Aβ levels and therefore indicating the pore-forming C9 as a potential driver of Aβ phagocytosis able to lower Aβ 
concentration in AD brains: fluorescence images of the C9-positive plaques (A,C,E) and corresponding dependence 
of Aβ from C9 levels within the area of their colocalization at the sites of the plaque core (B,D,F). The representative 
Pearson’s correlation coefficients R are also indicated on top. Scale bars in all panels, 10 µm. 
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The discriminative pattern of C9 and ASC speck co-activation within the Aβ plaque areas between 
the frontal lobe and hippocampal brain regions might depend from the plaque size. Statistically, 
cortical plaques are observed to be significantly more compact compared to the hippocampal ones 
as evident by small p-value (𝑝  =  2.7 ∙  10−11 in Fig. 8.12). Therefore, I hypothesize that cortical 
Aβ plaques of statistically smaller diameters are more prone to MAC-associated clearance. Indeed, 
quantification of C9 (indicative of MAC pores) correlation with the size of plaque core reveals 
that MAC pore coverage of cortical plaque cores decreases while the plaque core grow (Fig. 
8.13A), whereas hippocampal plaques do not show a clear dependence of MAC activation from 
the plaque core diameter (Fig. 8.13B). This observation might imply that the pro-phagocytic MAC 
activity on local reduction of Aβ levels is inversely correlated with the size of cortical plaques. 
Analysis of ASC speck correlation with the size of plaque in turn shows that ASC speck coverage 
is greater for smaller plaques in the hippocampus (Fig. 8.13H). In contrast, cortical plaques do not 
exhibit a distinct dependence in a degree of ASC speck activation from the plaque diameter (Fig. 
8.13G). 
 
Fig. 8.12: Quantification of plaque diameter in two brain regions showing a striking difference in the size of cortical 
plaques compared to hippocampal ones. A resulting p-value is given.  
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Fig. 8.13: (A-D) Quantification of C9 correlation with the size of plaque core (A,B) and whole plaque diameter 
(C,D) in the frontal lobe and the hippocampal brain regions revealing a reduced pore-forming C9 coverage of 
cortical plaques with larger core diameter. (E-H) Quantification of ASC speck correlation with the size of plaque 
showing a decreased ASC speck coverage of larger plaques in the hippocampus (H). Pearson’s correlation 
coefficients R are also given. 
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8.4. Findings 
The analysis of correlative fluorescence images of the Th-S stained Aβ plaques co-immunolabelled 
with the complement component 9 (representing MAC pores) and ASC specks (indicative of 
NLRP3 inflammasome activation) of AD brain sections shows that the MAC pores strongly 
colocalize with the Aβ plaque core of AD human brains, and the statistical significance of this 
effect has been demonstrated. ASC specks in turn are observed to cluster around the MAC pores, 
and therefore indicating the MAC as a trigger of the inflammasome activation at the sites of the 
Aβ accumulation.  Quantitatively, the deposition of MAC pores and ASC specks within the 
hippocampal plaques are found to be a balanced effect with similar degree of activation. In 
contrast, the cortical plaque cores show a specific pattern. The plaque core in this brain region is 
found to be associated with the significantly upregulated activation of the MAC pores compared 
to ASC specks as evident by a surprisingly small p-value (𝑝  =  4.7 ∙  10−7). Along this 
observation, quantification of the plaque cores testifying an inverse correlation of C9 with Aβ 
intensities using a Pearson’s correlation coefficient reveals the local decrease of Aβ levels at the 
sites of the cortical plaque cores, where MAC is upregulated. Collectively, these two observations 
might suggest that the MAC pores incorporated into the Aβ core can play a neuroprotective role 
by contributing to the Aβ phagocytosis, that results in shrinkage of the Aβ plaque areas.  Strikingly, 
this possible MAC function with a potential Aβ clearance capacity is found to be inversely 
correlated with the plaque size as evident from the quantification of cortical plaques that are 
statistically more compact and therefore more prone to the MAC effect. My data might suggest 
that Aβ aggregation cause a persistent activation of the complement cascade followed by formation 
of the MAC pores within Aβ aggregate, that locally reduce Aβ levels through phagocytosis. While 
Aβ plaque grows, a pro-phagocytic function of MAC is decreasing, leading to an uncontrollable 
expansion of the Aβ plaque areas and thereby the amplified neurotoxicity in human AD brains. 
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Chapter 9. Discussion and conclusions 
My thesis studied in detail spatially resolved chemical composition of Aβ plaques and their 
lipidomic and inflammatory microenvironment in post-mortem AD human brains using label-free 
confocal Raman micro-spectroscopy and high-resolution laser-scanning fluorescence microscopy. 
In the course of this chapter, I will summarise novel research outcomes of my thesis and emphasize 
its potential biomedical applications.    
9.1. Raman micro-spectroscopy as a label-free tool for 
correlative 2D and 3D chemical imaging of Aβ plaques 
with both neuroinflammatory and lipidomic biomarkers 
of altered metabolism in AD human brains            
In Chapter 5 and Chapter 6, I investigated in detail the chemical composition and performed 
correlative imaging of Aβ plaques with both neuroinflammatory biomarkers and lipids in post-
mortem AD human brains by Raman micro-spectroscopy. For the formalin-fixed-paraffin-
embedded brain sections studied in the hippocampal and frontal lobe brain regions by point-scan 
Raman micro-spectroscopy (Chapter 5), Raman micro-spectroscopy has been proven to detect 
striking differences in lipid composition as well as elevated concentration levels of oxidative stress 
and inflammatory bio-markers strongly colocalizing to the Aβ plaque areas of diseased tissues 
compared to controls. Specifically, Aβ plaque areas found spatially correlating with significant 
accumulations of chemical components assigned to a mixture of cholesteryl esters with saturated 
long-chain FAs and Aβ fibrils, a mixture of fibrin and arachidic acid, CLAC, β-carotene, 
magnetite, and calcium phosphate, that altogether and individually reflect oxidative damage of AD 
brains and neuroinflammation. Not only did I find the altered levels of lipid components between 
AD and non-demented control brains, but I also was able to detect the functional changes in lipid 
composition of AD tissues that are hallmarks of oxidative damage (Chapter 5). Specifically, 
human AD brains are observed to contain the abundant pathological signatures of lipid 
peroxidation as evident by presence of trans double bonds in the Raman spectrum of the saturated 
CE-Aβ fibril mixed component. Also, oxidative stress in AD brains was revealed by the 
accumulations of arachidic acid known to be generated through oxidative modification of AA. As 
another marker of oxidative damage, the significant accumulations of calcium phosphate are found 
to colocalize with the cores of cortical Aβ plaques, possibly reflecting the lethal neurotoxic and 
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pro-inflammatory effect of Aβ species on cells through the pathogenic formation of Aβ ion pores 
in the neuronal membranes of affected cells that is in turn linked to severe Ca2+ pathway disruption 
(Yatin et al. 1998; Kayed and Lasagna-Reeves 2013).  
Altogether, Chapter 5 shows that AD brains accumulate excessive levels of the oxidative stress 
and inflammatory markers, spatially colocalized with amyloid and lipids in the Aβ plaques, 
thereby reflecting oxidative damage as a central player in the AD pathogenesis. Importantly, my 
data support the model that this plaque environment, shown to consist of the significant deposits 
of saturated cholesteryl esters, fibrin/arachidic acid, β-carotene and iron oxide, might contribute 
to plaque aggregation and Aβ pathology spreading.  
Similarly, for the frozen AD human brain tissues without fixative artefacts studied by label-free 
line-scan Raman micro-spectroscopy in Chapter 6, 3D Raman images of Aβ plaque pathology 
lesions surrounded by lipidomic environment were acquired and chemically unmixed to produce 
individual biochemical profiles of the pathological brain composition. In agreement with the 
results of Chapter 5, the analysis on frozen AD brain samples also revealed that label-free Raman 
micro-spectroscopy is capable to distinguish significant intracellular and extracellular 
accumulations of pathogenic Aβ species assembled into in the cross-β structured fibrils manifested 
by a profound marker band at 1668 cm-1 combined with the missing band between 1662–
1655 cm-1, characteristic of the α-helix structured proteins (Rygula et al. 2013). For the lipid 
content, the analysis found two types of lipid deposits spatially colocalizing with the Aβ plaques. 
In particular, significant accumulations of polyunsaturated lipids, spectrally attributed to an 
oxidized form of a trans isomer of AA, that are co-deposited with the Aβ protein in one chemical 
component, were discovered colocalizing to the Aβ plaque core and the cell bodies of neurons. 
The abundant pathological signatures of lipid peroxidation in the composition of this amyloid-
lipid component is evident by a high presence of trans double bonds in its Raman spectrum, which 
is consistent with the research findings of Chapter 5. These observations might manifest 
unresolved neuroinflammation and oxidative damage affected human AD brains in response to 
chronic Aβ accumulation. The results also revealed the halo tightly enveloping the Aβ core and 
composed of lipoproteins with a high CE content. This CE-rich halo is observed to colocalize with 
the activated microglial processes and spatially correlate with the pro-inflammatory 
immunolabelled components of the immune system such as the pore-forming gasdermin D protein, 
reflecting the cell pyroptosis, and the ASC specks, indicative of the NLRP3 inflammasome 
activation. Furthermore, the analysis found the ellipsoid-shaped cloud clustering around the Aβ-
containing neurons consisting of the actin protein, possibly originated from the lytic material of 
the dead neuronal cells underwent the cell pyroptosis.  
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Importantly, as presented in Chapter 6, the Aβ and AA interplay can be possibly explained through 
their association with lipid cellular membranes. In particular, assembled Aβ oligomers are 
documented to disturb the integrity of neuronal membranes by creating the Aβ pores within 
them (Kayed and Lasagna-Reeves 2013), whereas AA as an essential polyunsaturated FA in the 
composition of the lipid bilayers is shown to facilitate growth/repair of new/damaged 
neurons (Darios and Davletov 2006). To that end, the co-existence of Aβ fibrils with the 
oxidatively modified trans isomer of AA in one complex at the sites of plaque core revealed by 
label-free 3D Raman imaging of human brains as presented in Chapter 6 might point to another 
possible mechanism of brain neurodegeneration through the conversion of AA to its peroxided 
forms within lipid membranes induced by Aβ toxicity that lead to the dysregulation of the AA 
enzyme cascade and subsequent cell death. 
Altogether, Chapter 5 and Chapter 6 show that Raman micro-spectroscopy is capable to distinguish 
spatially resolved chemically specific accumulations of lipid and proteins, composed of aggregated 
bioproducts of lipid peroxidation and protein signatures of the oxidative damage and 
neuroinflammation, that colocalize to Aβ plaque pathology lesions in label-free human AD brains. 
Therefore, my thesis suggests the use of non-destructive label-free Raman micro-spectroscopy as 
an imaging tool for the identification of the biochemical molecular signs of AD tissue pathology. 
Application of quantitative hyperspectral image analysis methods to large-scale Raman datasets 
from high-content human samples shown in my thesis will in turn stimulate further large-scale 
biomedical data analyses that could help to identify new imaging biomarkers and structural 
molecular features associated with various diseases.  
9.2. Revealing novel brain imaging biomarkers for AD 
diagnosis  
In Chapter 5 and Chapter 6, I showed that Raman micro-spectroscopy allowed to detect and 
quantify pathogenic Aβ1-42 chemical component of plaques from completely label-free brain tissue 
samples. Therefore, my thesis proposes the Raman spectral profile of Aβ as a brain imaging marker 
of AD pathology to be potentially used in clinical applications. As revealed in my thesis, this 
pathogenic Aβ protein is found in coupling with the lipid aggregate of the high oxidatively-
modified FA content representing one chemical component, thereby supporting the model of a 
close interaction of Aβ with lipids. This lipid-bound Aβ complex is observed to be the main 
constituent of Aβ plaques. Therefore, my thesis utilizes the Raman spectral profile of oxidized 
FAs characterised by the significantly enhanced marker band of lipid peroxidation at 1668-1670 
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cm-1 together with the signatures of saturated lipids in the CH-stretch vibrational region (2700-
3100 cm−1) as an imaging lipidomic marker of AD human brains. The diagnostic signatures of 
lipids with saturated high-order FA chains in the CH-stretch region have been revealed by the 
increased 2880/2850 cm-1 intensity ratio by factor of 2 and above (Chapter 5) combined with the 
lacking Raman band near 3004 cm-1 (Chapter 5-6).  It is important to note that recent studies 
already indicated the lipid effect on Aβ pathology spreading in the AD brains, elucidating that 
lipids can destabilise the Aβ aggregate by pulling out Aβ oligomers from its halo, thereby seeding 
a new neurotoxic Aβ nucleation (Kiskis et al. 2015). Specifically, it has been shown in the previous 
studies that both microglia-derived lipid micro-vesicles and ApoE-lipid complex, bind to fibrillar 
plaques, upon which they can either disintegrate the Aβ deposit into toxic Aβ oligomers (Joshi et 
al. 2014) or facilitate its aggregation and possibly clearance (Burns et al. 2003). The interplay of 
the Aβ protein with the CE-rich lipids as revealed in Chapter 5 is in line with the previous studies 
on cholesterol-mutant cell lines, indicating the positive correlation of Aβ production with the 
upregulated CE levels, controlled by acyl-coenzyme A:cholesterol acyltransferase 
(ACAT) (Puglielli et al. 2001). Additionally, these studies demonstrated that the pharmacological 
ACAT inhibitor efficiently supressed the generation of both CE and Aβ, pointing to its potential 
use in AD treatment. To note, the animal trial of this strategy already gave encouraging results 
using an AD mouse model (Murphy et al. 2013).   
Further to clinical impact, my thesis demonstrated that the statistical parameters of identifying 
biochemical components found from quantitative brain imaging with Raman micro-spectroscopy 
separate AD tissues from non-demented ones, that might be beneficial for AD diagnosis. In 
relation to inflammatory components of human AD brains, my data showed that the levels of β-
carotene are significantly upregulated in AD human brains compared to the controls and these 
accumulations are strongly associated with Aβ plaque pathology lesions (Chapter 5). Therefore, 
my PhD thesis also propose the Raman spectral profile of β-carotene as an imaging marker of AD 
pathology, in which β-carotene might be a measure of neuroinflammatory response. 
9.3. Revealing pro-inflammatory microglia phenotype as a 
signature of human AD brains affected by Aβ amyloidosis 
As presented in Chapter 7, the analysis of fluorescence images with triple immunohistochemical 
staining of human AD brain sections for Aβ, ASC specks and microglia reveals the significance 
of the activated pro-inflammatory microglia phenotype in response to sustained Aβ accumulation, 
which is tightly linked to the greatly enhanced ASC speck assembly within microglial soma. 
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Therefore, the ASC speck-associated microglia state can be considered as a unique pro-
inflammatory phenotype of AD brains with chronic Aβ aggregation. Importantly, these data might 
indicate that the therapeutic chemical agents which selectively block ASC speck formation within 
microglia have a great potential to tilt the ASC speck-specific pro-inflammatory microglia 
phenotype towards a neuroprotective state with increased Aβ clearance and reduced Aβ toxicity 
spreading capacities. It has been recently reported in the studies using cultured cells and mouse 
AD models that anti-ASC speck antibody treatment results in decreased levels of Aβ oligomers 
that in turn contribute to reduction of Aβ accumulations (Venegas et al. 2017). The results of my 
thesis support two mechanisms for a beneficial neuroprotective effect of anti-ASC antibody as 
previously suggested in recent studies (Venegas et al. 2017; Lee et al. 2019). One of these is 
targeting intracellular ASC. My data and previous studies indicate that, following Aβ aggregation, 
the inflammasome is activated in neuronal cells surrounding Aβ plaque lesions (Heneka et al. 
2013) resulting in the ASC speck assembly within the inflammasome-activated cells. When ASC 
protein is polymerised into fibrils and ultimately to an assembled speck, it can initiate the  
maturation of IL-1β cytokine through caspase-1 activation (Broderick et al. 2015). At this point, 
anti-ASC speck antibody binding to intracellular unassembled ASC will block caspase-1 
activation and subsequent IL-1β cytokine generation, which will supress inflammatory response 
and reduce neurodegeneration. Indeed, caspase-1 has been recently established to activate pore-
forming GSDMD that in turn was discovered to drive an inflammatory type of cell death known 
as pyroptosis (Rathkey et al. 2017). If the ASC speck assembly is not blocked by the selective 
antibody treatment, the inflammasome-activated cell undergoes pyroptosis, ultimately resulted in 
the release of ASC specks and IL-1β cytokines into extracellular space, where IL-1β cytokines can 
recruit new immune cells to the sites of infection and skew the microglial polarization towards the 
pro-inflammatory state (Cherry et al. 2014).  Strikingly, when accumulated in the extracellular 
space, ASC specks show prion-like (prionoid) activities to recruit new ASC and caspase-1 in cells 
ingested ASC specks, thereby leading to continuous secretion of IL-1β cytokines and unresolved 
inflammation (Franklin et al. 2014). At this point, anti-ASC speck antibody can also bind to 
extracellular ASC specks (Lee et al. 2019), thereby blocking maturation of new IL-1β and 
contributing to switch to the anti-inflammatory microglial phenotype (Subramaniam and Federoff 
2017) with increased Aβ phagocytic capacity, that results in decreased Aβ accumulations (Sarlus 
and Heneka 2017).  If  extracellular ASC specks are not neutralised by the antibody, ASC specks 
further induce inflammasome activation upon their phagocytosis by microglia, that result in the 
microglial pyroptosis (Sarlus and Heneka 2017), ultimately leading to uncontrollable growth of 
Aβ areas and neurodegeneration. In addition, anti-ASC speck antibody can block microglial 
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pyroptosis by binding to intracellular inflammasome and therefore suppressing/impeding its 
activation (Lee et al. 2019). 
9.4. Pro-phagocytic effect of MAC pores on clearance of small 
Aβ plaques vs. pro-inflammatory potential of MAC pores 
on ASC speck-induced spreading of Aβ pathology in 
human AD brains: hypothetic cycle of AD pathogenesis 
In Chapter 8,  the analysis of fluorescence images with triple immunohistochemical staining of 
AD brain sections for Aβ, ASC specks and complement component 9 of MAC revealed a strong 
colocalization of MAC pores to the Aβ plaque core and ASC specks clustering around the MAC 
deposits, possibly implying the MAC as a driver of the inflammasome activation at the sites of Aβ 
accumulation. In view of these results, the hypothesis-driven cycle of AD pathogenesis can be 
proposed as follows. In immune system response to Aβ aggregation, the MAC pores are formed 
at the sites of Aβ plaques within membranes of surrounding cells. These MAC pores can 
permeabilize the Aβ-affected cell membranes, through which ASC specks undergo release into the 
extracellular space. Upon secretion of ASC specks through the MAC pore-containing membranes, 
free ASC specks can promote further Aβ oligomer assembly (Venegas et al. 2017), thereby 
contributing to Aβ pathology spreading. To note, my data are consistent with the model proposed 
in (Venegas et al. 2017). My results show a colocalization of ASC specks with Aβ in the plaque 
cores of AD human brains and the statistical significance of this effect is demonstrated.  
Importantly, my data on 3D reconstruction of fluorescently labelled Aβ plaques co-immunostained 
for pore-forming C9 of MAC and ASC specks can indicate that C9 complex punches holes in the 
surface of Aβ plaque core and the site of C9 activation is observed to form a cavity with 
significantly decreased immunoreactivity levels of Aβ and ASC specks within the plaque core. 
Interestingly, this effect is more significant for the plaques of smaller diameter, that might 
represent newly formed deposits, that are more prone to the pro-phagocytic MAC effect with 
enhanced Aβ clearance capacity as clearly observed for cortical plaques. Therefore, my data 
suggest that activation of MAC to “small” Aβ plaque might trigger destabilization of Aβ aggregate 
resulting in its local clearance, thereby suppressing/impeding the pro-inflammatory inflammasome 
activation. It is plausible that this beneficial activity of MAC pores in response to Aβ aggregation 
that is a more pronounced effect for newly formed Aβ deposits of smaller diameter can be linked 
to activation of signalling pathways. Prevailing evidence from previous studies suggest that 
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activation of MAC is upregulated in AD brains (McGeer et al. 1989; Rogers et al. 1992; Itagaki 
et al. 1994; Shen et al. 1997; Webster et al. 1997). A lethal effect of MAC (C5b-9) on cells through 
assembly of a lytic pore, mainly consisting of numerous units of C9 protein, on cell surface is well-
known (Emmerling et al. 2000). The effect of MAC on initiation of signalling pathways has been 
also documented showing that sublytic MAC pores on target cells can activate signal transduction 
pathways that might lead to cell proliferation/migration (Niculescu and Rus 2001; Fosbrink et al. 
2006) and phosphorylation of tau protein (Britschgi et al. 2012). Here, the assembly of C5b-9 into 
MAC pore on the surface of pathogenic Aβ plaque might trigger specific cellular and 
immunological events that impede further Aβ aggregation and promote Aβ phagocytosis in human 
AD brains, thereby preventing the pro-inflammatory inflammasome activation. It is important to 
mention that the assembly of MAC into a pore requires lipid bilayers, into which the complements 
components C5b, C6, C7, C8, and C9 are incorporated (Serna et al. 2016). Aβ plaque appears not 
to have the lipid membrane, implying that MAC might not be able to create pores in the Aβ 
aggregate. However, in Chapter 5 and Chapter 6, I showed that Aβ fibrils spatially colocalize with 
lipid micro-vesicles of high saturated long-chain FAs content, representing one tightly bound 
complex of Aβ plaque chemical composition. Therefore, I am hypothesising that MAC can punch 
holes in Aβ plaque through interaction with Aβ-associated lipid micro-vesicles. 
Taken together, the quantitative analysis shows that the MAC pores inserted into the Aβ core can 
support Aβ phagocytosis as evident by local reduction of Aβ immunoreactivity levels at the sites 
of MAC activation and these locations are also observed to have low ASC speck fluorescence 
intensities, implying the downregulation of the inflammasome activation at these sites. This 
observed effect of MAC is more profound for newly formed Aβ aggregates of smaller size (less 
than 25 µm in average as evidenced in this thesis on the investigated population of cortical 
plaques), possibly implying that excessive aggregation of Aβ in the course of AD is difficult to 
overcome by clearance mechanisms of defensive immune system that is known to be 
downregulated/impaired in the elderly brains of decreased/defective repair function (Busse and 
Mathur 2012). On the other hand, the quantitative analysis also revealed the colocalization of the 
ASC specks to MAC pores within the Aβ cores of predominately the hippocampal plaques with 
50 µm average size, reflecting the MAC as a driver of neuroinflammatory processes in human AD 
brains. Therefore, my thesis indicates the MAC as a double-edged sword with distinct pro-
phagocytic and pro-inflammatory effects on Aβ pathology, interrelation between which depends 
from the size of plaques and therefore from the relative area of human AD brains affected by Aβ 
accumulation. 
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9.5. Concluding remarks on the link between Aβ amyloidosis 
and neuroinflammation 
All in all, my PhD thesis extensively investigated and characterised the inflammatory and 
lipidomic chemical environment of Aβ plaques in human AD brains using state-of-the-art high-
resolution imaging techniques. The results show the sustained accumulations of oxidative stress 
and neuroinflammatory components of innate immune system colocalizing to Aβ plaque lesions, 
indicating inflammation as major contributor to AD pathology spreading. Specifically, 
quantitative imaging of chemical composition of Aβ plaque areas in human AD brains using two 
independent optical tools revealed spatial colocalization of numerous MAC pores with ASC 
specks (as shown by immunofluorescence) and calcium crystals (as shown by Raman micro-
spectroscopy) in Aβ plaque cores, possibly indicating the link between these inflammatory 
signatures. The potential association of MAC pores with calcium deposits and ASC speck 
accumulations within the Aβ plaque cores can be explained by the previous study in human lung 
epithelial cells showing that the formation of MAC pores in the cell membranes leads to Ca2+ 
accumulations in the mitochondrial matrix, which recruits the NLRP3 assembly and ASC speck 
accumulation, thereby initiating further pro-inflammatory response and apoptosis (Triantafilou et 
al. 2013). As another important outcome, my PhD underlines a possible non-lethal beneficial effect 
of MAC complex on reduction of Aβ accumulations in AD brains, implying that MAC pores might 
act as a promoter of Aβ clearance. This activity of MAC which is exclusively applied to newly 
formed Aβ aggregates might indicate on the possibility that sustained growth of Aβ plaque areas 
in the course of AD may be linked to decreased/impaired phagocytic function mediated by the 
MAC. 
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Appendix A  
Appendix A represents the results of two separate 20 component Q-US/PS-NMF analyses on the 
acquired Raman biomedical datasets of formalin-fixed-paraffin-embedded human AD brain 
tissues together with controls in hippocampal or cortical regions that report the biochemical 
composition of AD human brains as investigated in Chapter 5. In the analysis of the hippocampus, 
the datasets of 30 regions containing Aβ plaques from 5 AD individuals and 10 control regions 
from elderly humans without AD were included. In the analysis of the cortex, the datasets of 31 
Aβ plaque areas from 6 AD subjects together with 7 control maps from 2 non-demented humans 
were participated. Each Fig. A-1 to A-20 (the hippocampus) and Fig. A-23 to A-42 (the cortex) in 
the given brain region provides the component spectra (on the left) and its corresponding spatial 
concentration profile (on the right) in the investigated samples, as retrieved from the factorization 
analysis. Figs. A-21 and 43 show the spatial (on the left) and spectral (on the right) mean absolute 
factorization error resulting from the factorization analysis of the hippocampal and cortical 
samples, respectively. The value for relative factorization error is also given on the top of each 
figure. Fig. A-22 and 44 illustrate the mean spatially resolved subtracted fluorescence intensity 
found by averaging over the same spectral regions as for the component spectra and normalizing 
on the component spectral integral for each respective hippocampal and cortical Raman image. 
Chemical composition of the human hippocampus in AD presented below: 
 
 
Fig. A-1: The component spectra ℂ1 and its spatial distributions of the Raman concentration for the measured AD 
hippocampal brain regions together with controls (labelled according to the sample source as Ah1,..., Ah5, and 
Ch1, Ch2, respectively) on colour scales as indicated, retrieved from the simultaneous Q-US/PS-NMF unmixing 
analysis of 30 hippocampal Aβ plaques (5 AD patients) together with 10 control Raman maps (2 elderly humans 
without AD). 
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Fig. A-2: As Fig. A-1, but for ℂ2. 
 
 
Fig. A-3: As Fig. A-1, but for ℂ3. 
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Fig. A-4: As Fig. A-1, but for ℂ4. 
 
 
Fig. A-5: As Fig. A-1, but for ℂ5. 
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Fig. A-6: As Fig. A-1, but for ℂ6. 
 
 
Fig. A-7: As Fig. A-1, but for ℂ7. 
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Fig. A-8: As Fig. A-1, but for ℂ8. 
 
 
Fig. A-9: As Fig. A-1, but for ℂ9. 
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Fig. A-10: As Fig. A-1, but for ℂ10. 
 
 
Fig. A-11: As Fig. A-1, but for ℂ11. 
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Fig. A-12: As Fig. A-1, but for ℂ12. 
 
 
Fig. A-13: As Fig. A-1, but for ℂ13. 
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Fig. A-14: As Fig. A-1, but for ℂ14. 
 
 
Fig. A-15: As Fig. A-1, but for ℂ15. 
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Fig. A-16: As Fig. A-1, but for ℂ16. 
 
 
Fig. A-17: As Fig. A-1, but for ℂ17. 
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Fig. A-18: As Fig. A-1, but for ℂ18. 
 
 
Fig. A-19: As Fig. A-1, but for ℂ19. 
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Fig. A-20: As Fig. A-1, but for ℂ20. 
 
 
Fig. A-21: The spatial (on the right) and spectral (on the left) mean absolute factorization error resulting from the 
simultaneous Q-US/PS-NMF unmixing analysis of 30 hippocampal Aβ plaques (5 AD patients) together with 10 
control Raman maps (2 elderly humans without AD). 
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Fig. A-22: The mean spatially resolved subtracted fluorescence intensity of the same hippocampal samples found 
by averaging over the same spectral regions as for the component spectra and normalizing on the component 
spectral integral. 
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Chemical composition of the human cerebral cortex in AD presented below: 
 
 
Fig. A-23: The component spectra ℂ1 and its spatial distributions of the Raman concentration for the measured AD 
cortical brain regions together with controls (labelled according to the sample source as Ac1,..., Ac7, and Cc1, Cc2, 
respectively) on colour scales as indicated, retrieved from the simultaneous Q-US/PS-NMF unmixing analysis of 
31 cortical Aβ plaques (7 AD patients) together with 7 control Raman maps (2 elderly humans without AD) 
 
 
Fig. A-24: As Fig. A-23, but for ℂ2. 
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Fig. A-25: As Fig. A-23, but for ℂ3. 
 
 
Fig. A-26: As Fig. A-23, but for ℂ4. 
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Fig. A-27: As Fig. A-23, but for ℂ5. 
 
 
Fig. A-28: As Fig. A-23, but for ℂ6. 
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Fig. A-29: As Fig. A-23, but for ℂ7. 
 
 
Fig. A-30: As Fig. A-23, but for ℂ8. 
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Fig. A-31: As Fig. A-23, but for ℂ9. 
 
 
Fig. A-32: As Fig. A-23, but for ℂ10. 
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Fig. A-33: As Fig. A-23, but for ℂ11. 
 
 
Fig. A-34: As Fig. A-23, but for ℂ12. 
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Fig. A-35: As Fig. A-23, but for ℂ13. 
 
 
Fig. A-36: As Fig. A-23, but for ℂ14. 
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Fig. A-37: As Fig. A-23, but for ℂ15. 
 
 
Fig. A-38: As Fig. A-23, but for ℂ16. 
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Fig. A-39: As Fig. A-23, but for ℂ17. 
 
 
Fig. A-40: As Fig. A-23, but for ℂ18. 
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Fig. A-41: As Fig. A-23, but for ℂ19. 
 
 
Fig. A-42: As Fig. A-23, but for ℂ20. 
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Fig. A-43: The spatial (on the right) and spectral (on the left) mean absolute factorization error resulting from the 
simultaneous Q-US/PS-NMF unmixing analysis of 31 cortical Aβ plaques (7 AD patients) together with 7 control 
Raman maps (2 elderly humans without AD). 
 
Fig. A-44: The mean spatially resolved subtracted fluorescence intensity of the same cortical samples found by 
averaging over the same spectral regions as for the component spectra and normalizing on the component spectral 
integral. 
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Appendix B  
Appendix B represents the results of the 11 component Q-US/PS-NMF analysis on the acquired 
3D Raman biomedical datasets of frozen human AD brain tissues and controls in the hippocampal 
brain region that report the biochemical composition of the AD human hippocampus without 
fixative artefacts as investigated in Chapter 6. Each Fig. B-1 to B-11 provides the component 
spectra (on the left) and its corresponding spatial concentration profile (on the right) in the 
investigated samples, as retrieved from the factorization analysis. Fig. B-12 shows the spatial (on 
the left) and spectral (on the right) mean absolute factorization error resulting from the 
factorization analysis. The value for relative factorization error is also given on the top of each 
figure.  
 
 
Fig. B-1: The component spectra ℂ1 and its spatial distributions of the Raman concentration for the measured AD 
hippocampal brain regions together with controls (labelled according to the sample source as A1, A2, A3, and C1) 
on colour scales as indicated, retrieved from the simultaneous Q-US/PS-NMF unmixing analysis of frozen human 
brain tissues without fixative artefacts. In all panels, 2D Raman images from different focal planes of the 
representative z-stack were shown sequentially. 
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Fig. B-2: As Fig. B-1, but for ℂ2. 
 
 
Fig. B-3: As Fig. B-1, but for ℂ3. 
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Fig. B-4: As Fig. B-1, but for ℂ4. 
 
 
Fig. B-5: As Fig. B-1, but for ℂ5. 
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Fig. B-6: As Fig. B-1, but for ℂ6. 
 
 
Fig. B-7: As Fig. B-1, but for ℂ7. 
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Fig. B-8: As Fig. B-1, but for ℂ8. 
 
 
Fig. B-9: As Fig. B-1, but for ℂ9. 
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Fig. B-10: As Fig. B-1, but for ℂ10. 
 
 
Fig. B-11: As Fig. B-1, but for ℂ11. 
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Fig. B-12: The spatial (on the right) and spectral (on the left) mean absolute factorization error resulting from the 
simultaneous Q-US/PS-NMF unmixing analysis of the frozen AD brain tissues together with non-demented 
controls shown in Fig. B-1 - Fig. B-11. 
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Supplementary material 
The supplementary material includes a Power Point presentation showing a 3D volume view 
movie of merged chemical ℂ9 (red) and ℂ1 (blue) generated based on the AD1_02z1-z7 Raman 
images acquired from the frozen human brain tissue affected by AD.  A 3D projection allowed to 
illustrate the spatial volumeric distribution of the intracellular Aβ aggregated with the oxidised 
polyunsaturated trans lipids (ℂ9) within the neuronal cells that colocalize with the 
phosphatidylcholine-rich lipid droplets (ℂ1). 
Supplementary material (movie) can be found online at 
https://www.dropbox.com/sh/shvp56x8agof6lc/AADluH5gpWXSw0BvLcjGWXx4a?dl=0 
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